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Abstract 
 
G protein-coupled receptors (GPCRs) are membrane proteins responsible for myriad physiological 
functions. Around a third of drugs on the market already target GPCRs. However, the emphasis on 
developing GPCR assays to screen compound libraries for potential GPCR-interacting drugs is still very 
strong. One such cell-based assay was developed at GlaxoSmithKline (GSK) by Dowell and Brown [1, 
2]. This assay uses a cheap, rapidly growing unicellular organism – baker’s yeast. In this organism the 
pheromone signalling pathway is one of only two GPCR-activated pathways. Yeast engineering done 
at GSK in 2000 produced MMY strains lacking the native yeast Ste2 GPCR and other key proteins, 
together with the integration of chimeric yeast/mammalian G protein alpha subunits thereby allowing 
mammalian GPCRs to couple to the yeast signalling machinery [2]. A significant limitation of the assay 
has been that some pharmacologically-important receptors cannot be tested using the current MMY 
strains and protocols. The aim of this study was to optimise the functional expression of adrenergic 
receptors that had previously been difficult to express and/or characterise pharmacologically in these 
yeast strains. The work described here examined both the MMY strains themselves and the expression 
constructs, asking the question how these features might contribute to a robust assay readout for two 
GPCR classes; the α- and β-adrenoceptors. The origin of the instability of some of the MMY strains was 
traced to the experimental strategy originally used to delete the URA3 marker gene and a stable MMY 
strain was generated as a proof-of-principle. A systematic comparison between different expression 
vector designs identified that the addition of the mating factor α (MF-α) leader sequence to the amino-
terminus of the β1- and β2-adrenoceptors is required to produce a pharmacological response in the 
yeast assay. Notably, this permitted reproducible functional expression of the β2-adrenoceptor, which 
had not been previously possible at GSK, despite being published in the scientific literature. These 
improvements allowed for the pharmacological characterisation of a panel of interacting β-AR ligands, 
yielding data that has shed new light on ligand bias. Finally, a cholesterol-expressing yeast engineering 
strategy was designed to specifically investigate the role of plasma membrane composition in GPCR 
functional studies. The insights gained from the experiments described this thesis should allow for 
improved testing of other GPCRs in the drug development pipeline. 
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Chapter 1 - Introduction 
 
This project examines the use of a yeast-based assay system to study the functional expression of G 
protein-coupled receptors (GPCRs) for use in the drug discovery pipeline. The focus of the project was 
adrenoceptors, some of which had previously been difficult to characterise pharmacologically in this 
yeast system. The yeast strains used are named the MMY strains developed in 2000 at GlaxoSmithKline 
[2]. The work described in this thesis examines the MMY strains themselves and the GPCRs expression 
constructs, asking the question how an improved understanding of both would contribute to a robust 
assay readout for adrenoceptors. In this introduction, the importance of GPCR research to the drug 
discovery and the development of the MMY strains is described, following by a discussion of the 
limitations of the MMY-based assay and the consequent aims and objectives of the thesis project. 
 
1.1. G protein coupled receptors 
 
The G protein-coupled receptor family – the largest receptor family is comprised of around 800 
members, a large proportion of which are of significant physiological and pharmacological importance. 
These membrane proteins are involved in a myriad of physiological functions in humans and are 
implicated in many diseases ranging from diabetes, cancer, cardiovascular diseases, inflammatory 
diseases such as asthma, hormonal disorders, narcotic substance abuse, and many others. Not 
surprisingly, around a third of all drugs on the market target G protein-coupled receptors (GPCRs). 
Despite this, the mechanism of majority of these drugs are poorly understood. For this reason a great 
effort is focused on understanding the relationship between the receptors’ structure, downstream 
signalling effects on the cell’s function and therapeutic effect. This subchapter will introduce the basic 
concepts of GPCRs and their mechanism of function. More detail on adrenergic-specific function is 
described in section 1.5. 
 
1.1.1. The structure  
 
Direct structural data on GPCRs were not available until 2000 when the first eukaryotic (bovine) GPCR 
crystal structure of the light sensing receptor rhodopsin was published [3]. The second high resolution 
structure of a GPCR was not published until seven years later and was a result of extensive crystal 
growth optimisation trials and sophisticated protein engineering which allowed Kobilka and colleagues 
to determine the β2 adrenoceptor structure at 2.4 Å resolution [4]. However, the isolation and 
sequencing of rhodopsin and the β2 adrenoceptor back in the mid-1980s had already hinted that the 
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clusters of hydrophobic amino acids made up the seven transmembrane helices and was then believed 
to be a common feature of many membrane proteins [5].  
Our current knowledge confirms that the GPCRs are large transmembrane receptors composed of 
seven alpha-helices, an extracellular N-terminus and three extracellular loops, a cytosolic or 
intracellular C-terminus and three intracellular loops (Figure 1.1) [6]. The extracellular domain is facing 
outside of the cell and is often the site for ligand binding, especially for larger molecules [6]. The 
intracellular domain, and the third loop in particular, are important for receptor coupling to the G 
protein complex Gαβγ [6] and also for interaction with other proteins of mostly regulatory nature, 
such as GPCR kinases and arrestins [7].  
The other important entity of the GPCR signalling mechanism is the G protein complex composed of 
sub-units Gα, Gβ, and Gγ. When the receptor is inactive, the G protein trimer sits anchored to the 
membrane through a fatty acid chain and only couples to the receptor when it is activated. A more 
detailed mechanism of activation and signalling is explained in the next section and section 1.5 in a 
context of β-adrenoceptors. The specificity of G protein coupling to a receptor and activation of 
different effectors is determined by the Gα subtype, of which there are four main classes – Gs, Gi, 
Gq/11, and G12 The main effectors of Gαs and Gβγ are adenylate cyclase (AC), phospholipase C (PLC), 
ion channels, Rho A/Rho kinase, and MAP kinase. The Gα sub-unit can either activate or inhibit them. 
  
Figure 1.1 The general structure of a G protein-
coupled receptor. The large protein is comprised of 
seven membrane-spanning helices, 3 extracellular 
loops together with an extracellular N terminus, 
and 3 intracellular loops and the C terminus in the 
cytosol. The intracellular domain binds to G 
proteins, arrestins and other proteins in the case of 
a mammalian GPCRs. The endogenous or synthetic 
ligands, neurotransmitters or hormones bind at the 
extracellular domain.  
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1.1.2. Mechanism of function  
 
GPCRs are important in human physiology because they allow the cell to respond to signals coming 
from the external environment and induce physiological changes in response. These receptors achieve 
this by translating that signal into an internal message, often amplifying it. Upon the conformational 
changes, caused by an external stimulus, GPCRs couple to the G protein trimer in turn causing the α 
subunit to exchange its bound GDP into GTP [7]. This exchange causes further conformational changes 
on the Gα subunit which dissociates from the Gβγ subunit. Both entities then associate with their 
target proteins, which are mentioned in the previous section, activating them and generating further 
amplification of the message via second messengers, such as cyclic adenosine monophosphate 
(cAMP), diacylglycerol (DAG), and inositol-1,4,5-trisphosphate (IP3) [6, 7]. The Gα association with its 
target also causes hydrolysis of GTP into GDP, inactivating Gα. Inactivated Gα re-associates with Gβγ 
[6]. The external signal that is capable of inducing conformational changes can be a neurotransmitter, 
hormone, neuropeptide, or other small molecules such as purines, prostanoids, cannabinoids and 
others [6]. Conformation changes can also be induced by protease mediated cleavage of the N 
terminus or conformational changes of covalently bound ligand, such as retinal bound to rhodopsin, 
one of the earliest models of GPCR structure [3, 6].   
 
1.2. An overview of approaches to study GPCRs  
 
The yeast chimeric Gα proteins allow the investigation of different mammalian GPCR coupling to Gα 
proteins in the single cell background, with the same output – the measurement of growth, and 
presumably the same number of receptors. However, in mammalian cells the Gα protein coupling 
dictate which signalling pathways are modulated and therefore assessment is made by monitoring the 
change in the effector protein activity upregulation or downregulation. The effectors often produce 
second messengers to amplify the signal. For this reason the outputs are different too, ranging from 
calcium or cyclic AMP quantification to cytoskeleton re-arrangement. This sub-chapter will review 
these assays because it is important to understand how these assays work in order to explain any 
discrepancies in pharmacological parameters generated in mammalian cell assays vs the yeast assay 
data.  
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1.2.1. Radioligand binding assays 
 
The radio-labelled ligand binding assays were developed based on work described Yalow and Berson 
in 1959 [8] and are used for assessing parameters such as affinity of a ligand to a receptor, receptor 
density in tissue, cellular or membrane preparations [9]. The assay involves the binding of a radio-
labelled compound to GPCR receptors. Affinities of ligands can be compared by performing a 
competition binding assay where a fixed concentration of a known radioligand is applied along with 
increasing concentrations of an unlabelled ligand. The non-specific binding has to be determined (using 
a competitive unlabelled ligand at high concentrations), as the ligand will bind to other sites within 
membrane and assay tubes [9]. The common problem with this assay is that often agonist binding to 
GPCRs will display biphasic curves that do not fit theoretical competition binding curve model with a 
Hill coefficient of unity. To overcome this, GTP can be added to stabilise receptor conformation and in 
turn agonist’s affinity to the receptor [9]. However, GTP will lock the Gα subunit in the active 
conformation, which has low affinity for the receptor. The agonist has a higher affinity for the Gα-
bound (inactive) receptor, and therefore adding GTP can diminish the signal for the agonist assay.  
Allosteric ligands also potentially pose a problem to a lot of GPCR work, as they are able to bind to 
other sites and make a ternary complex with a competitor ligand. The radio-labelled ligand assays 
require optimisation of assay incubation time and temperature, buffer composition, as well as cell 
type-dependent culturing and receptor expression conditions. The radio-isotope label has been 
increasingly replaced by a fluorescent label as it is much safer [10]. However, it does pose some issues 
such as: a) the adaptability of the fluorescent tag to a smaller molecules without affecting its 
pharmacological properties; b) determining binding-specific fluorescence from background and 
unspecific binding fluorescence; c) fluorophore’s sensitivity to pH and other environment properties.  
Although binding and competitive binding assays are fairly old techniques and do not give information 
about receptor interaction with the signalling pathways, nor there is a linear relationship between 
binding saturation and maximum cellular response, the techniques are still widely used especially 
determining whether the protein is folded when expressed in recombinant production host and for 
quantification of total receptor level (expressed as saturation of binding sites) [11-13]. 
 
1.2.2. Second messenger assays 
 
Another type of GPCR assay uses the second messenger, generated by GPCR activation events, as a 
functional measure of ligand efficacy on the receptor. Upregulation or downregulation of cyclic 
adenosine monophosphate (cAMP), inositol trisphosphate (IP3), calcium ions (Ca2+), or mitogen-
activated protein kinases (MAPKs) depend on the subtype of Gα that is coupled to the activated 
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receptor, therefore, unlike in yeast, Gα is the main determinant of which second messenger is 
regulated [14].  
There are several ways in which changes in second messenger can be determined. For example, cAMP 
can be measured by competitive binding between radiolabelled cAMP and cellular cAMP binding in 
immunoassays that report quantities of bound cAMP by inversely proportional colorimetric or 
fluorescent change [14]. Several commercial assays are available for measuring cAMP in a cell lysate, 
for example Lance and AlphaScreen (Perkin Elmer) which are also based on competitive binding of the 
cellular molecule with a fluorophore-conjugated or biotinylated version of that molecule (cAMP or IP3) 
and measurement of FRET (Figure 1.2 [A]) [15]. Another method for detection of cAMP uses enzyme 
fragment complementation technology where cAMP is labelled with a fragment enzyme which 
competes with cellular unlabelled cAMP and under high cellular cAMP produces a chemiluminescence 
signal (Figure 1.2 [B]) [16].  
Calcium ions are measured by either UV light based ratiometric indicator techniques, or visible light 
fluorescence indicators. The activated ERK1/2, which is a MAPK, can result from Gβγ signalling as well 
A 
B 
Figure 1.2 Working principles of commercially available cAMP assays. The cAMP second messenger is measured 
competitive binding between cellular cAMP and engineered cAMP to either contain a fluorophore [A] or an 
enzyme fragment [B]. The later technique requires engineered cell lines but can be measured in whole cells. The 
diagrams were taken from PerkinElmer and DiscoverX product literature [14, 15]. 
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as Gi/0 and Gs, making it a useful indicator when a particular Gα is unknown or when wider coverage of 
receptors or agonists is desired. However, ERK1/2 can also be activated by other non-GPCR regulated 
pathways. This can be tested by applying pertussis toxin which specifically blocks Gαi and has no effect 
on ERK1/2 activation by other pathways. ERK1/2 can be detected using conventional protein detection 
techniques such as Western Blotting or ELISA as specific antibodies are available commercially [14]. 
The quantification of second messenger assays are attractive because they measure physiological 
response in the cell and can inform on the potency and efficacy of the drug. The second messenger 
assays can also be adapted for larger automated screening studies. However, they should be used in 
conjugation with drug binding studies, because functional assays do not inform us on the affinity of 
the drug. All the mentioned parameters are important in determining a drug’s suitability for clinical 
application. 
 
1.3. Hijacking the yeast pheromone pathway 
 
Yeast as a single-celled organism is very independent and unlike mammalian cells does not have a great 
need for cell-to-cell communication. The exception to this is the pheromone mating pathway. Together 
with the Gpr1-mediated glucose sensing pathway these two pathways are the only two GPCR signalling 
pathways known in yeast. The pheromone pathway has been the focus of extensive genetic 
engineering with the aim of producing a tool for functional studies of human GPCRs. This pathway was 
discovered and characterised in 1980s and is unique to pheromone signalling, unlike the glucose 
sensing pathway, which is a more complex process in yeast and therefore less amenable to functional 
pathway engineering (both reviewed in [17]).  
This review will focus on different stages of pheromone signalling through the native GPCRs Ste2/Ste3, 
outlining genetic modifications that were introduced in the generation of the MMY strains used in this 
project and their physiological effects on the host. The MMY strains have been used to assay human 
GPCRs; the limitations in their use are discussed later (section 1.6). 
 
1.3.1. General introduction to Saccharomyces cerevisiae mating 
 
Yeast S. cerevisiae are able to mate with opposing partners, of which there are two genotypes – MATa, 
which secrete a-pheromone (also called mating factor a), and MATα, which secrete the α-pheromone 
(alternatively mating factor alpha) [18, 19]. The Ste2 receptor on the plasma membrane of MATa cells 
is responsive to the α-pheromone (encoded by MF(ALPHA)1 and MF(ALPHA)2 genes) [20, 21]; 
similarly, MATα is activated by the a-pheromone (MFA1, MFA2) [22, 23] binding to Ste3 [19].  As in 
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mammalian cells, the G protein complex is composed of three G proteins - Gα (encoded by GPA1), Gβ 
(STE4), and Gγ (STE18). These GPCR signalling mechanism components are unique in this organism 
because no other pathways are activated via this route. It has therefore been a good pathway in which 
to study and dissect the principles of cell signalling [24]. Signalling through the pheromone pathway 
induces the expression of a number of mating genes and several physiological changes occur to 
prepare the cell to mate with a cell of opposing mating type. The mating generally occurs during stress 
conditions and increases the cell’s chance of survival.  
To prevent any spontaneous signalling or competition for the Gα subunit with the mammalian GPCR, 
the native Ste2 was deleted in the MMY strains, which are the subject of this thesis.  
 
Figure 1.3 Schematic representation of yeast pheromone response pathway. Upon binding of the 
pheromone (orange circles) conformational changes in the receptor activate the Gα subunit (encoded by 
GPA1) permitting GDP to be exchanged into GDP. This action releases the Gβγ subunit (encoded by STE4 
and STE18) which then activates target proteins Ste20 and Ste11, as a result bringing them in close 
proximity to each other. Ste11, anchored by Ste5 which acts as a scaffold for other mitogen-activated 
protein kinases, is then phosphorylated by Ste20. This initiates a further activation cascade of kinases Ste7, 
Fus3 and Kss1. The latter two activate their targets Far1 and Ste12 both of which have significant roles in 
preparing yeast cells for mating. Transcription factor Ste12 binds to the pheromone response element (PRE) 
on the promoters of mating genes, including FUS1 and FUS2. Ste12 is inhibited by regulators Dig1 and Dig2. 
Negative feedback regulator Sst2 accelerates GTP hydrolysis on Gα returning it into rest state and re-
coupling with Gβγ. The signalling is then terminated. 
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1.3.2. Signal initiation  
 
The sequences of both a-pheromone (YIIKGVFWDPAC) and α-pheromone (WHWLQLKPGQPMY) are 
available; however, because the latter is easier to purify or synthesise, it is usually the MATa cells that 
are treated with the α-pheromone [24]. Upon binding of the pheromone to the receptor, the changes 
in receptor conformation allow the Gα subunit to catalyse the exchange of GDP to GTP, which in turn 
releases the Gβγ subunit. Although the Gα subunit has other than regulatory roles, the main signalling 
cascade in yeast continues via the Gβγ subunit.  
Mammalian receptors generally cannot effectively couple to yeast G-proteins. A number of groups 
have worked on engineering modified variants of Gα and Gβγ that would complete a functional 
signalling mechanism with mammalian GPCRs [1, 25]. The crystal structure of the G protein trimer 
mapped out a large N-terminal region crucial for Gα-Gβγ binding as well as several other residues in 
the Switch region (where GDP is exchanged to GTP) that made also contacts, and finally the C-terminus 
which was important for receptor coupling, structured as an α helix [26]. The Gα-Gβγ interaction needs 
to be fully functional because, if Gα is unable to release Gβγ, then signalling will not proceed even if 
the receptor is stimulated with an appropriate ligand. If association of the two entities is not adequate, 
a high background will result. The engineering work carried out at GSK revealed that the most efficient 
Gα-Gpa1 chimeras were those in which 5 amino acids at the C-terminus of Gpa1 were replaced with 5 
amino acids of the mammalian Gαs [1]. Eleven chimeric Gα-Gpa1p were constructed and introduced 
into MMY strains [1, 2]. 
 
1.3.3. Downstream signalling cascade and their effectors 
 
The Gγ subunit anchors the dimer to the membrane via lipid groups while Gβ binds to the effectors 
Ste5/Ste11 complex, Ste20, and Far1/Cdc24 complex.  
The key effect of Gβγ disassociation is firstly the recruitment of the elements and kinases of the 
signalling cascade to the plasma membrane where they can take their action on one another (Figure 
1.3). For example, the Far1/Cdc24 activates Cdc42, and in turn GTP-bound Cdc42 activates Ste20. The 
Ste20 protein is brought closer to Ste11 and is then able to phosphorylate and activate Ste11, which 
in turn activates other kinases Ste7, Kss1 and Fus3. The latter two kinases are thought to phosphorylate 
transcription factor Ste12 which regulate the transcription of mating genes by binding to the 
pheromone response elements within the promoter region and recruiting transcription machinery. 
Dig1 and Dig2 are involved in repression of Ste12 and are also phosphorylated by Fus3 when their 
suppression of Ste12 is not needed.  
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The activated Fus3 kinase acts on various targets within the cell and is important in many aspects of 
mating process. One of the processes, induced by Fus3 phosphorylation of Far1, induces the formation 
of the mating projection which changes the cell’s morphology to a pear-like shaped structure called a 
‘shmoo’. Far1 also mediates cell cycle arrest in G1 phase [27]. Studies have shown that Far1, although 
required for the formation of ‘shmoo’ and induction of the cell arrest, is not essential in other 
pheromone signalling pathway branches which also involve Cdc24 [28]. Furthermore, deletion of FAR1 
was shown to increase agonist-induced signalling of mammalian GPCR SSTR2 expressed via the 
pheromone pathway in yeast [25]. FAR1 was also deleted in the MMY yeast (Figure 1.4) 
These processes are reviewed in detail in [24, 29]. 
 
1.3.4. Down-regulation of the pheromone pathway 
 
Receptor internalisation and recycling has been known to occur in yeast for several decades, but only 
recently it was described how several α-arrestins down-regulate the pheromone receptor Ste2. The 
first α-arrestin, Ldb19, was shown to regulate basal Ste2 levels, most likely as part of the quality control 
of missfolded protein. Rod1 was shown to initiate the internalisation of pheromone-bound Ste2 
receptor. An orthologue of Rod1 – Rog3 – inhibited pheromone signalling via Rsp5 independent 
manner; authors suggest that Rog3 might be physically blocking the Gpa1 (Gα subunit) [30]. Rod1 is 
thought to be able to promote receptor endocytosis and destruction via uniquitination by E3 ligase 
Rsp5 and Rsp-independent pathways [31]. Rsp5 function is inhibited by kinases Snf1 and Ypk1 which 
are upregulated during stress conditions to favour cell mating and enhance survival. It is thought that 
phosphorylation of Rod1 promotes its disassociation from the Ste2. Although no Ste2-Rod1 crystal 
structure is available, the α-arrestin Rod1 is proposed to interact with Ste2 in a similar way as visual 
and β-arrestins interact with their cognate receptors in mammalian cells [31]. 
Another mechanism for desensitisation of the pheromone signalling has been defined early in the 
pheromone research. The Sst2, a member of RGS family, accelerates GTP hydrolysis to GDP on Gα 
subunit by approximately 20-fold, making the G protein trimer reform into the inactivated state, that 
way negatively regulating the signalling cascade. Sst2 is closely associated with Gpa1, therefore its 
proximity also provides rapid response to activation of Gpa1 to prevent its spontaneous disassociation 
from the Gβγ subunit. Deletion of Sst2 greatly enhances the stimulation intensity which is beneficial 
for measuring agonist activity on human GPCRs in the MMY yeast.   
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1.3.5. Physiological response to pheromone stimulation 
 
As a result of Ste2 or Ste3 GPCR stimulation and pheromone-induced signalling pathways, the cell cycle 
is arrested in the G1 phase, the expression of around 200 genes, many of which have other roles 
outside pheromone signalling pathway, begins, cytoskeleton proteins and sphingolipid rafts rearrange 
to form mating projections towards the opposing pheromone mating partner [19, 32]. The cells 
conjugate at the projections, fuse their plasma membranes and later both nuclei and the diploid zygote 
cell forms. The cell will divide meiotically or mitotically depending on the environment conditions, as 
outlined earlier [18]. Once the changes are initiated there is no need for further pathway stimulation 
via the pheromone receptor which is desensitised as outlined in 1.3.4. The diploid cells that form do 
not respond to the pheromone at all.  
The laboratory strains are usually a homogenous population of either mating type and therefore 
unable to form diploids; the MMY strains used in this project are MATa. Nevertheless, the cell cycle 
arrest and other physiological responses associated with preparation for mating are unfavourable for 
functional or structural studies of GPCRs and therefore the yeast has been engineered to grow 
continuously.   
Figure 1.4 Modified pheromone signalling pathway in MMY yeast strains. The deletions of SST2 and FAR1 
prevent the desensitisation of the pathway and cell cycle arrest in G1 phase as well as other morphological 
changes in the cell. Two reporter genes – HIS3 and lacZ have been introduced under the regulation of FUS1 
and FUS2 promoters respectively. Native STE2 receptor gene has also been deleted to prevent any 
sequestration of Gαβγ trimer. The Gpa1 (a Gα) was also replaced by chimeric Gpa1-Gα proteins to allow 
coupling to human GPCRS. 
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1.3.6. Summary of MMY strains 
 
In summary, SST2, STE2 and FAR1 genes have been deleted in the MMY strains to allow human GPCR-
mediated pheromone signalling pathway continuous activation. Instead of inducing cell changes in 
preparation for mating, this signalling promotes cell growth in the absence of histidine or the 
expression of lacZ reporter gene under the FUS2 promoter. Because of deletion of SST2 the pathway 
is not rapidly desensitised which allows accumulation of the signal to detectable levels in a ligand 
concentration-dependent manner. The full genotypes of MMY strains can be found in Table 2.1. 
These changes greatly improved the sensitivity of this functional coupling detection. However, central 
to this interaction is the engineered chimeric Gpa1-Gα proteins, referred from now on as chGαs. As 
reviewed by Dowell and Brown [1] several Gpa1-human Gα chimeric protein combinations have been 
described by different groups, together with the crystal structure of the G protein trimer mapping out 
the interactions between the receptor, Gα protein to which it couples and Gβγ complex which activates 
the signalling cascade in yeast. The N-terminus helix of the Gα appeared to have most contacts with 
the Gβγ dimer but other residues, such as S229 and A348 have been shown to be important too. 
Interestingly the replacement of only 5 amino acids at the Gpa1 C-terminus had conferred greater 
coupling efficiency to mammalian GPCRs when compared with a larger Gpa1 C-terminal sequence 
replacements with the mammalian Gα protein sequences made by Kang et al [1, 2, 33]. These chGα 
proteins also demonstrated receptor coupling specificities comparable to those observed in 
mammalian Gα proteins. A Gpa1 in which 5 C-terminal amino acids were deleted without replacement 
failed to couple to Ste2 or mammalian GPCR, indicating that these amino acids are essential for 
coupling to the receptor [2]. 
 
1.4. GPCR research in yeast 
 
1.4.1. General introduction 
 
The pheromone pathway has attracted a lot of research interest as outlined in the previous section. 
There are several reasons for this. Firstly, yeast has a reputation as a good model system to study basic 
cellular mechanisms such as cell cycle and was also attractive for studying cell signalling. The 
availability of research and genetic engineering tools has also contributed to this and so did the 
sequencing of Saccharomyces cerevisiae genome in 1996 [34]. 
Secondly, the increasing interest in GPCR research has prompted researchers to look for recombinant 
production hosts. To obtain naturally occurring GPCRs is difficult because of low abundance in native 
cells and sample heterogeneity, making it difficult to study receptor functionality or obtain crystal 
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structures. Yeast has been favoured in this respect due to easy and cheap growth, comparable to that 
of Escherichia coli, but with superior protein processing machinery and post-translational modification 
mechanisms. The trafficking of proteins is also more similar to mammalian cells in yeast. Bacteria lack 
these properties and therefore more complex proteins, such as GPCRs, are easier to express and study 
in yeast. 
GPCR research, and membrane protein research in the wider context, has proven to be successful in 
yeast at large and continues to grow to this date. Several membrane structures have been solved using 
yeast – mainly Saccharomyces cerevisiae and Pichia pastoris – including Adenosine A2A [35]. However, 
there are still many obstacles to overcome when expressing membrane proteins in recombinant 
protein production hosts, such as different glycosylation patterns [36]. The lipid role in membrane 
protein function has also gained more interest recently and with more tools available yeast has 
provided to be useful in this respect as well. This review will outline the technological developments 
relevant to GPCR research in yeast. 
 
1.4.2. An overview of GPCR expression optimisation in yeast 
 
Although yeast are very good  at producing recombinant protein in high yield once the protein 
expression is optimised, the level of optimisation can vary greatly depending on the protein and other 
factors relating to the host. The first variable to be selected is usually the host itself. When the goal of 
the study is to obtain protein for structural studies, Pichia pastoris is usually the host of choice for its 
ability to grow to high densities and therefore higher production yields [37, 38]. However, 
Saccharomyces cerevisiae is better researched and adapted to genetic manipulation, and is often 
selected if the protein production in P. pastoris is troublesome. The functional GPCR studies which do 
not necessarily require high production yield are also carried out in S. cerevisiae because of genetic 
tools available. The construction of the MMY strains was no exception.  
The strain background also has to be considered as there are myriad of wild-type and engineered 
strains available. The most popular backgrounds are various deletion strains. For example, if further 
engineering is desired, the deletions or mutations in selectable marker genes are advantageous; if 
protein degradation is an issue, a protease deficient strains are often chosen.  
Several growth conditions can be optimised to increase production yield and quality, for example 
temperature and medium composition, such as addition of a ligand, DMSO or other supplements [38]. 
The need for a signal to direct the mammalian GPCR through the correct expression pathways and 
eventually trafficking to the plasma membrane was recognised early on. The reason behind using a 
yeast secretion signals was that the mammalian protein signals may not be recognised in a foreign 
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host. To use amino-terminal sequences of either Ste2 receptor or the mating factor α (MFα), also 
referred as the α pheromone, was an intuitive choice because the mammalian GPCR would be 
expected to go through the same translation pathway as the native GPCR. The amino-terminal 
sequence of the Ste2 receptor was used either as replacement or as a fusion protein [12, 39, 40]. 
However, Ste2 leader sequence did not always produced a clear advantage over a wild type construct 
[12]. The MFα from S. cerevisiae, on the other hand, is routinely used in S. cerevisiae, P. pastoris and 
S. pombe expression vector designs and are also included in standard commercial vectors such as 
pPICZα. 
 
1.4.3. The beginning of GPCR research in yeast  
 
The first reported successful signalling of a mammalian GPCR in yeast was published in 1990 by King 
et al. [39]. In this study β2-AR was co-expressed with rat GαS subunit under strong promoters GAL1 and 
CUP1 respectively in gpa1Δ cells and was shown to induce physiological changes associated with the 
pheromone signalling pathway activation upon agonist stimulation and blocked by an antagonist. The 
N-terminus of β2-AR was replaced with the Ste2 N-terminus to increase the receptor’s expression to 
the plasma membrane (presumably) in S. cerevisiae and S. pombe [39, 40]. A patent was filed and 
granted based on this work [41], however some groups in academia and industry have struggled to 
replicate this work (GSK archive). The Strain 8c used in original work is not publicly available and the 
experiments in W301-1A strain failed to show dose-dependent response to isoprenaline. As shown in 
published work, the full length mammalian Gαs do not provide enough contacts for efficient Gα 
sequestration of yeast Gβγ (reviewed in [1]). 
In summary, β2-AR has been expressed in Saccharomyces cerevisiae [39], Schizosaccharomyces pombe 
[40], and Pichia pastoris [42] but functional studies and application for high-throughput screening have 
not been successful. 
 
1.4.4. Notable functional GPCR studies in yeast 
 
Since the engineering of MMY strains and protocol development many GPCRs have been tested and 
compared to mammalian cell assays at GSK. The targets included well known GPCRs as well as orphan 
GPCRs. Examples include adenosine A2A, cannabinoid receptors CB1 and CB2, Melatonin ML1B, 5-HT1A, 
5-HT1D, somatostatin sst2 and sst5, P2Y1, P2Y2, GPR55, FFA2, GPR41, GPR43 and many others [2, 43-45]. 
The stability of the yeast assay has been demonstrated on cannabinoid receptors which produced 
consistent pEC50 values over several years [46]. 
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In addition to the functional studies and screening programmes developed for GPCRs in yeast at GSK, 
several other groups used the engineered yeast for functional studies and have described several novel 
aspects of GPCR biology. The adenosine A1 receptor was assessed for its coupling to three different 
signalling pathways when stimulated with two agonists R-PIA and VCP-189 [47]. The rat muscarinic M3 
receptor was shown to couple to 3 out of 5 strains tested, representing the coupling of the M3 to G 
proteins consistent with coupling described in mammalian cells [48]. The actions of agonist carbachol 
and antagonists atropine, scopolamine, and pirenzepine were also assessed. The antagonists displayed 
a range of modulation on M3 from inverse agonist, to neutral antagonist and a week agonist in different 
MMY strains. The findings were confirmed in mammalian cell assays, albeit different ligand potencies. 
A novel action of the aforementioned ligands on chimeric Gα12 strain has shown that the yeast system 
can be useful in determining signalling bias of ligands [48].  
Other notable GPCR studies in engineered yeast has been published on family B GPCRs. For example 
GLP-1 receptor involved in diabetes was shown to have comparable pharmacology in yeast with that 
in mammalian cells. The yeast assay was used to show GLP-1 coupling to both GαS and Gαi1. 
Furthermore, several natural and synthesised ligands indicated preferential induction of coupling to 
Gαi1 with the exception of liraglutide, a GLP-1 mimetic, and also some allosteric modulators displayed 
reduced efficacy in the Gαi1 strain. Both these observations provide more insight into mechanisms of 
adverse symptoms associated with the therapeutic use of these ligands [49]. Another case study 
involving CLR and accessory RAMP proteins showed bias towards coupling to certain Gα strains 
depending on the bound ligand. This is an interesting example showing how yeast can further our 
understanding of pharmacology in complex systems where two recombinant proteins may need to be 
co-expressed [50]. 
 
1.4.5. Lipid role in GPCR functionality – the future direction 
 
The first crystal structure of β2-AR has reported a presence of lipids, including cholesterol, packed in 
between the receptors [4]. However, long before the structural evidence emerged it was postulated 
that cholesterol plays a role in GPCR signalling. Cholesterol can have direct effects through binding to 
residues on the receptor and indirect effects by changing the properties of the surrounding membrane 
environment. For example cholesterol can change the thickness of lipid bilayer and affect lipid bilayer 
curvature stress [51, 52]. 
Overall, the cholesterol binding sites, and therefore conformational effects on the receptor, are 
receptor-dependent although they tend to be at the hydrophobic residues. The cholesterol 
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concentration-dependent effects have been shown on β2-AR and serotonin 1A receptor by simulations, 
affecting its dimerisation in terms of plasticity and flexibility of dimer conformation as well as stability 
of dimer interactions [51, 53]. In the absence of cholesterol the dimer conformation of serotonin 1A 
receptor was more rigid and changed with increasing cholesterol concentrations. However, in very 
high concentrations of cholesterol less stable dimer formations were observed. This has physiological 
relevance since cells in different tissues vary in their cholesterol content, contributing to an 
explanation of age and tissue-dependent responses to various ligands. Similar simulations also showed 
the effects of cholesterol on dimersiation of chemokine receptor type 4 (CXCR4). Cholesterol was 
required to form correct symmetry of the dimers for functional activation of CXCR4 [54]. Similarly the 
helices involved in dimer formation of β2-AR changed upon increasing concentrations of cholesterol. 
In the absence of cholesterol the dimers formed between helices H4 and H5 and shifted towards H1 
and H2 formation upon addition of cholesterol, which is likely have an effect on GαS protein coupling 
because pocket formed by H3, H5 and H6 is important in this interaction as discussed later [53, 55]. 
Yeast also produce a similar sterol called ergosterol which is important in membrane protein function. 
Some effects of sterol are also thought to be a result of direct binding to membrane proteins and some 
effects of plasma membrane plasticity are also postulated. This has been shown by genetically 
modifying sterol synthesis pathway in yeast to produce cholesterol or ergosterol intermediates [56-
59]. This was achieved by deleting ERG6 and ERG5 genes of ergosterol biosynthesis pathway and 
replacement with mammalian genes DHCR7 and DHCR24. These gene products were identified as key 
enzymes that saturate the sterol intermediates at positions C-7 and C-24 in cholesterol but not in 
ergosterol synthesis, while Erg5 introduces double bond at position C-22 and Erg6 adds methyl group 
at position C-24 in ergosterol synthesis therefore also competes with Dhcr24 for the substrate.  
The Tat2, a high affinity tryptophan permease, Can1, another amino acid permease which plays role in 
canavanine resistance, and Pdr12, an ABC transporter which can efflux weak amino acids under toxic 
accumulation in the plasma, were the subjects of the first study by Souza et al. [56]. For Tat2, 
cholesterol was an adequate replacement of native sterol for function comparable nearly to that of 
wild type strain levels, but ergosterol intermediates in erg5/6Δ strain were not. On the other hand 
Pdr12 and Can1 had a strict preference for ergosterol and lost their functions when the synthesis 
pathway was disrupted. The methyl group at C-24 appeared to be required for Pdr12 function. All 
proteins investigated were localised to the plasma membrane in the presence of cholesterol suggesting 
the trafficking was not affected [56].  
The second study investigated the native yeast GPCR – the Ste2. It was found that MFα retained 
potency on this receptor in both WT and cholesterol producing strain. However, the efficacy of it was 
lower in the latter group – the maximum response at 10-5M MFα was around half of that observed in 
the WT yeast [58]. 
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Another study investigated if mammalian recombinant protein production can be improved by 
engineering P. pastoris to produce cholesterol using the same genetic engineering strategy described 
above. The improvement of functional sodium-potassium pump production was apparent from just 
comparing the expression patterns on western blots. As previously mentioned, in ergosterol producing 
strains the maximum expression was at 8h post-induction, while in cholesterol strain the production 
increased over time, producing much higher yields over 72h post-induction. That was attributed to 
cholesterol interaction with the β subunit. This effect seems to stabilise the expression of the β subunit 
and the overall assembly of the β1α3 dimer, whereas in ergosterol producing strains the β expression 
was poor, leading to the retention of both subunits in the ER and consequent degradation. The radio-
ligand binding assay on intact cells confirmed that cholesterol-producing strain demonstrated 2.5 to 
4-fold increase in binding sites compared to the wild type and protease deficient strains producing 
ergosterol [57].  
The structural, functional and simulation studies clearly show that cholesterol is required for GPCR 
function and more details are emerging on individual receptors. Although it is possible to reconstitute 
a more native-like lipid environment during the purification of membrane proteins for structural 
studies, this work has implications for functional GPCR studies in whole cell. 
 
1.5. The signalling of β-adrenoceptors 
 
A great effort has been focused on determining signalling mechanisms of GPCRS at a molecular level 
in order to design better drugs. The β-adrenoceptors are archetypical class A GPCRs on which many 
structural and mechanistic functions of the GPCRs have been elucidated. The structural studies is quite 
a laborious process and has required some modification of the receptor, for example, replacement of 
highly motile domains with stabilising proteins or antibodies, or replacement of individual residues to 
increase thermostability. The number of crystal structures increased immensely from 2007 when β2-
AR structure was reported [4] and although crystal structures give only snapshots of receptor’s active 
or inactive state in the presence or absence of various ligands, combined with other functional studies 
the picture of how GPCRs bring about their function is becoming clearer.  
The signal transduction through β-adrenoceptors can be divided into several stages: 1) binding of the 
ligand; 2) transition between inactive (R) and active (R*) states; 3) conformational change-induced 
coupling to the signalling molecules, 4) activation of effector proteins and regulation of second 
messenger cAMP. In the case of β1-AR and β2-AR it can be the G protein trimer or β-arrestin. The 
relationship between binding of a ligand and cellular response is not linear because the signal is 
amplified by cAMP and different cell types will respond to the same type of stimulation differently due 
to different receptor expression levels and other factors, such as lipids, enzymes etc.  
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To characterise this pharmacologically the operational model of ligand binding was developed by Black 
et al in 1985 [60, 61]. It describes the relationship between the agonist concentration and receptor 
binding, and subsequently, the amount of agonist-receptor complex and the response. In this model, 
the agonist is designated a modulator role and the conduit to the GPCR, while the signalling molecule, 
in case of β-ARs a G protein or a β-arrestin, is the guest protein denoted in E. Below an overview of 
structural of each of these stages is given. 
This is important to bare this in mind when interpreting results of ligand activity on the same receptor 
in different assays and cell backgrounds, including the yeast. The advantages of assessing compound 
ability to induce coupling to different Gα proteins in yeast is that the cellular background is uniform 
and that it lacks other interacting proteins. The significance of this is that cross-talk with signalling 
pathways in mammalian cells can make the interpretation of data challenging and can also lead to 
some discrepancies when comparing mammalian assay data to that of yeast.  
As already mentioned in section 1.3.6 the MMY yeast Gα subunit Gpa1 has been replaced with a 
chimeric Gα proteins which contain 5 amino acids of human Gαs at the C terminus to provide specificity 
and efficiency for human GPCR coupling to yeast signalling cascade. The sections below provide more 
detail on how the domains of β-adrenoceptors change upon binding to the ligands and how the 
receptor couples to the trimeric G protein.  
 
1.5.1. Catecholamine binding site 
 
The binding pocket of all adrenergic receptors is an archetypical class A GPCR binding pocket tucked 
inside the membrane segment of the receptor between the transmembrane helices. There are two 
main entities of the catecholamines – the catechol ring ‘head’ and ethanolamine ‘tail’. The 
catecholamine binding pocket is highly conserved at the residues that interact with the molecule, but 
the residues that move outside this region during the conformational transition to the active state are 
different. 
Figure 1.5.The operational model 
developed by Black and colleagues. 
Figure taken from paper by Kenakin 
et al [61] 
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Crystallographic studies have shown several important residues involved in ligand binding. Ser5.43 (5.43 
according to the Ballesteros-Weinstein numbering system [62], S212 in β1-AR, S204 in β2-AR according 
to the protein sequence) on H5 (helix 5) formed a bridge between H5 and H6 via hydrogen bond with 
Asn6.55 (N310 in β1-AR, N293 in β2-AR). The rotational change allowing this occurred when full agonist, 
partial agonist, or an inverse agonist was bound, but not when antagonists was present in the binding 
pocket [63, 64]. 
Another closely located Ser5.46 (S215 in β1-AR, S207 in β2-AR) residue was bound directly to full 
agonists, via hydrogen bond to the catechol moiety ‘head’. No other activity modulators, including 
partial agonists, interacted with this residue, which is what is thought to be crucial for full agonistic 
effect of a ligand [63]. Ser5.46 is also seen in a different rotational conformation when it’s not bound to 
a full agonist.  
The contraction of the binding pocket by 1Å [63] was also observed with full and partial agonists within 
the β1-AR binding pocket. This contraction in thought to be important in the activation process and the 
authors suggest that because antagonist molecules have a greater distance between the head group 
and amine group they are unable to make this contraction.  
The inverse agonists bucindolol and carvedilol have a β-hydroxyl group between the head group and 
the secondary amine as a general structure, also characteristic of other antagonists. The β-hydroxyl 
forms a potential hydrogen bond with Asn7.39 on H7 (N329 in β1-AR) and the amine form a hydrogen 
bond with Asp3.32 on H3 (D121 in β1-AR) (Figure 1.6) [64]. However, their aromatic substituents at the 
amine ends make additional contacts in the extended ligand pocket to residues in helices 2, 3, 7, and 
ICL2 [64] which is different to other antagonists. The authors of the paper believe that this explains 
their ability to signal through non-G protein signalling pathways, mainly the β-arrestin signalling 
pathway, but the exact conformational changes of the receptors for this event are still unknown.  
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1.5.2. Transitioning between the inactive (R) and active (R*) states and coupling to GαS  
 
The current understanding of GPCR-G protein trimer interaction is that an agonist bound receptor 
stabilises coupling to the G protein trimer and in turn bound Gα stabilizes the active conformation of 
the receptor increasing the receptor’s affinity to the ligand [55, 65]. Crystal studies of β-adrenoceptors 
also showed that a large 14Å outward movement of intracellular portion of H6 was associated with 
receptor activation and binding of GαS-Gβγ trimer [55]. Furthermore, the GαS protein’s C-terminal 5α 
helix has been shown to insert into a pocket formed by intracellular portions of H3, H5, H6 and 
intracellular loop 2 (ICL2). Important residues of the 5α helix of the GαS protein include Tyr391, which 
is within the last 5 amino acid region of C-terminus and is present on the chimeric GαS in MMY15 
(Figure 1.7) [2, 55]. Additional contacts with Glu384 and Asp381, which is highly conserved residue on 
the 5α helix of GαS (Figure 1.7), are also shown in the structure, although not discussed in the paper 
[55]. The efficacy of agonists are thought to be determined by how well they are able to change the 
conformational state of the receptor and stabilise this pocket for GαS coupling [65]. The formed 
complex allows the release of GDP from the Gα switch pocket; the GTP binds to nucleotide-free Gα 
Figure 1.6 Catecholamine binding 
pocket as shown in crystal structure of 
β1-AR. The stabilised turkey β1-AR was 
co-crystallised with antagonist 
bucindolol [A], [B], and inverse agonist 
carvedilol [C], [D]. The key interacting 
residues are discussed in 1.5.1. Adapted 
from [64]. 
31 
 
which is then able to disassociate from Gβγ and activate adenylate cyclase causing cAMP production 
as already mentioned in section 1.1.2.  
Figure 1.7 C-terminal sequence alignment of different Gα proteins including yeast Gpa1. The green shading 
indicates 5α helix, as mapped out in [26], which was shown to be central to GPCR-G protein trimer coupling [55]. 
The red shading indicates the C-terminal amino acids which were used to engineer chimeric Gαs in MMY strains 
[2]. The blue arrows indicate important residues on GαS which were shown by crystallography studies to make 
contacts with the β2-AR [55].  
 
1.6. Project aims and objectives 
 
The yeast functional GPCR assay is an excellent tool in drug discovery for G protein-coupled receptors. 
However, not all GPCRs have been successfully adapted to this system due to low or absent functional 
expression. The aim of this study was to optimise the functional expression of adrenergic receptors 
that had previously been difficult to express and/or characterise pharmacologically in these yeast 
strains. Further understanding of the host’s response to protein expression was sought after along this 
process. 
This following objectives were set to achieve this: 
• First of all, a set of experiments were performed in order to understand the assay parameters 
in well coupling α2A and α2B adrenoceptors. The objective was to establish what is a receptor 
dependent variable and how technical parameter optimisation can improve assay signal read 
out (Chapter 3). 
 
• Secondly, a systematic comparison between different expression vector designs was 
performed to identify whether the addition of the mating factor α (MF-α) leader sequence to 
the amino-terminus of the β1- and β2-adrenoceptors is required to produce a pharmacological 
response in the yeast assay (Chapter 4). 
 
Tyr391 Asp381 Glu384 
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• Thirdly, when the functional expression of the β-adrenoceptors was achieved, a 
pharmacological characterisation was performed to gain more insight into the signalling 
mechanisms of these receptors (Chapter 5) 
 
• Lastly, to increase the number of pharmacological targets compatible with the yeast functional 
assay, strategies were designed to further engineer the host to provide a more native-like 
environment for the G protein coupled receptors (Chapter 6).  
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Chapter 2 – Materials and Methods 
 
2.1. Materials 
 
2.1.1. Yeast strains, growth and maintenance  
 
2.1.1.1. MMY yeast strains 
 
The yeast strains were obtained from the GSK archive BioCat [46] and are listed below. 
Table 2.1 The summary of MMY yeast strain genotypes and phenotypes 
Strain Genotype   Corresponding 
human  
Gα subunit type 
Signal transduction  
in human cells 
W303-1A               MATa his3 ade2 leu2 trp1 ura3  can1   
MMY9 W303-1A trp1 fus1::FUS1-HIS3 LEU2::FUS1-
lacZ far1∆::URA3 gpa1∆::ADE2 sst2∆::URA3 
ura3::p140 
  
MMY11 MMY9 ste2∆::G418R   
MMY12    MMY11 TRP1::GPA1   
MMY14 MMY11 TRP1::Gpa1/Gα q(5)  q Activation of phospholipase C 
MMY15 MMY11 TRP1::Gpa1/Gα s(5) S Activation of adenylate cyclase 
MMY16 MMY11 TRP1::Gpa1/Gα 16(5) 16 Activation of phospholipase C 
MMY19 MMY11 TRP1::Gpa1/Gα 12(5) 12 Activation of the Rho GTPases 
MMY20 MMY11 TRP1::Gpa1/Gα 13(5) 13 Activation of the Rho GTPases 
MMY21 MMY11 TRP1::Gpa1/Gα 14(5) 14 Activation of phospholipase C 
MMY22   MMY11 TRP1::Gpa1/Gα o(5) O Inhibition of adenylate cyclase 
MMY23    MMY11 TRP1::Gpa1/Gα i1(5) i1 Inhibition of adenylate cyclase 
MMY24 MMY11 TRP1::Gpa1/Gα i3(5) i3 Inhibition of adenylate cyclase 
MMY25    MMY11 TRP1::Gpa1/Gα z(5) Z Inhibition of adenylate cyclase 
MMY28 MMY11 TRP1::Gpa1/Gα s(5) S Activation of adenylate cyclase 
YIG152 MMY25 URA3::pRS306GPD-ADRA2A Z  
YIG153    MMY20 URA3::pRS306GPD-ADRA2B 13  
Strain Phenotype   
MMY9 Ade+, Trp-, Leu+, Ura-, His+ 
  
  
MMY11 Ade+, Trp-, Leu+, Ura-, His+   
MMY12-28 Ade+, Trp+, Leu+, Ura-, His- (upon activation of GPCR becomes His+)  
 
For the data presented in Chapter 3, the MMY strains with genome integrated ADRA2A or ADRA2B 
receptors were used. The ADRA2A was integrated into MMY25 (pRS306GPD-ADRA2A) and ADRA2B 
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was integrated into MMY20 (pRS306GPD-ADRA2B). The resulting strains were named YIG152 and 
YIG153 respectively; this nomenclature will be used from now on to describe these strains. The 
integrations were performed and validated earlier at GSK and were stored in the GSK’s archive system 
BioCat (Cat# 118197 and 118198 respectively). 
2.1.1.2. General 
 
• Deionised water for all microbial work was obtained from a Millipore Elix Type 2 water purification 
system, unless stated otherwise.  
 
• Higher purification grade MiliQ Ultrapure Synthesis A10 Type 1 water was used where stated.  
 
2.1.1.3. Yeast extract-peptone-dextrose medium (YPD)  
 
1% Bacto-yeast extract (Cat#212750, Difco), 2% Bacto-peptone (Cat#211677, Difco) were dissolved in 
water. For plates, 2% Difco granulated agar (Cat# 214530, Difco) was added. 40% D-glucose was added 
to a final concentration of 2% after the medium had been autoclaved at 121°C for 15min and cooled 
to less than 50°C. Media were stored at room temperature for short periods, for longer periods at 4°C. 
Plates were stored at 4°C.  
40% glucose 
D-glucose (Cat# G8270, Sigma-Aldirch) was dissolved in water to make a 40% solution, filter sterilized 
(0.2 mm pore size) and stored at 4°C. 
 
2.1.1.4. 5-FOA/YPD medium 
 
The 100x 5-FOA was diluted in warm YPD to 1x concentration to make 5-FOA/YPD medium. 
100x 5-FOA 
5-Fluoroorotic acid monohydrate (5-FOA) (Cat# PC4054, Apollo Scientific) was dissolved in DMSO at 
2mg/mL for a 100x stock. 
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2.1.1.5. Complete synthetic WHAUL medium 
 
WHAUL is a complete synthetic medium that was developed at GSK and is used to grow MMY yeast 
strains. It lacks tryptophan, histidine, adenine, uracil and leucine. The medium is composed of 1x 
WHAUL liquid at pH 5.5 or pH 7.0, 1x yeast nitrogen base (YNB), 2% glucose and sterile water. The 
medium is also supplemented with 1x histidine while the GPCR receptors are not being activated. 2% 
Difco granulated agar was added if plates were desired. 
10x WHAUL liquid 
L-arginine HCl (Cat# A5131, Sigma-Aldrich) – 205mg/L; 
L-aspartic acid (Cat# A7219, Sigma-Aldrich) – 1023mg/L; 
L-glutamic acid sodium salt (Cat# 37106, BDH Biochemicals) – 1023mg/L; 
L-lysine (Cat# L5626, Sigma-Aldrich) – 307mg/L; 
L-methionine (Cat# M9625, Sigma-Aldrich) – 205mg/L; 
L-phenylalanine (Cat# P2126, Sigma-Aldrich) – 512mg/L; 
L-serine (Cat# S4311, Sigma-Aldrich) – 3837mg/L; 
L-threonine (Cat# 29578582, Molekula) – 2046mg/L; 
L-tyrosine (Cat# T3754, Sigma-Aldrich) – 307mg/L; 
L-valine (Cat# 11273495, Molekula). 
The pH was adjusted as required with NaOH pellets. 
10x YNB 
6.7g yeast nitrogen base without amino acids and ammonium sulphate (Cat# 233520, Difco) was 
dissolved in 100mL MilliQ water, filter sterilized (0.2 mm pore size) and stored at 4°C. 
100x Histidine 
2mg/mL L-histidine monohydrochloride monohydrate (Cat# M49020584, Molekula) solution in MiliQ 
water, filter sterilized (0.2 mm pore size). 
100x Uracil 
2mg/mL L-uracil (Cat# M82294919, Molekula) solution in MiliQ water, filter sterilized (0.2 mm pore 
size). 
100x Tryptophan 
2mg/mL L-tryptophan (Cat# M56990934, Molekula) solution in MiliQ water, filter sterilized (0.2 mm 
pore size). 
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2.1.1.6. Yeast transformation reagents 
 
1M LiAc 
1M lithium acetate (Cat# L6883, Sigma-Aldrich), autoclaved and stored at room temperature. 
 
50% PEG 
50g PEG3350 (Cat# 88276, Fluka) were dissolved in distilled water to a final volume of 100 mL, 
autoclaved and stored at room temperature. 
10x TE 
0.1M Tris-HCl (pH 7.5), 0.01M EDTA. 
LiAc-TE  
5mL 1M LiAc, 5mL 10 x TE, 40mL H2O. 
LiAc-PEG-TE 
5mL 1M LiAc, 5mL 10x TE, 40mL 50% PEG. 
ssDNA 
1mL aliquots of single-stranded DNA (Salmon Testes DNA; Cat# D1626 Sigma-Aldrich)  were heated at 
95°C for 10 min and placed on ice if not used immediately. 
 
2.1.2.  FD-glu GPCR functional assay medium, reagents, ligands 
 
2.1.2.1. FD-glu GPCR assay medium 
 
The FD-glu assay medium consisted of 1x WHAUL pH 7.0 liquid, 1x YNB, 1x BU salts pH 7.0, 2% glucose, 
10-100µM FD-glu, 2-50mM 3-AT, water.  
10x Buffering (BU) salts 
46.5g Na2HPO4•2H2O and 30g NaH2PO4 were dissolved in 995mL water, the pH adjusted to 7.0. This 
solution was used to buffer the assay medium as pH 7.0 is optimal for human GPCR receptors. 
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1M 3-AT 
The powdered 3-AT was dissolved in water according to manufacturer’s instructions, then aliquoted 
into 50mL falcon tubes. Stored at -20°C. 
 
10mM FD-glu 
5mg of fluorescein di-β-D-glucopyranoside (FD-glu) (Cat# F-2881, Life Technologies) powder were 
dissolved in 761.5µL of 100% DMSO (Cat# D2650, Sigma-Aldrich). Stored at -20°C. 
 
Note 1: Protocols for preparing yeast culture media were taken from “G Protein-Coupled Receptors in 
Drug Discovery” (2009) Chapter 15: Yeast Assays for G Protein-Coupled Receptors by Simon J. Dowell 
and Andrew J. Brown [46]. 
2.1.2.2. FD-Glu GPCR assay plates and other consumables 
 
Greiner black wall-clear bottom sterile 96-well plates (Cat# 655090, Greiner) and 384-well plates (Cat# 
781090, Greiner) were used.  
Breathe-Easy membrane (Cat# Z380059, Sigma-Aldrich) were used for sealing the plates. 
2.1.2.3. FD-glu GCPR assay compounds 
 
Different compound panels were obtained for experiments with the α2-AR receptors and the β1-AR 
receptors. All compounds tested at GSK were dissolved in 100% DMSO. The compounds from both 
panels were supplied pre-dispensed on black-walled clear bottom Greiner 384-well plates. 
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Table 2.2 The panel of adrenoceptors α2A and α2B interacting compounds used in Chapter 3 experiments. The 
compounds without the generic name are GSK proprietary compounds.   
Compound ID Generic 
/other name 
Receptor interaction 
C1 GSK Library C Unknown 
C2 GSK Library C Unknown 
C3 GSK Library C Unknown 
C4 GSK Library C α2 binder 
C5 xylazine α2 partial agonist  
C6 tizanidine α2 agonist 
C7 GSK Library C Unknown 
C8 yohimbine α2 antagonist 
C9 GSK Library C Unknown 
C10 GSK Library C Unknown 
C11 GSK Library C Unknown 
C12 mianserin α1 antagonist 
C13 GSK Library C α2 agonist 
C14 GSK Library C α2 agonist 
C15 GSK Library C α2 agonist 
C16 idazoxan α2 antagonist 
C17 GSK Library C α2 agonist 
C18 GSK Library C α2 agonist 
C19 UK 14,304 
(Brimonidine) 
α2A full agonist α2B partial agonist 
C20 GSK Library C Unknown 
C21 GSK Library C α2 binder 
C22 octopamine TA1 receptor agonist 
C23 GSK Library C α2 agonist 
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Table 2.3 The panel of adrenoceptors β1 and β2 interacting compounds used in Chapter 6 experiments. 
Agonists   
   
Compound ID  Generic name Receptor interaction (from IUPHAR) 
C21 orciprenaline  β2 agonist 
C22 xamoterol β1 partial agonist 
C25 dobutamine  β1 and β2 partial agonist 
C31 procaterol  β2 agonist 
C33 zinterol  β2 agonist 
C34 fenoterol  β2 agonist 
C36 terbutaline  β2 partial agonist 
C39 mirabegron  β1 and β2 agonist 
C40 indacaterol  β1 and β2 agonist 
C42 isoprenaline  β1 and β2 full agonist 
C46 pindolol  β1 and β2 partial agonist 
   
Antagonists   
   
Compound ID  Generic name Receptor interaction (from IUPHAR) 
C20 levobetaxolol  β1 and β2 antagonist 
C23 labetalol  β1 and β2 antagonist 
C24 metoprolol  β1 and β2 antagonist 
C26 nadolol  β1 and β2 antagonist 
C27 propranolol  β1 and β2 antagonist 
C28 alprenolol  β2 antagonist 
C29 sotalol  β1 and β2 antagonist 
C30 carvedilol  β1 and β2 antagonist 
C35 levobunolol  β1 and β2 antagonist 
C37 esmolol β1 antagonist 
C38 propafenone  β1 and β2 antagonist 
C41 atenolol  β1 and β2 antagonist 
C43 acebutolol β1 antagonist 
C44 practolol β1 antagonist 
C48 bupranolol  β1 and β2 antagonist 
C49 betaxolol  β1 and β2 antagonist 
 
The concentration of ligands ranged from 10mM to 169nM diluted in 3-fold dilutions, except β-AR 
compound panel which ranged from 10mM to 6nM. 
For colony screening and assay optimisation at Aston brimonidine (UK 14,304) and isoprenaline were 
purchased from Sigma-Aldrich (cat# U104 and I6504 respectively). Brimonidine was dissolved in 100% 
DMSO. Isoprenaline was dissolved in water and supplemented with 1mM ascorbic acid to minimise 
degradation. 10mM stocks were aliquoted and stored at -20°C. 
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2.1.3.  Molecular biology 
 
2.1.3.1. Bacterial transformation  
 
Escherichia coli strains 
XL10-Gold Ultracompetent (Cat# 200315, Agilent) and XL1-Blue Competent (Cat# #200249, Agilent) 
Escherichia coli cells were available in the laboratory, and were prepared as chemically competent cells 
according to the protocol detailed section 2.2.3.1. 
NEB® 5-α F'Iq Competent E. coli (High Efficiency) (Cat# C2992H, NEB) commercially prepared E. coli 
were used for the ligation of ERG6 plasmids. 
 
Luria Bertani (LB) -/+ ampicillin (LBA) 
20g/L of LB broth powder (Cat# l3022, Sigma-Aldrich), which contains 10g/L tryptone, 5 g/L yeast 
extract and 5 g/L NaCl, was dissolved in water. 15g/L of Difco granulated agar was added when making 
plates. For selection of transformed cells, the medium was supplemented with 100mg/L of ampicillin 
(LB-amp media).  
 
Super optimal broth (SOB)  
SOB medium was prepared by enriching LB medium with 186mg/L of KCl, 10mM MgCl2, and 10mM 
MgSO4. This medium was used for preparation of chemically competent E. coli cells [66]. 
Super optimal broth with catabolite repression (SOC)  
The SOC medium was prepared by supplementing SOB medium with 2% glucose. This medium was 
used to recover heat-shocked E. coli cells during transformation experiments[66].  
 
1x TB buffer 
10mM HEPES, pH 6.7, 15mM CaCl2, 55mM MnCl2, 250mM KCl, MiliQ water. 
The solution was filter sterilised and stored at 4°C when not in use.  
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Note 2: The materials for preparing chemically-competent E. coli cells were taken from the European 
Molecular Biology Laboratory (EMBL) website [66], Cloning methods section. The procedures and 
recipes were adopted from the original publication by Inoue et al. (1990), Gene, 96:23-28. 
2.1.3.2. Cloning enzymes and other reagents 
 
Enzymes 
Table 2.4 The list of enzymes used for molecular biology 
Name  Application Manufacturer Cat# Buffer 
AvrII Restriction Clontech 1022A Buffer K 
BalI Restriction Clontech 1009A BalI buf. 
BamHI Restriction Fermentas ER0051 BamHI 
BshTI (AgeI) Restriction Fermentas ER1461 Orange 
EcoRI Restriction Fermentas ER0271 EcoRI 
HindIII Restriction Fermentas ER0501 Red 
NcoI Restriction Fermentas ER0571 Tango 
NdeI Restriction Fermentas ER0581 Orange 
NotI Restriction Fermentas ER0591 Orange 
PvuII Restriction Fermentas ER0631 Green 
SalI Restriction Fermentas ER0641 Orange 
SmaI Restriction Fermentas ER0661 Tango 
SpeI (BcuI) Restriction Fermentas ER1251 Tango 
Van91I Restriction Fermentas ER0711 Red 
XagI (EcoNI) Restriction Fermentas ER1301 Red 
XbaI Restriction Fermentas ER0681 Tango 
XhoI Restriction Fermentas ER0691 Red 
FastAP Phosphatase/cloning Fermentas EF0654 FastAP 
Rapid ligation kit Ligation/cloning Fermentas K1422 5x RL buf. 
Gibson Assembly 
cloning kit Ligation/cloning NEB E2611  
 
Note 3: Fermentas is part of Thermo Fisher Scientific group. The supplier of Fermentas enzymes is 
Fisher Scientific UK Ltd, Loughborough, United Kingdom. 
Note 4: The Takara enzymes and vectors were obtained from Takara Bio USA, Inc., Saint-Germain-en-
Laye, France. 
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DNA marker 
 
GeneRuler DNA Ladder Mix, ready-to-use 
GeneRuler 1kb DNA ladder (Cat# SM0331, Thermo Scientific) was used for the reference of DNA 
fragment size, pictured below: 
 
 
Tris-Acetic acid-EDTA buffer gel electrophoresis: 
50x stock TAE: 40mM Tris-HCl, 20mM Acetate, 1mM EDTA. 
1x working solution TAE: 20mL 50x TAE, 980mL water. 
1% agarose: 1g agarose (Cat# A40702, AGTC Bioproducts) per 100mL of 1xTAE was heated in 
microwave to dissolve the powder. After the agarose cooled down, theRedSafe DNA stain (Cat# 
BT41003, Cambridge Bioscience) was added at 1µL per 10mL. 
  
Figure 2.5 GeneRuler 1kb DNA ladder. 
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Plasmid releasing reagent for yeast plasmid isolation 
2% Triton X-100, 1% SDS, 100mM NaCl, 10mM Tris-HCl (pH 8.0), 1mM Na2-EDTA. 
 
2.1.3.3. Polymerase chain reaction (PCR) 
 
PCR reactions 
0.5µL of Herculase II fusion DNA polymerase (Cat# 600675, Agilent) was used per 25µL PCR reaction, 
with 1x Herculase II reaction buffer 0.2mM dNTPs (Cat# 18427-013, Invitrogen), 250nM of Forward 
and Reverse primer. For b1_for_1 and b1_rev_1 primers 10% DMSO (Cat# D2650, Sigma-Aldrich) was 
also added. For amplification from the plasmid, 29ng DNA template was used. For genomic detection 
– between 100-250ng of gDNA was used. The composition of the reaction was determined based on 
the manufacturer’s recommendations.  
Primers 
All primers were synthesised by Invitrogen, in Paisley, United Kingdom (part of Thermo Fisher Scientific 
Ltd). 
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Table 2.6 List of primers 
For p426GPD plasmids 
 
Name 
 
Gene 
 
Application 
 
Sequence from 5' to 3' Direction 
Optimised 
Annealing 
Temp 
PCR 
Protocol 
b1_For_1 ADRB1 Cloning AAAAAAGGATCCCACCATGGGCGCGGGGGTG For 65°
C 1 b1_Rev_1 ADRB1 Cloning AAAAAAGGATCCCTACACCTTGGATTCCGAGGCG Rev 
b1_For_2 ADRB1 Cloning AAAAAAGAATTCACCATGGGCGCGGGGGTGCTC For 65°
C 1 b1_Rev_2 ADRB1 Cloning AAAAAAGTCGACCTACACCTTGGATTCCGAGGC Rev 
b2_For_1 ADRB2 Cloning AAAAAAGAATTCACCATGGGGCAACCCGGGAACG For 65°
C 1 b2_Rev_1 ADRB2 Cloning AAAAAAGTCGACTTATAGCAGTGAGTCATTTGTAC Rev 
Primer 7 ADRB1 Sequencing CAATGACACACAGGGTCTCG Rev   
Primer 8 ADRB1 Sequencing TCCTTCTTCTGCGAGCTGTG For   
Primer 9 ADRB1 Sequencing TCAAGACGCTGGGCATCATC For   
Primer 10 ADRB2 Sequencing CAGCACATCAATGGAAGTCC Rev   
Primer 11 ADRB2 Sequencing GACTTTTGGCAACTTCTGGTG For   
Primer 12 ADRB2 Sequencing CTAACGTCTTGAGGGCTTTG Rev   
Primer 13 ADRB2 Sequencing CATTGTGCATGTGATCCAGG For   
For ura3 deletion 
 
Name 
 
Gene 
 
Application 
 
Sequence from 5' to 3' 
Direction 
Optimise
d 
Annealin
g Temp 
PCR 
Protocol 
1_URA3 URA3 Genomic 
detection 
CCTAGTCCTGTTGCTGCCAA Rev 
60°C 2 2_URA3 URA3 Genomic 
detection 
TTCCCAGCCTGCTTTTCTGT For 
5_YAP1 YAP1 Genomic 
control 
TGTCAGGTGATGATGGCAGC For 
60°C 2 
6_YAP1 YAP1 Genomic 
control 
CCGAGATGGGTTTCTTGGGA Rev 
For DHCR7/24 gene integration 
 
Name 
 
Gene 
 
Application 
 
Sequence from 5' to 3' Direction 
Optimised 
Annealing 
Temp 
PCR 
Protocol 
3_ERG5 ERG5 Cloning CCGCATTGACTTCGACGGAT For 
57°C 3 
4_ERG5 ERG5 Cloning GCTGTCATGCTCGCCTTCA Rev 
3_ERG6 ERG6 Cloning AAAAAAgagctcCCGATTTTGGGCAGTCCTCT For 
60°C 3 
4_ERG6 ERG6 Cloning AAAAAAgaattcAATACTGGTCGTTTGCCACG Rev 
Primer 24 erg5prom Sequencing GCATATAGACGCAGGTTTGG Rev   
Primer 25 erg5prom Sequencing CGCTGCTGACAAAACATAGC For   
Primer 26 DHCR24 Sequencing CCACCAACAGTCAAATCATCC Rev   
Primer 27 DHCR24 Sequencing CTATTGGTTGGACATTGCCAG For   
Primer 28 DHCR24 Sequencing CGTCACCTTTTGGATGAACC Rev   
Primer 29 DHCR24 Sequencing CCAAATCAACCTGGTATGGT For   
Primer 30 erg5term Sequencing TTCAGGAAACCAAAGCTGGCAG Rev   
Primer 31 erg6prom Sequencing GGATGCGTAAGGTCTTAAGAG Rev   
Primer 32 erg6prom Sequencing TCGGTAAACGGAAGACTA For   
Primer 33 DHCR7 Sequencing GTAAACAAAGTTGCGTCACC Rev   
Primer 34 DHCR7 Sequencing CCAATGTTCTATCTCACATCC For   
Primer 35 DHCR7 Sequencing GGGTTTGGTTGGTTACTACA Rev   
Primer 36 DHCR7 Sequencing GGGTTTGGTTGGTTACTACA For   
Primer 37 erg6term Sequencing GAATTCGCTGTAGGGGAGCA Rev   
Primer 38 ERG5 Sequencing GACTTCTCCAGTAATTGGGTC Rev   
Primer 39 erg5prom Genomic detection 
GGAGTCAGAGTCATCCAAATC For 
57°C 4 
Primer 40 erg5term Genomic detection 
GTATCATCTACCGCTGTCAT Rev 
Primer 41 ERG6 Sequencing GTTGCTTCTTGGGAAGTTTGGG Rev   
Primer 42 erg6prom Genomic detection 
CCTTCATCTTCCTCTCCTTACG For 
57°C 4 
Primer 43 erg6term Genomic detection 
CACTTGCCGCTGTAGACAATAG Rev 
Primer 44 AUR-1C Sequencing CGGACGAACGAGAAACAGAAGT Rev   
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2.1.3.4. Vectors and plasmids 
 
Both p426GPD and p306GPD vectors have a common backbone containing the following components 
[67]: 
• A yeast GPD promoter, which in its genomic location induces the expression of the house 
keeping gene, glyceraldehyde 3-phosphate dehydrogenase;  
• multiple cloning site (MCS); 
• cytochrome C gene terminator sequence; 
• URA3 for nutrient selection; 
• 2 micron yeast replication origin; 
• AmpR for ampicillin resistance selection in E. coli. 
 
Table 2.7 List of vectors 
# Name Backbone Size 
What's 
inserted? 
Other additions/tags Cloning strategy 
1 p426GPD p426 6602 bp MCS  Deposited from GSK 
 
2 
 
p426GPD-DEST-ADRB1 
 
p426 
 
8120 bp 
 
ADRB1 
Gateway sequences 
around 
ADRB1 
 
Deposited from GSK 
3 p426GPD-HA-ADRB2 p426 7990 bp ADRB2 HA tag at 5' of ADRB2 Deposited from GSK 
4 p426GPD-MFα p426 6902 bp MCS MFα leader sequence Deposited from GSK 
 
5 
 
p426GPD-STE2L 
 
p426 
 
6647 bp 
 
MCS 
Ste2p receptor 
leader sequence, 5' 
of MCS 
 
Deposited from GSK 
 
 
 
 
6 
 
 
 
 
p426GPD-ADRB1 
 
 
 
 
p426 
 
 
 
 
8046 bp 
 
 
 
 
ADRB1 
 
Amplified from #2 using 
b1_for/rev_1 PCR primers 
with Bam HI sites at 5' 3' 
added, then digested, ligated 
 
7 
 
p426GPD-ADRB2 
 
p426 
 
7850 bp 
 
ADRB2 
 
From #3 cut and ligated using 
Bam HI into #1 
 
 
 
8 
 
 
 
p426GPD-MFα-ADRB1 
 
 
 
p426 
 
 
 
83332bp 
 
 
 
ADRB1 
 
 
MFα leader sequence 5' 
of ADRB1, in frame 
Cut from #6 at Bam HI, purify, 
cut with NcoI. #4 double-cut 
with Bam HI and Nco I. Then 
ligated. 
 
 
 
9 
 
 
 
p426GPD-MFα-ADRB2 
 
 
 
p426 
 
 
 
8140 pb 
 
 
 
ADRB2 
 
MFα leader sequence 5' 
of 
ADRB2 , in frame 
Cut from #7 at Nco I, purify, 
cut with Bam HI. #5 double 
cut with Bam HI and Nco I. 
Then ligated 
 
 
 
 
10 
 
 
 
 
p426GPD-STE2L-ADRB1 
 
 
 
 
p426 
 
 
 
 
8063 bp 
 
 
 
 
ADRB1 
 
 
 
Ste2L leader sequence 5' 
of 
ADRB1 , in frame 
Amplified from #2 using 
b1_for/rev_2 PCR primers 
with Eco RI at 5' and Sa lI at 3' 
added. Then digested, ligated 
 
 
 
 
11 
 
 
 
 
p426GPD-STE2L-ADRB2 
 
 
 
 
p426 
 
 
 
 
7898 bp 
 
 
 
 
ADRB2 
 
 
 
Ste2L leader sequence 5' 
of 
ADRB2 , in frame 
Amplified from #2 using 
b2_for/rev_1 PCR primers 
with Eco RI and Sal I sites at 
5' 3' added, then digested, 
ligated 
12 p306GPD p306 5266 bp MCS  Deposited from GSK 
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13 
 
p306GPD-ADRB1 
 
p306 
 
6710 BP 
 
ADRB1 
 
Cut from #6 and ligate into 
#12 at Spe I + Hind III sites 
 
14 
 
p306GPD-ADRB2 
 
p306 
 
6514 bp 
 
ADRB2 
 
Cut from #7 and ligate into 
#12 at Spe I + Sal I 
 
15 
 
p306GPD-MFα-ADRB1 
 
p306 
 
6970 bp 
 
ADRB1 
with MFα 
 
MFα leader sequence 
Cut from #8 and ligate into 
#12 at Spe I + Hind III 
 
16 
 
p306GPD-MFα-ADRB2 
 
p306 
 
6778 bp 
 
ADRB2 
with MFα 
 
MFα leader sequence 
Cut from #9 and ligate into 
#12 at Spe I + Hind III 
 
 
17 
 
 
p426GPD-ERG5 
 
 
p426 
 
 
9224 bp 
 
 
ERG5 
 
ERG5 with 5' and 3' 
flanking sequences 
Amplified with 3_ERG5 and 
4_ERG5, then digested with 
Eco RI and insterted into #1 
 
 
 
18 
 
 
 
p426-ERG6 
 
 
 
p426 
 
 
 
8420 bp 
 
 
 
ERG6 
 
 
ERG6 with 5' and 3' 
flanking sequences 
Amplified with 3_ERG6 and 
4_ERG6, then digested with 
Sac I and Eco RI and insterted 
into #1 
19 pUC57-DHCR24 pUC57 4601 bp DHCR24  Synthesised by GenScript 
20 pUC57-DHCR7 pUC57 4886 bp DHCR7  Synthesised by GenScript 
 
21 
 
p426GPD-erg5-DHCR24-
cys1t-erg5 
 
p426 
 
9441 bp 
 
DHCR24 
DHCR24 reading frame 
replacing ERG5 
 
Yeast gap repair 
 
22 
 
p426GPD-erg6-DHCR7-
cys1t-erg6 
 
p426 
 
8960 bp 
 
DHCR7 
DHCR7 reading frame 
replacing 
ERG6 
 
Gibson assembly 
23 pAUR135 pAUR135 6074 bp  
Aureobasidin A 
resistance 
Purchased 
24 
pAUR135-erg5-DHCR24-
cys1t-erg5 
pAUR135 8885 bp 
erg5-
DHCR24 
Aureobasidin A 
resistance 
Cut from #21 at EcoRI and 
inserted into #23 
25 
pAUR135-erg6-DHCR7-
cys1t-erg6 
pAUR135 9117 bp 
erg6-
DHCR7 
Aureobasidin A 
resistance 
Cut from #22 at SacI and EcoRi 
and inserted into #23 
26 pJL164  8400 bp  ura3 Δ casette purchased 
27 p140  pUC19 3364 bp 
 Truncated 
ura3 
Sta1 and EcoRV 
fragment cut out of 
URA3 coding region 
Deposited from GSK 
 
2.1.3.5. DNA purification and isolation 
 
• QIAquick PCR Purification Kit (Cat# 28104, Qiagen) and Wizard® SV Gel and PCR Clean-Up 
System (Cat# A9282, Promega) were used to purify the DNA from the PCR and restriction 
digestion reactions. 
• QIAquick Gel Extraction Kit (Cat# 28704, Qiagen) was used to purify the DNA from agarose gel. 
• QIAGEN Plasmid Maxi Kit (Cat# 12162, Qiagen), QIAGEN Plasmid Mini Kit (Cat# 12123, Qiagen), 
and GeneJET Plasmid Miniprep Kit (Cat# K0503, Thermo Scientific) were used to isolate 
plasmid DNA from E. coli strains. 
• Thermo Scientific™ Pierce™ Yeast DNA Extraction Kit (Cat# 10473985, Thermo Scientific) was 
used to isolate genomic yeast DNA for colony screening. 
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Phenol-chloroform DNA extraction reagents 
Phenol: chloroform: isoamyl alcohol mixture (Cat# 77617, Sigma-Aldrich) 
Absolute and 70% ethanol (Cat# E/0665DF/17, Fisher Chemical) 
3M Sodium Acetate (Cat# S2889, Sigma-Aldrich) 
Thermo Scientific™ Glycogen, molecular biology grade (Cat# 11883933) 
 
2.1.4.  Western blot reagents and consumables 
 
2.1.4.1. Membrane isolation reagents and buffers 
 
Breaking buffer, pH 7.4 
50mM Na2HPO4, 2mM EDTA (pH 7.4), 100mM NaCl, 5% glycerol 
Buffer ‘A’ pH 7.0 
20mM HEPES, 50mM NaCl, 10% glycerol 
Membrane resuspension buffer 
50mM Tris-HCl (pH 8.0), 150mM NaCl, 2mM EDTA 
Glass beads 
Acid-washed glass beads (Cat# G8772, Sigma-Aldrich). 
Protease inhibitor cocktail (PIC) 
A yeast specific protease inhibitor cocktail set IV (Cat# 539136, Merk-Millipore) was used. 
BCA and cupric sulfate 
Bicinchoninic acid solution (Cat# B9643, Sigma-Aldrich) and copper(II) sulfate solution (Cat# C2284, 
Sigma-Aldrich) were used for determining membrane protein concentration. 
BSA standards 
Bovise serum albumin (Cat# 82516, Sigma-Aldrich) was diluted at 0.8mg/mL, 0.6mg/mL, 0.4mg/mL and 
0.2mg/mL in membrane resuspension buffer. 
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2.1.4.2. Acrylamide gels 
 
Separating gel  
4.4mL water, 3mL 1.5M Tris-HCl (pH 8.8), 3.8mL 30% Protogel acrylamide mix, 120µL 10% SDS, 40µL 
20% ammonium persulfate, 9µL TEMED. 
Stacking gel 
1.3mL water, 3.1mL 0.5M Tris-HCl (pH 6.8), 0.7mL 30% Protogel acrylamide mix, 50µL 10% SDS, 20µL 
20% ammonium persulfate, 5µL TEMED.   
1.5M Tris-HCl (pH 8.8) 
9.09g of Sigma 7-9® Tris-base (Cat# T1378, Sigma-Aldrich) dissolved in 50mL water, then pH adjusted 
to 8.8. 
0.5mM Tris-HCl (pH 6.8) 
3.94g of Trizma® hydrochloride (Cat# T5941, Sigma-Aldrich) dissolved in 50mL water, then pH adjusted 
to pH 6.8. 
10% SDS 
5g of SDS (Cat# L3771, Sigma-Aldrich) dissolved in water to a final volume of 50mL. 
20% ammonium persulfate 
The solution was freshly made before preparing gel solution. 200mg of powder (Cat# A9164, Sigma-
Aldrich) were dissolved in 800µL of water. 
30% acrylamide solution 
Protogel is a pre-mixed 37:5:1 Acrylamide to Bisacrylamide stabilized solution (Cat# A2-0072, 
Geneflow). 
TEMED (Cat# T9281, Sigma-Aldrich). 
Pre-made gels 
12% Mini-PROTEAN® TGX™ Precast Protein Gels, 10-well gels (Cat# 4561044) and Novex 12% Tris-
glycine gels (Cat# XP00122BOX, Invitrogen) were used.  
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2.1.4.3. Running buffers 
 
For running acrylamide gels 
10x Tris/Glycine/SDS buffer (Cat# B90032, Geneflow) was diluted in water to make 1x working 
concentration. An equivalent 1x Laemli running buffer: SDS-Tris-Glycine was made in-house at GSK 
and was used to run Novex gels.  
 
For protein transfer onto the membrane 
10x Tris/Glycine transfer buffer (Cat# B90056, Geneflow) was made to 1x working concentration with 
20% methanol.  
iBlot® Transfer Stack, PVDF, mini (Cat# IB401002, Invitrogen) stacks for dry blotting system was used 
at GSK. 
 
2.1.4.4. Antibody binding and detection 
 
Primary antibodies 
Anti-beta 2 Adrenergic Receptor antibody (Cat# ab182136, Abcam) 
Anti-beta 1 Adrenergic Receptor antibody (Cat# ab3442, Abcam) 
Secondary antibody 
Anti-rabbit IgG, HRP-linked Antibody (Cat# 7074S, Cell Signalling Technology) 
PBS 
PBS tablets (Cat# 1282-1680, Fisher Chemical), 1 per 100mL, were dissolved in water to give 1x PBS 
solution. 
Milk-PBS 
2.5g skimmed milk powder was dissolved in 50mL PBS 
Tween wash buffer 
2ml of Tween-20 (Cat# P9416, Sigma-Aldrich) was dissolved in 998mL to make 0.2% tween 20 in 1x 
PBS. 
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EZ-ECL substrate 
SuperSignal™ West Dura Extended Duration Substrate (Thermo Scientific, Cat# 34076) and EZ-ECL 
Chemiluminescence Detection Kit for HRP (Cat# K1-0172, Geneflow) were used as HRP substrate for 
detection. 
 
2.2. Methods 
 
2.2.1. Yeast strains, growth and maintenance  
 
2.2.1.1. General 
 
• All incubations for yeast were carried out at 30°C, and for bacteria (E. coli) at 37°C both for growth 
on Petri plates and liquid culture. Liquid cultures, in addition, were shaken at 220 oscillations per 
minute. The capacity of glass or plastic flasks was 5x the volume of the culture medium to allow 
adequate aeration. 
• Untransformed MMY strains were grown in YPD. 
• Transformed yeast were grown in complete synthetic WHAUL medium at pH 5.5 (WHAUL-5.5) for 
general work and pH 7.0 (WHAUL-7.0) in FD-Glu assay conditions. 
 
2.2.1.2. Yeast transformation 
 
Yeast transformations were carried out as previously described (Dowell and Brown, 2009). Briefly, a 
single MMY colony was inoculated into 3mL YPD for MMY11 or WHAUL-5.5 + His + Ura for other MMY 
strains and grown overnight at 30°C with shaking at 220rpm. The next morning 500µL of the overnight 
culture were subcultured into 20mL of the same medium in a 100mL conical shake flask. After 4 hours 
of further growth, the cells were washed with 1 vol of sterile double distilled water, resuspended in 
1mL of water and transferred into a 1.5mL eppendorf tube. The centrifugations for the washes were 
performed at 600g, 4min, room temperature. The pelleted cells were resuspended into 400µL of LiAc-
TE buffer. 50µL of cell suspension was used per transformation, mixed with 300µL LiAc-PEG-TE, 5-25µL 
ssDNA and 1µg of DNA for test samples only. The mixtures were incubated at room temperature for 
10min, then heat-shocked at 42°C. 100µL of the transformed cell mixture were plated onto WHAUL-
5.5 + His plates. Colonies generally appeared after 42-72h.  
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2.2.1.3. Colony selection for ura3Δ 
 
Day 1-2 
The above described yeast transformation protocol was used with some modifications. After the cells 
were heat-shocked, instead of directly plating them on the selection plates, the yeast were grown for 
2h at 30°C in 1mL 5-FOA/YPD to increase the selection stringency. After that, the cells were diluted 
with further 1mL of medium and then plated on 5-FOA/YPD plates, 100µL of the culture per plate. 
 
Day 4 
Plates were left to grow for 48h post-transformation until small-to-medium size colonies formed. 
Because a high number of colonies usually appeared on the plates, a number of colonies were picked 
and diluted to approximately 2.0 x 104 cells/mL and spread on fresh 5-FOA/YPD plates.  
Day 5-6 
When small colonies appeared, the plates were replica-plated onto a fresh 5-FOA/YPD and 
WHAUL+His+Trp-Ura (–Ura for short) plates. 
Day 6-8 
Colonies which appeared on the –Ura plates were selected for colony PCR (protocol 2). 
A crude DNA extraction directly from colonies was done as follows: 
Colonies were resuspended in 200µL of water to make a back-up colony on a fresh plate. Then, the 
cells were pelleted at 15,000rpm for 1min. Supernatant discarded. The pellets were resuspended in 
100µL 1% SDS – 0.2M LiAc and incubated at 70°C for 5min. 300µL of absolute ethanol were then added 
and the suspensions were vortexed for 1min to break open the cells. The samples were centrifuged at 
15,000rpm for 3min. Supernatant discarded. The pellets were washed with 1vol of 70% ethanol. 
Supernatant discarded. The pellets were resuspended in 100µL of water. The samples were briefly 
spun (~15s) at 15,000rpm to pellet the cellular debris. 1µL of this crude fresh extract was used for PCR. 
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2.2.2. FD-glu GPCR assay set-up and conditions 
 
2.2.2.1. Assay set-up for ligand measuring induced yeast growth 
 
Day 1 
For preparation of the assay, a single colony of transformed yeast were inoculated into WHAUL-5.5 
medium for overnight culturing at 30°C. For screening assays the colonies were inoculated into 200µL 
of culture in 96-well sterile plates, and grew to lower OD600 than normal. For other assays 3mL of 
medium was used for the overnight culture.  
Day 2 
The assay set-up required several steps. Firstly, the ligand dilutions were dispensed (please see below). 
Secondly, the assay medium was prepared (2.1.2.1), and finally, the cell density from the overnight 
culture was measured and diluted into the assay medium to a final OD600 of 0.02. The total volume per 
well in 96-well plate was 200µL, in 384-well it was 50µL. The prepared plates were sealed with Breathe-
Easy membrane and incubated at 30°C for 18-48h.  
Day 3 or 4 
The final data were collected and analysed on the last day.  
 
2.2.2.2. Ligand preparation 
 
The GSK compounds 
At GSK both panels of compounds were aliquoted into 384-well plates by an automated system. The 
compounds were dissolved in 100% DMSO and aliquoted in 0.5µL volumes in each well. The sealed 
plates were stored at 4°C for up to two months.  
Compounds at Aston 
Brimonidine, or UK 14, 304, was used as an agonist for α2A-AR and α2B-AR receptor stimulation studies 
at Aston. 5mg of brimonidine were dissolved in 1.712mL 100% DMSO to give concentration of 10mM. 
The stock solution was stored at -20°C. 
Isoprenaline, or isoproterenol, was used as an agonist for β1-AR and β2-AR receptor stimulation studies 
at Aston. The isoprenaline powder was dissolved in water at concentration of stock solution at 10mM, 
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supplemented with 1mM of ascorbic acid (Cat# 92902, Sigma-Aldrich). 200µL aliquots were stored at 
-20°C for a single use. 
For the 3-fold serial dilutions in 96-well plates, 200µL of 10mM solution were pipetted into well 1. 
133µL of 100% DMSO were dispensed into wells 2-12. 66µL were drawn from well 1 and transferred 
into well 2. With a fresh tip, the contents of well 2 were mixed, then 66µL were drawn again and 
transferred into well 3. The procedure was repeated until well 12, in which only DMSO was present. 
2µL of each dilution were transferred into the Greiner assay plate, which equalled 1% of the overall 
assay mix in the well. The same principle was applied to 384-well plates where 0.5µL of the ligand was 
mixed in the final assay volume of 50µL. The final concentrations ranged from 10mM to 169nM with 
no ligand in well 12. 
 
2.2.3. Data collection and analysis 
 
The fluorescence was read as relative fluorescence units (RFU) with an EnVision Multilabel plate reader 
(PerkinElmer) and SpectrafluorPlus (Tecan) at GSK and a Gemini GM fluorescence reader (Molecular 
Devices) a Mithras (Berthold) at Aston University. Where possible, data were normalised against the 
highest signal produced by brimonidine stimulation as the upper asymptote and the negative DMSO 
control as the lower asymptote. The pEC50 and R2 values were retrieved from a non-linear three 
parameter fit data analysis. All data simulations were performed with MS Excel and GraphPad Prism 
V.7. 
One-way ANOVA was used to compare EC50 values in Chapter 3.  
For correlation analyses in Chapter 5 Pearson’s correlation coefficient was calculated. Linear regression 
plots were plotted on the XY scatter to indicate the differences between slopes. The data for assay 
comparison in Figure 5.18 and Table 5.19 can be found in the Appendix E. 
P values <0.05 were deemed to be significant. 
GraphPad Prism was used to obtain all calculations. 
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2.2.4.  Molecular Biology 
 
2.2.3.1. Bacterial transformation 
 
Preparation of competent E. coli cells 
Frozen stocks of E. coli XL-BLUE were inoculated into 3mL LB for overnight growth at 37°C. 1.5mL of 
the overnight culture were sub-cultured into 250mL of SOB medium and grown at reduced 
temperature of 30°C until OD600 reached 0.4. The cells were then chilled for 15min, pelleted at 
6000rpm, 4°C, 10min. The cell pellet was resuspended in 50mL ice-cold TB buffer, then incubated on 
ice for 10min, and finally centrifuged at 6000rpm, 4°C, 10min. The resulting pellet was re-suspended 
in 9.3mL TB buffer with 0.7mL 100% DMSO. The cells were aliquoted in pre-chilled Eppendorf tubes 
and frozen at -80°C immediately. 
All handling after culturing were done in the cold room, keeping the cells on ice-cold water at all times.  
 
Heat shock transformation of competent E. coli cells  
The cells were transformed with either ligated DNA or plasmid DNA by incubating a mixture of DNA 
and 50µL of thawed cells for 30min on ice, then heat-shocking the mixture at 42°C for 90s, and 
returning it back on the ice for 5min. The cells were recovered in SOC medium at 37°C for 1h. After this 
incubation, the cells were plated out on LBA plates and left to grow at 37°C overnight.  
 
2.2.3.2. Cloning 
 
General 
Ultrapure water was obtained from a Type 1 Milli-Q Synthesis A10 water purification system and was 
used for all molecular biology work, except where water was supplied with other reagents, such as PCR 
and Ligation kits, and for making 1X TAE buffer. For the later, Type 2 deionised water from a Millipore 
Elix water purification system was used.  
 
Ligations 
Ligations were performed using a Rapid DNA Ligation Kit in accordance with manufacturer’s guidelines. 
The insert/vector molar ratio was aimed to be 3:1. 5µL of the reaction were transformed into 
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chemically competent E. coli. 90% of the transformation reaction was plated out on LBA plates 
overnight. 
FastAP Thermosensitive Alkaline Phosphatase was used to prevent the vector backbone from re-
ligating. The phosphatase reactions were carried out as per manufacturer’s instructions. 
A control with no T4 ligase enzyme and with the ‘backbone’ only were set up alongside all ligations to 
test the ligation efficiency and for the ligated vector size comparison. 
 
Standard digestion reactions 
All reactions were performed at 37°C, except where advised otherwise in the manufacturer’s 
instructions, for 2h in the buffers supplied. An excess of 5U of enzyme per 1µg of DNA was used.  
 
Agarose gel electrophoresis 
Agarose gel electrophoresis was performed in a MultiSub Horizontal gel electrophoresis system for 40-
60 min at 80-100V.  
 
Preparation of ura3Δ fragment 
The pJL164 vector (Cat# 87471, ATCC) was digested with SpeI and XhoI enzymes to release the ura3Δ 
cassette of approximately 3000 bp. This fragment was separated from the backbone on the agarose 
gel, then purified. 1µg of the fragment was used per transformation as detailed in the standard yeast 
transformation protocol.  
 
Yeast ‘Gap repair’ 
The first step of the yeast gap repair procedure is yeast transformation with the fragments to be 
ligated. For this, the standard yeast transformation protocol was used (2.2.1.2).  The second step was 
to extract the plasmids and transform them into E. coli because the yield of the yeast plasmid 
extraction is too low for any further analysis. The previously described release of plasmid from yeast 
was followed [68]. Briefly, a 1.4mL of overnight culture of selected colonies was pelleted, resuspended 
in 200µL of plasmid release reagent, 200µL phenol-chloroform, and 300µL of glass beads. The cell 
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mixture was vortexed for 2min, spun at 15,000rpm for 5 min to separate the organic and aqueous 
layers. 5µL of the aqueous layer was transformed into E. coli as described in section  
2.2.3.3. Polymerase chain reaction protocols and equipment 
 
Protocols 
Table 2.8 The list of PCR protocols 
 Protocol 1 Protocol 2 Protocol 3 Protocol 4 
Step Temp., °C Time, s Temp., °C Time, s Temp., °C Time, s Temp., °C Time, s 
Initial denaturation 95 180 95 120 95 600 95 600 
Denaturation 95 30 95 20 95 20 95 20 
Primer annealing 65 30 60 20 57/60 20 57 20 
Extension 72 120 72 30 72 90 72 360 
Final extension 72 300 72 180 72 180 72 600 
 
Steps 2-4 were repeated 34 times.  
Primer design 
• Primers were designed and selected based on ∆G (hairpin) and ∆G (dimer) energies, self-
annealing and 3’ annealing properties. The online Primer-Blast  
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) and NetPrimer 
(http://www.premierbiosoft.com/netprimer/) tools were used to design primers. 
• Primers for sequencing the genes after ligation into new vectors were designed to cover the 
whole gene in around 300-400bp fragments. Forward and reverse primers were used, and were 
also designed to extend into 5’ and 3’ end flanking regions.  
• All sequencing were carried out at GSK’s in-house sequencing facilities.  
 
2.2.3.4. Plasmid construction 
 
All vector and plasmid maps can be found in the Appendix B. 
 
p426GPD-ADRB1 plasmid  
The ADRB1 gene was amplified using b1_for_1 and b1_rev_1 primers (Table 2.6) using vector #2 as a 
DNA template. 10% DMSO was required in order to increase primer annealing temperature. Extensive 
optimisation of the PCR was performed, however multiple PCR products were unavoidable. To 
overcome this issue the PCR product was separated on 1.1% agarose-1x TAE gel for 70min at 90V. 
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Bands of nearly 1500bp size were well separated from other bands on the gel, making it easy to excise 
using a scalpel. The DNA was purified from the gel and digested with BamHI. The DNA was then purified 
using the phenol-chloroform-ethanol extraction method. The digested and purified ADRB1 gene 
fragment was ligated into p426GPD vector backbone which was also digested with BamHI and 
dephosphorylated with FastAP in preparation for ligation. 
BamHI, SacI and XmaI endonucleases were used to identify the correct orientation of the inserted 
fragment (see 4.1.1). 
 
p426GPD-ADRB2 plasmid  
The ADRB2 gene located in plasmid #3 (Table 2.7) had BamHI sites conveniently located at 5’ and 3’ 
ends of the gene. Therefore the plasmid was digested, separated on agarose gel and excised for 
purification. The p426GPD backbone was also digested with BamHI, dephosphorylated with FastAP 
and purified.  
BamHI, SacI, EcoNI + EcoRI endonucleases were used to determine the correct orientation of the 
inserted fragment (see 4.1.1). 
 
p426GPD-MFα-ADRB1 plasmid 
For the ADRB1 gene to be inserted in p426GPD-MFα (#4, Table 2.7) in-frame with the pre-pro leader 
sequence upstream of the 5’ end, restriction sites NcoI at the 5’ end and BamHI at the 3’ end were 
used. The gene was cut out from the p426GPD-ADRB1 plasmid (#6, Table 2.7) in which two BamHI sites 
exist – one at the 3’ end of the ADRB2 gene, and the second once at the 5’ end, just 5bp upstream 
from the NcoI site. Therefore, the gene donor plasmid #6 was first digested with BamHI, and then 
separated by standard gel electrophoresis. The lower band was purified from the gel and further 
digested with NcoI to give the correct ‘sticky ends’. The p426GPD acceptor vector was digested with 
NcoI and BamHI simultaneously. The ligated plasmid was analysed with a double NcoI + BamHI digest 
to demonstrate the presence of the insert, and with a single BamHI digest to show that only one BamHI 
restriction site was present as predicted (Figure 4.2). 
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p426GPD-MFα-ADRB2 plasmid 
The same design strategy was applied as for the p426GPD-MFα-ADRB1 plasmid; the gene was inserted 
into NcoI at the 5’ end and BamHI at the 3’ end. Similar procedures were followed, however the gene 
donor plasmid p426GPD-ADRB2 (#7, Table 2.7) had two restriction sites for both enzymes. Firstly, it 
was cut with NcoI, which produced two bands of the predicted sizes. The lower band was separated 
on an agarose gel and purified. The retrieved DNA was then subjected to BamHI digestion to give 
correct ‘sticky ends’. The backbone p426GPD-MFα was treated as before. Again, the ligated plasmid 
was analysed with a double NcoI + BamHI digest to demonstrate the presence of the insert, and with 
a single BamHI digest to show that only one BamHI restriction site was present as predicted (Figure 
4.2). 
 
p426GPD-Ste2L-ADRB1 
The ADRB1 gene was amplified using b1_For_2 and b1_Rev_2 primers (Table 2.6) which introduced 
EcoRI and SalI restriction sites at the 5’ and 3’ of the gene, respectively. Similarly to b1_For_1 and 
b1_Rev_1, primer amplification required the addition of 10% DMSO. Multiple unspecific products were 
separated on a 1.1% agarose-1x TAE gel. The correct size band was cut out and purified, then subjected 
to double EcoRI + SalI digestion. The purified DNA fragment was ligated into a donor plasmid #5 (Table 
2.7) which had an Ste2L leader sequence upstream from the EcoRI restriction site. Single and double 
EcoRI and SalI digestions were used to confirm the insertion of the ADRB1 gene. 
 
p426GPD-Ste2L-ADRB2 
The ADRB2 gene was also amplified using primers b2_For_1 and b2_Rev_1 (Table 2.6) in order to 
introduce EcoRI and SalI restriction sites. No gel separation of the PCR product was required and the 
DNA was purified for digestion directly. After the double digest with the mentioned enzymes, the gene 
was ligated into plasmid #5 (Table 2.7) similarly to the ADRB1 plasmid described above. 
 
p306GPD-ADRB1 plasmid 
The p426GPD-ADRB1 plasmid #6 (Table 2.7) was digested with SpeI and HindIII and so was the 
p306GPD vector #12. The purified digested ADRB1 DNA fragment was ligated into a dephosphorylated 
purified backbone. 
 
 
59 
 
p306GPD-ADRB2 plasmid 
The p426GPD-ADRB2 plasmid #7 (Table 2.7) was digested with SpeI and HindIII and so was the 
p306GPD vector #12. The purified digested ADRB2 DNA fragment was ligated into a dephosphorylated 
purified backbone. 
 
p306GPD-MFα-ADRB1 plasmid 
The p426GPD-MFα-ADRB1 plasmid #8 (Table 2.7) was digested with SpeI and HindIII and so was the 
p306GPD vector #12. The purified digested ADRB1 DNA fragment was ligated into a dephosphorylated 
purified backbone. 
 
p306GPD-MFα-ADRB2 plasmid 
The p426GPD-MFα-ADRB2 plasmid #9 (Table 2.7) was digested with SpeI and HindIII and so was the 
p306GPD vector #12. The purified digested ADRB2 DNA fragment was ligated into a dephosphorylated 
purified backbone. 
 
p426GPD-ERG5 plasmid 
The 3_ERG5 and 4_ERG5 primers (Table 2.6) were used to amplify the ERG5 gene and sequences 
flanking 5’ and 3’ ends. The PCR product was then digested with EcoRI to obtain a 2622 bp fragment 
which was then inserted into the p426GPD plasmid at the same restriction site to obtain p426GPD-
ERG5. The EcoRI sites were endogenously present in the genomic sequence close to the primer 
annealing sites.  
SacI restriction was used to determine the correct orientation of the inserted fragment.  
 
p426-ERG6 plasmid 
The 3_ERG6 and 4_ERG6 primers (Table 2.6) were used to amplify the ERG6 gene and the sequences 
flanking 5’ and 3’ ends. No usable endogenous restriction sites were present therefore aforementioned 
primers were designed to include SacI restriction site 5’ of the PCR product and EcoRI at the 3’ end. 
These restriction sites were used to insert the fragment into p426GPD. In this process the GPD 
promoter was lost, however, the promoter was not required for this cloning strategy.  
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p426GPD-erg5-DHCR24-cys1t-erg5 plasmid 
The DHCR24 gene was synthesised by GenScript and supplied in the pUC57 vector. The gene was cut 
out at the SacI and BamHI sites at 5’ and 3’ ends respectively. The yeast ‘gap repair’ method was used 
to insert the gene into the p426GPD-ERG5 by homologous recombination, replacing the ERG5 reading 
frame with DHCR24. The p426GPD-ERG5 was linearised with BalI which linearises the plasmid within 
ERG5 prior to reaction set up. Correctly ligated clones were selected by HindIII digestion, which 
linearises the plasmid if the DHCR24 gene is present while cutting it into 1376 and 7848 bp fragments 
if ERG5 is present.   
 
p426-erg6-DHCR7-cys1t-erg6 plasmid 
The ‘gap repair’ method was not successful for this method, therefore an alternative Gibson Assembly 
method was used. For this, the p426-ERG6 plasmid was digested with Van91I and AgeI to cut out a 
large fragment from the ERG6 region within the plasmid. The synthesised pUC57-DHCR7 plasmid was 
digested at XbaI and SmaI to release the DHCR7 gene fragment. The purified DNAs were set up in a 
reaction according to manufacturer’s instructions and later transformed into E. coli 5α F’lg strain. 
The correctly-ligated colonies were identified using BamHI, HindIII, and PvuII enzymes which cut the 
DHCR7 and ERG6 gene-containing plasmids differently (see Figure 6.7) 
 
pAUR135-erg5-DHCR24-cys1t-erg5 plasmid 
The final plasmid for DHCR24 integration into the S. cerevisiae genome, the integration cassette, 
consisting of ERG5 upstream sequence (termed promoter), the DHCR24 gene, ERG5 downstream 
sequence and CYS1 terminator sequence, was inserted into the MCS of pAUR135 vector at the EcoRI 
restriction site. 
 
pAUR135-erg6-DHCR7-cys1t-erg6 plasmid 
Similarly to the previous plasmid the integration cassette, consisting of ERG6 upstream sequence 
(termed promoter), the DHCR7 gene, ERG6 downstream sequence and CYS1 terminator sequence, was 
inserted into the MCS of pAUR135 at the SacI and EcoRI restriction sites.  
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2.2.3.5. DNA purification methods 
 
The DNA cut from agarose gel was purified from the gel using Wizard® SV Gel and PCR Clean-Up System 
and QIAquick PCR Purification Kit were used to extract the DNA from agarose gel according to 
manufacturers’ instructions. 
The DNA from PCR or other liquid reactions was purified using the QIAquick PCR purification kit 
according to the instructions provided in the kit or the phenol-chloroform-ethanol extraction method 
detailed below. 
 
Phenol-chloroform-ethanol extraction method  
- The DNA was extracted with 1vol of Phenol-chloroform. The mixture was mixed and spun at high 
speed for 5min. The top layer of the biphasic mixture was collected and transferred into a new 
Eppendorf tube. 
- 2vol of absolute ethanol were added as well as 1-2µL of glycogen and sodium acetate to make up 
concentration of 0.3M. The mixed solution was let to precipitate for a few minutes, and then spun 
it at high speed for 5-10 min. 
- The final wash was done with a large volume (~500μL) of 70% ethanol which was again spun at 
high speed for 5min.  
- The supernatant was removed completely, letting the pellet to dry for a couple of minutes. 
- The pellet was re-suspended in a small volume of water.  
 
2.2.5.  Membrane isolation and western blotting procedures 
 
2.2.4.1. Membrane isolation 
 
Yeast cultures were grown in 50mL WHAUL-5.5 + His (+ Ura for untransformed samples) until OD600 of 
2.0-2.5, pelleted at 600g for 4min, room temperature, and resuspended in 1mL buffer ‘A’. The cell 
suspension was transferred into breaking tubes and again pelleted to remove the buffer. Next, the 
pellet was resuspended in 500µL of breaking buffer, from which point the samples were kept on ice at 
all times. 1mL of acid-washed beads was added along with PIC at 1:500 dilution. The cells were 
disrupted in TissueLyser LT (Qiagen) for 10min at 50 oscillations per second. The lysate transferred into 
a fresh Eppendorf tube and spun at 15,000rpm for 15min to separate the membranes from cellular 
debris and the beads. Final ultra-high speed centrifugation at 66,000rpm was carried out for 60min 
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during which all membranes were pelleted. The supernatant was removed. The membranes were left 
to soak in 100µL membrane resuspension buffer overnight at 4°C. 
The concentration of total protein was determined the next date using the BCA assay (see below). 
2.2.4.2. BCA assay for membrane protein concentration 
 
BCA and cupric sulfate were mixed at 50:1 ratio. BSA standards were added at 20µL into 180µL of the 
assay mix. 5µL of test samples were mixed with 15µL of membrane resuspension buffer and then with 
180µL of BCA assay mix. The standards and test samples were incubated at 37°C for 10min and then 
measured at 562nm. The standard curve was plotted from the standard measurement to determine y 
= mx + b where x was the protein concentration and y the absorbance at 562nm. 
 
2.2.4.3. Sample preparation 
 
35-70µg of total yeast membranes, isolated from a range of ADRB1 and ADRB2 receptor expressing 
yeast, were incubated with reducing SDS sample buffer and membrane resuspension buffer on ice for 
1h before loading on the gel. 
 
2.2.4.4. Acrylamide gels 
 
To make the gel, the reagents were mixed in the order as listed in the recipe (2.1.5.1). The separating 
gel was made first and left to set for 20 min. Then, the stacking gel was prepared. 
Both in-house made and pre-made gels were run at 130V for around 60-100min until the blue dye 
reached the bottom. 
2.2.4.5. Protein transfer 
 
Proteins from the acrylamide gel were transferred onto a nitrocellulose membrane sandwiched 
between filter paper sheets, immersed in transfer buffer and an ice pack for 50 min at 100V.  
For dry transfer, the proteins were transferred onto a PVDF membrane using iBlot dry transfer system 
from Invitrogen for 7min on setting P3. 
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2.2.4.6. Antibody directed detection of β1-AR and β2-AR 
 
The membrane was blocked in milk-PBS for 1h before adding the primary antibody at 1:5000 dilution. 
The primary antibody was added and incubated over-night at 4°C. The unbound antibody was washed 
off with Tween wash buffer in 3x 5min washes. The secondary HRP conjugated antibody was agitated 
in milk-PBS for 1h at 1:5000 dilution and after washed as before.  
The chemiluminescence signal was detected after the 3min incubation with the HRP substrate. 
GeneSnap software was used to acquire the images from the Syngene G:Box equipment. 
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Chapter 3 – Optimisation of the yeast functional GPCR assay 
 
3.1. Introduction 
 
The yeast functional GPCR assay for functional studies of G protein-coupled receptors (GPCRs) has 
been designed for the high-throughput screening of compound libraries for potential GPCR-interacting 
molecules. As with most high-throughput technologies, there are parameters that can be adjusted for 
a particular target, in this case a different GPCR. Because this assay is live cell-based, it is particularly 
amenable. Nevertheless, it is essential that the assay is reproducible with particular conditions to allow 
a reliable interpretation of the results. This chapter overviews the conditions and parameters that were 
tested using two strains – MMY25 with integrated p306GPD-ADRA2A plasmid and MMY20 with 
integrated p306GDP-ADRA2B plasmid, termed YIG152 and YIG153 respectively. These strains express 
recombinant adrenoceptors α2A and α2B respectively. Finally, the concluding results illustrate the effect 
of varying assay parameters on the readout and apparent pharmacology. 
The summary of assay conditions discussed in this chapter: 
• Stringency of background growth control with 3-AT 
• Substrate concentration effects on the signal 
• Instrument dependent signal dynamic range 
• Experiment-to-experiment variability 
 
  Figure 3.1 The workflow of the yeast functional GPCR assay set up. The assay generally takes three 
days from inoculation to data collection. Key steps and components are noted. 
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3.2. Effects of 3-amino triazole on reporter signal strength 
 
The 3-amino triazole (3-AT)  is used in this assay to control the unspecific background signal by 
inhibiting the HIS3 gene product which has a key role in histidine synthesis. Generally in other systems 
where this reporter gene is used, the stringency of background inhibition can be adjusted by titrating 
the concentration of 3-AT [69]. To investigate whether the same applies to our assay system and to 
what extent, concentrations of 3-AT ranging from 2 to 50mM were tested in YIG152  (α2A-AR) and 
YIG153 (α2B -AR).  
 
 
Figure 3.3 summarises the results of 3-AT titration on the α2B receptor. The results combine data from 
two experiments carried out at the same conditions with 3-AT concentration as a single variable. 
Results are presented as relative fluoescence units (RFU) against log compound concentration in molar 
units. The background reporter expression is much higher in the YIG153 strain expressing α2B-AR as 
compared to α2A-AR. For example, at 2mM 3-AT [A], regardless of compound concentration, the RFUs 
were very high and no concentration-response relationship was observable. At 5mM 3-AT [B] the 
fluorescence signal indicates an inhibition of the growth at lower compound 9 and 11 concentrations, 
however at a relatively low range of 50-140nM compound concentrations the signals plateaued. The 
pEC50 values for compounds 9 and 11 were generated using a non-linear three parameter fit, however, 
the concentration-response relationship appears to be too obscured by the high RFUs to judge 
whether those values are a true representation of the receptor stimulation. The 10mM 3-AT 
concentration lowered the unspecific yeast growth to allow the compound stimulation of the receptor 
Figure 3.2 The inhibition of His3p by 3-amino triazole. 3-AT has been used to control the background growth 
by inhibiting the activity of imidazoleglycerol phosphate dehydratase, a product of HIS3 gene which is often 
used as a reporter gene including the MMY yeast assay for functional GPCR studies. 
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to produce more robust concentration-response curves for all three compounds [C] with a good fit, 
pEC50 values, and a dynamic RFU range. At 20mM 3-AT [D] and [F] produced similar pEC50 values for 
compounds 11 and 19, but a lower value for compound 9. The overall fluorescence also decreased by 
approximately 1x106 RFUs indicating that the overall inhibition is more stringent. The same is true for 
50mM 3-AT [E]: the RFUs reached only about 1.67x106 at the highest Emax compared with 5.4x106 RFUs 
observed at 10mM 3-AT.  
Results presented in Figure 3.4 show effects of three increasing concentrations of 3-AT on α2A-AR 
receptor in YIG152, presented as relative fluoescence units (RFU) against log compound concentration 
in molar units. There was not much difference between the responses in the presence of 2mM (Figure 
3.4 [A]) and 5mM [B] 3-AT in terms of fluorescence intensity and pEC50 and Emax ([D] and [E]). The pEC50 
values were slightly lower at 5mM 3-AT [D]. At 10mM of 3-AT [C] there was a significant reduction in 
fluorescence, also reflected by the lower pEC50 values. Compound 9 seemed to produce a stronger 
pathway activation in terms of His3 production to overcome the effects of the 3-AT inhibition 
compared with the other two compounds. Concentrations higher than 10mM 3-AT were not tested 
with this receptor, as a further reduction in signal would be expected.  
Overall, 3-AT appeared to be a powerful modulator of His3 promoted cell growth and consequently 
the assay reporter signal. The inhibition required depends on the receptor type. The YIG152 yeast 
required less 3-AT to produce a desired signal window compared with the YIG153 which appears to 
have a high unspecific cell growth and required a more stringent background inhibition. 
Out of the three compounds presented in section 3.2, compound 19 is commonly available under the 
generic name brimonidine or UK 14,304; the other two compounds are from the GSK compound library 
and therefore only available for testing on the GSK site. However, brimonidine as a previously 
characterised full α2A-AR full agonist and α2B-AR partial agonist was deemed to be a suitable control 
for futher experiments on these receptors discussed in this chapter.   
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Figure 3.3 Effects of 3-AT on α2B-AR receptor expressed in YIG153.  The results are shown for fluorescence 
signal development on compounds 9, 11, and 19 with 2mM [A], 5mM [B], 10mM [C], 20mM [D], and 50mM 
[E] 3-AT. The pEC50 values were obtained from a non-linear three parameter fit using GraphPad Prism, V6. 
Panels [A] and [B] indicate that 2mM and 5mM are not adequate to produce the concentration-response 
relationship expected for this receptor. Results in [C] show the widest signal window, while in [D] and [E] the 
inhibitory effect appears to be too strong and the positive signal is reduced along with the unspecific signal 
resulted from background growth. The pEC50 values are summarised in [F], Emax in [G] and R2 in [H]. For all the 
data in this figure n=1. 
68 
 
 
  
Figure 3.4 Effects of 3-AT on α2A-AR receptor expressing YIG152.  Compounds 9, 11, and 19 were 
incubated over the same period of 24h with an increasing 3-AT concentrations. In [A] the results at 2mM 
is shown, in [B] at 5mM, and in [C] at 10mM of 3AT. pEC50 values did not change significantly and are 
summarised in the [D]. Emax values in [E] indicate that C9 was less affected by increasing 3-AT in terms 
of efficacy as compared to C11 or C19. R2 [F] values indicate the goodness of data fit. n=1 
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3.3. Substrate concentration effects on the signal 
 
Fluorescein di-β-D-glucopyranoside (FD-glu) is another important component of the assay mix. It acts 
as a substrate for the exoglucanase secreted in growing yeast cells, which use the enzyme to cleave 
off glucose from polysaccharides, and consequently upon cleavage releasing the fluorescein, the 
fluorescent molecule, from this conjugate. The concentration of FD-glu in the standard protocol is 
Figure 3.5 Effects of increasing FD-glu substrate on the signal development and pEC50 of brimonidine. RFUs 
increase with FD-glu concentrations in YIG153 [A] and YIG152 [B]. 10μM (    ) is the standard protocol 
concentration, but 20μM (    ), 40μM (    ) and 80μM (    ) were also tested. Although 80μM FD-glu in the 
assay medium produced around a 10-fold increase in the RFU signal as compared to the starting 10μM 
concentration, the pEC50 values did not increase significantly [C].  Emax [D] and R2 [E] are also presented. The 
base line RFU was subtracted from the signal for a clearer representation of the stimulation-specific signal. 
n=1.  
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10μM. However, experiments were designed to assess how increasing the concentration of the 
substrate affected the output signal and the pharmacology of brimonidine on α2A-AR and α2B-AR. A 
range of 10-80μM of FD-glu in doubling increments was therefore tested and is presented in Figure 
3.5.  
Not surprisingly, with increasing substrate, the RFU values were higher in both experimental groups 
([A] and [B]), 80μM of the substrate providing approximately a 10-fold increase in the signal window 
compared with the standard 10μM concentration. However, the pEC50 values did not increase with the 
higher signal output, and did not vary significantly [C]. The maximum RFUs increased in both YIG152 
and YIG153, although brimonidine is only partial agonist on α2B-AR expressed in YIG153, suggesting 
that the additional substrate only increases the sensitivity of signal detection. Although the increase 
in the signal window might be beneficial for a weakly expressed and/or coupling receptor, the standard 
FD-glu concentration was adequate to produce the same pharmacological parameters as the higher 
concentrations of the substrate [C].  
 
3.4. Instrument-dependent signal dynamic range 
 
During the assay optimisation phase of the project it was noted that different instruments at GSK and 
Aston University produced a different scale of RFUs and their dynamic range. This was examined in 
order to assess whether it had an effect on interpreting the data. A side-by-side experiments with a 
range of 3-AT concentrations in YIG152 and YIG153 stimulated with brimonidine are presented in 
Figures 3.6 and 3.7 respectively.  
The first observation that can be drawn is that the three instruments used for the optimisation of the 
assay – EnVision (PerkinElmer), Gemini (Molecular Devices), and Mithras (Berthold) – generate a 
different magnitude of RFUs, which can be ranked in the following order: 
1. EnVision (GSK) – 106 
2. Mithras (ASTON) – 104 - 105 
3. Gemini (ASTON) – 103 
The extent of the signal window can be also ranked in a similar order, with the EnVision producing a 
10-fold difference between the background RFU and Emax RFU on the YIG152 2mM 3-AT data, while 
Mithras and Gemini produce a 4-fold difference (deduced from Figure 3.6 graphs [A], [B], [C].  
The other noticeable difference in Figure 3.6 is that the Emax RFU drop substantially with increasing 3-
AT concentrations, as recorded on the Mithras and Gemini instruments ([A] and [B]), while the RFUs 
obtained on the EnVision instrument [C] do not show such decrease in the Emax, ([D] and [F]) which 
indicates that this instrument is set for a different dynamic range (gain can be adjusted) than the other 
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two instruments tested. The pEC50 values obtained with all three instruments, however, can still be 
averaged out with an acceptable variation [D], giving confidence in the robustnes of the assay. 
 
Figure 3.6 Variation of RFUs generated on different instruments in YIG152 strain. Three instruments were 
evaluated – Mithras [A], Gemini [B], and EnVision [C]. The EnVision data produced the greatest signal window 
between baseline and signal but showed little reduction in Emax RFU when 3-AT concentration was increased 
[C] and [D]. The Mithras – and Gemini – produced data showed a lower signal window, and a decrease in Emax 
RFU at 5mM and 10mM 3-AT as compared to the lower 2mM concentration, overall demonstrating how the 
RFU profiles can differ depending on which instrument is used [D] and [F]. The pEC50 values produced on 
different instruments did not differ significantly [E]. 3-AT induced largest drop of Emax RFUs on Gemini produced 
data while Mithras RFUs dropped proportionally [D]. The fit of the data for all experiments was R2>0.95 [G]. 
n=1. 
72 
 
Interpreting the brimonidine-stimulated functional coupling of the α2B-AR receptor in YIG153 is less 
straightforward. The signal window is smaller and is equal to an approximately 2-fold increase in all 
three instuments (Figure 3.6). As established in section 3.2, this strain has a higher unspecific 
background signal, but the smaller signal window can also be the result of a weaker stimulation, since 
brimonidine is only a partial α2B-AR agonist, while it is a full α2A-AR agonist. This could be investigated 
if both receptors were tested with dexmedetomidine or guanfacine, which are in reverse – full α2B-AR 
agonists and a partial α2A-AR agonists. Nevertheless, the high background growth at lower 
concentrations of the 3-AT, the brimonidine-specific RFU signal is obscured when measured using the 
EnVision, but is much clearer when the assay was measured on other instruments, indicating that not 
only did the assay condition play a role in this example, but also the instrument configuration has too.  
  
Figure 3.7 Variation of RFUs generated on different instruments in YIG153 strain. Similarly to figure 3.5 
Mithras [A], Gemini [B], and EnVision [C] were evaluated in the strain expressing α2B-AR. Because of the 
high background at low 3-AT concentrations, the EnVision generated data do not show a concentration-
response relationship and therefore were not included in pEC50 value analysis in [D]. The signal windows 
in all examples YIG153 are not as great as in the previous example, partly because the brimonidine is only 
a partial agonist of this receptor. Emax and R2 values are shown in [E] and [F] respectively. 
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3.5. Experimental variation 
 
Experimental variation is illustrated using a sample of data which are discussed in more detail in 
Chapter 5. These data were generated on the same instrument (SprectraFluor Plus, Tecan), therefore 
providing a more accurate representation of data variation that would be observed when setting up a 
drug screening project. The optimised β1-AR and β2-AR expression was assessed in various MMY strains 
carrying a different chimeric Gpa1-Gα protein (please refer to the legends in Figure 3.8 panels [A] and 
[B] or in [C]). Isoprenaline, or isoproterenol, is a well characterised, subtype non-selective β-AR full 
agonist, and was selected in this study as a control compound to which the data were normalised. The 
data were collected using the same conditions (please refer to the Methods section 2.2.2) but on 
different days with the aim to show experiment-to-experiment variation. The error bars on the data 
points in [A] and [B] indicate SEM. SEM of pEC50 values are presented in [C]. Both indicators 
demonstrate that the experimental variation is reasonably low. 
 
Figure 3.8 Experimental variation in β1-AR and β2-AR expressing strains. Isoprenaline stimulated 
responses in MMY strains expressing β1-AR [A] show acceptable error bars, expressed as the SEM, and 
similar pEC50 values [C], with the exception of the Gα14 (MMY21) strain. The β2-AR was found to couple to 
less strains and the error bars and the pEC50 values are even less variable ([B] and [C]). The pEC50 are 
expressed as a mean of 3 individual experiment values. The mean values and the SEM were obtained from 
the three-parameter curve fit model (Graphpad Prism, V7). 
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3.6. Compound screening on α2A-AR and α2B-AR in yeast  
 
To demonstrate the utility of the yeast functional GPCR assay, a panel of 23 compounds of known and 
unknown activity on α adrenoceptors (see Table 2.2) were tested. The results at 2mM and 10mM of 
3-AT are shown in Figure 3.9 to illustrate the improvement after optimal 3-AT concentration was 
determined. The data shows that there are three potent α2A agonists in this experiment ([A] and [C]). 
Three parameter non-linear fit analysis revealed pEC50 values of 4.79, 5.46, and 6.34 for compounds 9, 
11, and 19 respectively [C]. The remaining twenty compounds did not show significant effect on this 
receptor.  
For the other receptor in this sub-family – α2B – the profile appeared quite different ([B] and [D]). 
Nineteen compounds demonstrated strong to moderate agonistic effects at 10mM of 3-AT ([D]). 
Compound 22 shows a characteristic profile of a partial agonist. And finally, compounds 4, 8, and 21 
appeared as inverse agonists and showed strong inhibition of growth and hence the fluorescent signal 
even at 2mM 3-AT which was generally too low to inhibit background growth to reveal agonistic effect 
of other ligands. In fact, compound 8 is yohimbine, a known α2 antagonist [70]. Compounds 9, 11, and 
19 showed potency as agonists on α2B as well as on α2A with pEC50s of 6.48, 7.56, and 9.07 respectively 
([D]).  
Compound 19, which is generally known as UK 14,304 or brimonidine, is a potent α2 agonist [71], which 
data presented in Figure 3.9 confirm.  
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Figure 3.9 Compound profiling on α2A and α2B receptors. Results at 2mM [A] and 10mM [C] of 3-AT on α2A 
receptor. The relative fluorescence units are plotted against log compound concentration in molar units. 
Compounds 9, 11, and 19 emerged as potent agonists of α2A receptor. pEC50 values for these compounds are 
5.27, 5.74, and 6.59 respectively. Results at 2mM [B] and 10mM [D] of 3-AT on α2B receptor. The majority of 
profiled compounds showed agonistic effect on the α2B receptor with compounds 4, 8, 21, and 22 being an 
exception. Compounds 9, 11, and 19 appear to be potent agonists on the α2B receptor, pEC50 values of 6.34, 
7.47, and 8.38 respectively. For all data in this figure n=1. 
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3.7. The parameter-dependent variations of the functional GPCR assay in yeast – 
what to expect and how to interpret the data 
 
As with any pharmacological assay, it is important to establish which observations and changes can be 
attributed the interactions between the drug and the receptor, and which are the artefacts of the 
method. This chapter was aimed at establishing this in more detail than has been described in the past 
literature. In an industrial setting, the assay plate would be designed to include two controls: a positive 
– known full agonist, and a negative – a non-interacting molecule, each present in >8 wells, from which 
the ‘Z’ value is calculated. The purpose of these controls would be to build statistical significance in 
assay readiness, therefore the experimental variation associated with controls has to be well 
understood. The experiments described in 3.2 – 3.5 were aimed at understanding the behaviour of the 
positive control agonists, especially when attempting to express and characterise previously such as 
β1-AR and β2-AR receptors described in the later chapters. Some of the experiments were designed to 
confirm the observations previously made by colleagues at GSK, and some resulted from experience 
at the Aston University.  
What was quickly apparent is that 3-AT is a powerful inhibitor of His3-induced growth, which in some 
strains results from a high unspecific expression of the HIS3 gene.  This could be explained by the 
activation of the STE12 promoter by other factors than the Gβγ activated signalling cascade [72], 
although this effect would likely be consistent between the strains. Another important aspect of 
signalling fidelity is ratios of the Gα and Gβγ subunits; lower Gα ratio leaves uncoupled Gβγ, weakly 
activating the signalling cascade, while higher ratio sequesters the Gβγ reducing the signal. During the 
last stage of the MMY strain engineering the chGα proteins were introduced last and possibly 
integrated with a different copy numbers, however chGα protein expression levels have been shown 
to be very similar [2]. Nevertheless, it was observed at GSK that some strains always produce higher 
background, indicating that it is the strain background rather than the GPCR that will determine high 
unspecific RFU signal in the assay. 
Although this phenomenon can be controlled with variation of the 3-AT concentrations very 
effectively, what the 3-AT is less able to produce is a wider signal window, that is a difference between 
basal RFU and the maximum (Emax) RFU. If the ability of the agonist to keep the receptor in the active 
conformation is weak, as could be the case in α2B-AR examples presented in Figures 3.3 and 3.7, then 
the increased 3-AT concentration not only inhibits the unspecific but also the signalling cascade-
activated expression of His3 (Figure 3.3 [C], [D], [E]). The increased substrate FD-glu can somewhat 
increase the signal window (Figure 3.5) but it is a less desirable solution. If the control agonist is only 
able to produce several-fold signal induction, a pharmacology study of other modulators, such as 
potent partial agonists, would be difficult and perhaps even misleading, because in a small signal 
window lower efficacy may not be detected. Finding a more suitable control would be a better 
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solution, or look into other ways to improve the expression of the GPCR, which is discussed in results 
chapter 4. This is not always achievable because the pharmacology of GPCRs is a complex phenomenon 
and the role of the expression host are important, which is discussed further in this thesis.  
The final conclusion of this chapter is that the assay parameters can be adjusted to fine tune the best 
signal window, but a robust expression of the receptor is required. The illustration of this principle is 
the fact that even sub-optimal conditions (such as high 3-AT, lower substrate concentrations, less 
sensitive instrument obtained RFUs) were able to demonstrate a similar potency of the full agonists 
brimonidine on the α2A-AR expressing YIG152 as compared to the potency obtained at optimal 
conditions. It also shows that the functional yeast FD-glu assay is a robust method for assessing the 
pharmacology of the GPCR interacting molecules.  
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Chapter 4 – The functional expression of adrenoceptors β1 and β2 in 
MMY strains 
 
4.1. Introduction 
 
The adrenoceptors α2A and α2B expressed in the MMY yeast have been demonstrated in the previous 
chapter to facilitate a potential drug candidate high-throughput screening. Another sub-class of the 
adrenoceptors β1-AR and β2-AR are also drug targets for asthma, obstructive pulmonary disease, 
hypertension and other diseases. However these receptors were not successfully expressed in MMY 
strains at GSK in the past. The aim of this chapter is therefore is to investigate the different expression 
methods in the pursuit of functional expression of these two receptors.  
There are generally two methods for introducing recombinant genes for protein production in yeast – 
the first one relies on the gene being integrated in a specific locus together with transcription initiation 
elements upstream of the reading frame. In the second method, the genetic design of the expression 
cassette may be the same but the plasmid, in which these elements are constructed, is able to replicate 
independently from the genetic DNA in a form of the circular plasmid.  Both methods have been tested 
and presented in this chapter. Furthermore, different leader sequences, or cell surface expression 
signals, have been described in the literature that have various effects on membrane protein 
expression and localisation. In order to identify the best plasmid construct for the functional 
expression of adrenoceptors β1 and β2 Ste2 receptor N terminal and the mating factor α leader 
sequences (MFα) were tested.  
The episomal p426GPD plasmid transformant screening results indicate leader sequence and receptor 
dependent effects. Potentially coupling MMY strains - GαS, Gαq, Gα14 and Gpa1 (native yeast Gα) – 
were identified for β1-AR receptor. However, all β2-AR transformants seem to have lost any coupling 
over time. For this reason the functional expression of both receptors was tested using integrating 
p306GPD plasmids which is discussed in section 4.2. A major finding of this chapter is that the 
functional expression of β2-AR was finally achieved. Both receptors β1-AR and β2-AR remained stably 
expressed over time, allowing for further pharmacological characterisation for the first time in the 
MMY yeast strains. The section 4.3 compares to the protein expression differences between these 
different expression systems. It was found that non-functional colonies did not express the β-
adrenoceptor but further work is needed to investigate what it means in terms of cellular response 
and receptor localisation. 
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4.2. Episomal p426GPD plasmids for the expression of β1-AR and β2-AR 
 
Episomal expression plasmids are a useful tool in identifying the best coupling in chGα strains for 
individual receptor in MMY strains because they are maintained at high copy number [73] in the cell 
and when a strong constitutive promoter, such as GPD, is used the expression of the gene of interest 
is usually very efficient [73]. Furthermore, the 2 micron origin of replication present in the plasmid 
allows it to propagate independently and genomic integration is not required, increasing the success 
of the yeast transformation.  The p426GPD series vectors were used in this work with and without 
additional leader sequences, such as MFα and Ste2p secretion signals, upstream from 5’ end of the 
gene of interest.  
 
4.2.1. The construction of p426GPD-(MFα/Ste2)-ADRB1 and p426GPD-(MFα/Ste2)-
ADRB2  
 
Three variants of p426GPD were used to construct episomal expression plasmids – p426GPD (standard 
with no leader sequence), p426GPD-MFα, and p426GPD-Ste2L. The latter two contain secretion signal 
for protein translocation into the plasma membrane. The ADRB1 and ADRB2 genes were inserted into 
the MCS using conventional molecular biology tools. The strategy for each plasmid type is described 
below and the detailed procedures can be found in the Methods and Materials section and Appendix 
B.  
 
‘The standard’ p426GPD-ADRB1/ -ADRB2 expression constructs 
The ADRB1 (1434bp) and ADRB2 (1242bp) genes were inserted into the p426GPD vector (6602bp) 
using the BamHI endonuclease site. The ADRB1 gene was obtained by PCR amplification from the 
p426GPD-DEST-ADRB1 plasmid template and the ADRB2 was cut out from the p426GPD-HA-ADRB2 
plasmid (both these plasmids were constructed in GSK). The reason behind constructing these 
plasmids was to compare the receptors’ expression without any additional sequences, such as the 
‘Gateway’ cloning sequences and the HA tag. Several endonuclease digestions were performed to 
select for plasmids with a ligated insert, and, because the BamHI digested gene fragments were able 
to insert in the correct or the reversed order, correct orientation of the insert was tested too: 
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p426GPD-ADRB1 
1) BamHI: 2 fragments 1444bp + 6602bp; 
2) SacI: 1 fragment – 8046bp if insert is present, 6602bp if no insert; 
3) XmaI: 2 fragments – 171bp + 7875bp if correct insertion, 1285bp + 6761bp if reverse orientation. 
 
p426GPD-ADRB2 
1) BamHI: 2 fragments 1248bp and 6602bp; 
2) SacI: 1 fragment – 7850bp if insert is present, 6602bp if no insert; 
3) EcoNI + EcoRI: 2 fragments – 525bp + 7325bp if correct insertion, 756bp + 7094bp if reverse 
orientation. 
 
The correct plasmid constructs were successfully identified; the results of this are depicted in Figure 
4.1. 
  
Figure 4.1 Construction of p426GPD-ADRB1 and p426GPD-ADRB2. The top panel depicts the results of 
p426GPD-ADRB1 selected clones that were digested with BamHI (lanes 1-4), SacI (lanes 5-8) and XmaI (lanes 
9-12). Although lanes 1-8 show that all plasmids had the insert, lanes 9 and 11 show an additional band of 
around 1200bp, indicating that the gene in these plasmids has been inserted in a reversed orientation. 
Therefore only clones 2 and 4 (lanes 10 and 12) have the correctly inserted gene. In the bottom panel 
p426GPD-ADRB2 digestion results are shown. In this case only clones 1 and 3 had a gene inserted as 
demonstrated by the BamHI (lanes 13 and 15) and SacI (lanes 17 and 19) digestion patterns. However, clone 
1 when digested with EcoRI and EcoNI double digestion (lane 21) revealed an additional band of around 
700bp which indicates a reverted orientation. Clone 3 (lane 23) has however, produced the correct size bands 
and was selected as a positive ligation result for this plasmid. 
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The mating factor α p426GPD-MFα-ADRB1 / -ADRB2 expression constructs 
The second set of plasmids depicted in Figure 4.2 was designed to have a 242bp fragment of mating 
factor α sequence linked to the 5’ end of the gene. This fragment was already present in the parental 
vector designated p426GPD-MFα. Just as the ‘standard’ empty p426GPD, this vector has also a GPD 
promoter upstream of the MFα leader sequence, then a MCS for a convenient insertion of desired 
genes, and the CYC1 terminator downstream. The insertion of the ADRB1 and ADRB2 genes into the 
p426GPD-MFα was carried out using the NcoI endonuclease site at the 5’ end of the gene and BamHI 
at the 3’ end for both of the genes. Digesting the parental plasmid and the p426GPD-ADRB1/ADRB2 
plasmid, from which the genes of interest were obtained, with these enzymes resulted in the 
compatible ends at the correct orientation, therefore only the presence of the fragment was sufficient 
for confirming that the right construct was obtained following the ligation procedure.  
 
The Ste2 pre-pro leader sequence containing p426GPD-Ste2L-ADRB1 /-ADRB2 expression constructs 
Similarly to the p426GPD-MFα vector, the p426GPD-Ste2L has a 39bp leader sequence upstream from 
the MCS. The PCR amplified ADRB1 and ADRB2 genes were inserted into this parental vector at the 
EcoRI site at the 5’ end and the SalI at the 3’ of the gene. The resulting predicted plasmid maps are 
Figure 4.2 Construction of the p426GPD-MFα-ADRB1 and p426GPD-MFα-ADRB2. Two restriction analyses 
were performed with [A] NcoI and BamHI enzymes, lanes 1-4 on the ADRB1 construct and lanes 5-8 on the 
ADRB2 construct, revealing that only ADRB2 plasmid clone 3 (lane 7) did not have the insert. [B] The restriction 
with BamHI confirmed that in all 7 selected plasmids, the ADRB1 construct in lanes 1-4 and the ADRB2 
construct in lanes 5-7, the second BamHI restriction site at the 5’ end present in the donor vector has been 
deleted, as the enzyme is shown to cut only once. The small MFα leader sequence fragment has been inserted 
just downstream from the GPD promoter in both vectors. The constructs were designed so that upon 
activation via the GPD promoter the MFα leader and β1-AR or β2-AR would be translated as one protein with 
a short linker between the two subunits.  
1000bp 
1500bp 
3000bp 
8000bp 
1000bp 
1500bp 
3000bp 
8000bp 
1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 
A  p426GPD-MFα-ADRB1 | p426GPD-MFα-ADRB2 p426GPD-MFα-ADRB1  | p426GPD-MFα-ADRB2B 
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available in the Appendix B. One clone of each plasmid with the inserted gene was analysed using the 
same EcoRI or SalI endonucleases to demonstrate the full size of the linearised plasmid or both 
enzymes to show the inserted fragment (Figure 4.3). 
 
4.2.2.  The transformation of MMY 12-28 strains with p426GPD episomal plasmids 
 
The MMY yeast grew on WHAUL+His-Ura plates (supplemented with histidine because the receptors 
are not stimulated) in 48h when transformed with p426GPD-ADRB1/ -ADRB2 and p426GPD-Ste2L-
ADRB1/ -ADRB2 plasmids but an additional 48h were required for p426GPD-MFα-ADRB1/ -ADRB2 
transformants to grow. In addition, the colonies of variable size and irregular shape formed in the later 
transformant group as shown in Figure 4.4, insert C. In contrast, the ‘no leader’ and ‘Ste2 leader’ 
plasmid containing colonies appeared consistent in size and round in shape, insert B. This phenomenon 
was observed across all MMY strains; transformation of strains MMY 15, 22, and 28 are shown in Figure 
4.4.  
Both MMY15 and MMY28 carry a chGαS, however during the generation of MMY strains two colonies 
of GαS stain were observed to have different coupling properties to mammalian GPCRs and therefore 
were designated as separate strains – MMY15 and MMY28. 
  
Figure 4.3 Construction of the p426GPD-Ste2L-ADRB1 and p426GPD-Ste2L-ADRB2. [A] The endonuclease 
restriction analyses were performed with EcoRI (lanes 2 and 5), SalI (lanes 3 and 6) which show the linearised 
vector of around 8,000bp, or both the enzymes (lanes 4 and 7) which show a fragment of approximately 
1,500bp in case of the ADRB1 gene in lane 4, or 1,200bp in the case of the ADRB2 gene in lane 7.  
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p426GPD-ADRB1/ADRB2  
p426GPD-Ste2-ADRB1/ADRB2  
p426GPD-MFα-ADRB1/ADRB2  
MMY15 
MMY15 
MMY22 
MMY22 MMY28 
MMY15 
β1 β2 
MMY22 
β1 β2 β1 β2 
β1 β2 β1 β2 
β1 β2 
β1 β2 β1 β2 β2 
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β1 
MMY28 
B 
C 
Figure 4.4 MMY yeast transformation result. p426GPD-ADRB1/ADRB2 transformed MMY15 (Gs), 22 
(Go) and 28 (Gs) strains shown in the top row of the main panel, p426GPD-Ste2-ADRB1/ADRB2 
transformed yeast in the middle row, and p426GPD-MFα-ADRB1/ADRB2 in the bottom row. The same 
number of cells was plated on each half of the plate during the same transformation experiment. The 
standard and Ste2 vector transformed cells formed round, uniformly sized colonies (insert B). The MFα 
vector transformants took an additional 48h to form comparably sized colonies, which appeared to be 
irregular in shape (insert C), variable in size and lower in overall number. The growth was reduced even 
further in cells transformed with p426GPD-MFα-ADRB2.    
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4.2.3.  Overview of the pre-screening strategy for the identification of functional 
colonies 
 
 
 
Each of the 6 plasmid constructs was transformed into 12 MMY strains, generating 72 populations of 
transformed yeast. Because of the instability of the ura3-1 nutrient selection marker and low 
transformation efficiency, transformed colonies may or may not contain the desired plasmid at 
variable copy number. For this reason, four to eight colonies from each transformation population 
were screened based on their ability to elicit a response upon high concentration of known beta-
adrenergic agonist isoprenaline (or isoproterenol). Because not all chGαs were expected to 
demonstrate positive coupling with the receptor and in turn respond to agonist stimulation due to 
their different chGα protein, the functional screening was the most straightforward strategy to select 
colonies that had been correctly transformed and were capable of coupling with the β-adrenoceptors. 
The example in Figure 4.6 shows a typical profile of colonies that show positive growth induction and 
hence RFU signal when stimulated with 100µM isoprenaline as compared with background growth 
with no agonist present. MMY21 colonies transformed with β1-AR (Figure 4.6 [A]) and with β2-AR [C] 
are compared with MMY25 colonies also transformed with β1-AR [B] and β2-AR [D] gene carrying 
plasmids. A variation in total RFUs could be observed in isoprenaline stimulated and negative control 
groups represented by solid and hatched bars respectively. The differences of RFUs between these 
two groups were analysed based on duplicate raw data and taken as an indication of potential 
functional coupling. Although this is only a sample of all data collected, it accurately represents all data 
Figure 4.5 The overview of colony selection strategy for the identification of functional expression of 
β1-AR and β2-AR in p426GPD vectors. 
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collected. Using this approach a population of 69 colonies were selected as potentially functionally 
coupling. As can be seen from Table 4.7 [A], nearly two-thirds of all colonies were carrying the ADRB1 
plasmid. The majority of those were transformed with p426GPD-MFα-ADRB1 while ADRB2 colonies 
were mostly transformed with ‘no leader’ plasmid p426GPD (Table 4.7 [B]). 
  
Legend:
Pattern
- Induced growth
 - Background growth
Colour
 - p426GPD-ADRB1/ADRB2 (no leader sequence)
 - p426GPD-MFa-ADRB1/ADRB2 
 - p426GPD-Ste2-ADRB1/ADRB2
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Figure 4.6 An example of a pre-screening experiment. 
The transformants carrying episomal ADRB1 gene 
constructs [A and B] or ADRB2 gene constructs [C and 
D] are shown. For illustration of the example MMY21 [A 
and C] and MMY25 [B and D] colony pre-screening 
results are shown. Relative fluorescence units (RFU) are 
on the Y axis; on the X axis the values of isoprenaline-
stimulated growth are shown in solid colour, and 
background growth in hatched colour. The screening 
experiments were carried out in duplicates. Results of 
one replicate are shown. The different colours 
represent the type of vector, as shown in the legend. As 
summarised in Table 4.7.B, the majority of selected 
ADRB1 transformants carried the MFα construct 
(orange boxes in [A], while “no leader” constructs were 
more frequently selected for ADRB2 transformants 
(blue boxes in [B]). 
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4.2.4. Episomal plasmid screening results  
 
The 69 colonies obtained in the pre-screening process were further investigated using isoprenaline in 
serial 3-fold dilutions ranging from 1.69x10-9 to 1x10-4M. The full curve experiments revealed that the 
majority of colonies showing potential coupling did not show a concentration-dependent response to 
isoprenaline. Based on the initial experiment with fresh transformants, 14 were selected and frozen 
with glycerol added at -80°C for long term storage. The experiments with isoprenaline dilutions were 
repeated on those colonies that had undergone a freeze-thaw cycle to obtain 3 independent 
experimental repeats. The conditions were kept consistent throughout the experiments and the 
results for ADRB1 and ADRB2 transformants are depicted in Figures 4.9 and 4.10, respectively.  
The episomally-expressed ADRB1 was found to couple weakly to native yeast Gpa1, Gαq, Gα14 and GαS 
strains, summarised in Table 4.8. The most reproducible results were generated in the GαS strain 
MMY15 (Figure 4.9 [C]), however, the alternative strain MMY28 transformed with the same plasmid 
did not match the results observed in the MMY15. The highest pEC50 was obtained from the Gα14 strain 
clone 18B1 (pEC50=5.28, ±0.33, r2=0.58), but the standard error is high and the fit value is low. The Gαq 
strain MMY21 and Gpa1 strain MMY12 yeast clones have a relatively low standard error and closely 
fitting curves (Figure 4.9 [B] and Table 4.8).  
The ADRB2 transformants retained virtually no activity after the freeze-thaw cycle, which was initially 
observed in the first screening experiments with fresh colonies, as is demonstrated in Figure 4.10 – 
the left hand panels A, C, E, G show the average of 3 repeats while the right hand panels B, D, F, H are 
the results of the initial experiment on which basis the colonies were frozen for further 
experimentation.  
Table 4.7 Distribution of colonies pre-selected as potentially functional according to the strain and plasmid 
construct. All 69 colonies that were selected in the pre-screening experiments for further testing with a full 
range of isoprenaline are grouped in table A according to the MMY strain, plasmid and receptor. In table B the 
same colonies are summarised according to the receptor and plasmid type – no leader, MFα, or Ste2. 
A B
No leader MFα Ste2 No leader MFα Ste2
12 - 3 1 1 - - Vector ADRB1 ADRB2
14 - 4 1 1 - - No leader 5 11
15 2 3 1 - - - Mfa 27 6
16 - 2 1 2 - 1 Ste2 12 8
19 - - 1 1 - 1 Total 44 25
20 - 3 3 1 3 2
21 1 6 2 1 - 2
22 - - - 2 1 -
23 - 2 - - - -
24 - 1 - - - -
25 - - 2 - 1 -
28 2 3 - 2 1 2
Total 5 27 12 11 6 8
ADRB1 ADRB2 Summary of colonires 
responding to 100µM of 
isoprenaline
M
M
Y 
st
ra
in
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One common observation was that the RFU readings in the control wells with no isoprenaline very 
frequently were higher than the readings of the wells with the lowest isoprenaline concentrations. For 
this reason much of the curve on the graphs appear in the negative scale, since the background RFU 
has been subtracted. This is mostly observed in colonies with transformed β2-AR plasmids. At first it 
was thought to be an artefact of the well’s position on the plate, however, no significant evaporation 
in column 12 was observed across different experiments. Nevertheless, this observation does not 
change the main conclusion of this work, which is that none of the yeast colonies transformed with 
the episomal plasmids showed a significant β2-AR mediated responsiveness to the isoprenaline that 
would be robust and reproducible.  
Experiments were performed over the period of 48h; readings were taken at several intervals, 
including 24h and 48h, which were later used for data analysis. It was observed, that often 24h were 
not sufficient to produce RFUs indicative of a response to isoprenaline and after an additional 24h, the 
signal improved. 
 
Sample pEC50 SEM r2 Receptor Strain Plasmid Chimeric Gα 
3B2 N/A - 0.06 β2-AR MMY 16 Standard Gα16 
4B2 N/A - 0.08 β2-AR MMY 19 Standard Gα12 
5B2 N/A - - β2-AR MMY 20 Standard Gα13 
6B2 N/A - 0.04 β2-AR MMY 21 Standard Gα14 
13B1 5.07 0.30 0.63 β1-AR MMY 12 MFα Gpa1 
14B1 4.27 0.70 0.33 β1-AR MMY 12 MFα Gpa1 
16B1 4.89 0.25 0.71 β1-AR MMY 14 MFα Gαq 
18B1 5.28 0.33 0.58 β1-AR MMY 21 MFα Gα14 
19B1 4.91 0.52 0.37 β1-AR MMY 21 MFα Gα14 
26B1 4.93 0.34 0.57 β1-AR MMY 14 MFα Gαq 
57B1 5.07 0.23 0.74 β1-AR MMY 15 MFα GαS 
59B1 N/A -  β1-AR MMY 28 MFα GαS 
61B1 4.16 1.10 0.19 β1-AR MMY 28 MFα GαS 
62B1 4.64 0.15 0.88 β1-AR MMY 15 Ste2 GαS 
 
 
Table 4.8 Summary of episomal colony screening results. The colonies marked in blue carrying 
ADRB2 gene; failed to produce any response to isoprenaline after the freeze-thaw cycle and hence 
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Figure 4.9 The β1-AR expressing MMY strain responses to the isoprenaline stimulation. Response to 
increasing concentrations of β-AR agonist isoprenaline was detected in five different MMY strains 
transformed with an episomal vector construct: [A] – MMY12 (Gpa1), [B] – MMY14 (Gαq), [C] – MMY 15 
(Gαs), [D] – MMY21 (Gα14), [E] – MMY28 (Gαs). Only the colonies which showed concentration-response 
relationship upon full range of isoprenaline concentrations were frozen and tested again to obtain n=3.  As 
shown in this figure only 10 colonies out of initially selected 44 ADRB1 expressing colonies (Table 4.7) were 
frozen.  
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Figure 4.10 The β2-AR expressing MMY strain responses to isoprenaline stimulation. Response to 
increasing concentrations of β-AR agonist isoprenaline was detected in four different MMY strains 
transformed with the p426GPD-ADRB2 vector: [A] and [B] – MMY16 (Gα16), [C] and [D] – MMY19 (Gα12), [E] 
and [F] – MMY20 (Gα13), [G] and [H] – MMY21 (Gα14). The initial screening results are presented on the left 
hand-side. However, when the assay was repeated after freeze-thaw cycle (n=3), the isoprenaline-
stimulated growth could not be replicated in the same colonies as shown on the right hand-side.  
Freshly picked After freeze-thaw 
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4.2.5.  Summary of episomal plasmid screening results 
 
The purpose of testing the episomal plasmid system was to evaluate it as a tool for selecting the best 
coupling strain for a particular receptor. The episomal plasmids are maintained at high copy number 
and are easy to transform into yeast. The three different p426GPD constructs were designed for each 
receptor containing either one of the leader signal sequences – MFα or Ste2 – as well as no leader 
sequence. The native yeast leader sequences facilitate the target protein transportation to the cell 
membrane, and because GPCRs normally reside in the cell membrane it seemed it would be beneficial 
for its expression in the recombinant host. The first observation of leader sequence dependent effects 
was observed at the transformation level as shown in Figure 4.4 Inserts B and C show the difference 
in colony shape and uneven size which can be attributed to the MFα leader sequence as neither the 
‘no leader’ nor the Ste2 leader plasmids display this phenotype. Together with reduced overall number 
of colonies this could be a sign that the cells are stressed due the burden of recombinant protein 
expression.  
The second observation of plasmid construct dependent effects was made after the pre-screening 
experiments which concluded that there was a preference for a particular plasmid construct. As 
summarised in Table 4.7.B, the majority of β1-AR expressing colonies selected as potentially coupling 
carried the MFα sequence in the construct. However, β2-AR expressing colonies that were selected 
carried the ‘standard’ plasmid construct with no leader sequence. This could be linked to that fact that 
significantly fewer β2-AR colonies grew when transformed with the MFα plasmid construct.  
The pre-screening experiments identified 69 colonies which potentially demonstrated functional 
receptor expression. To follow this up, they were then tested with a range of isoprenaline to evaluate 
whether they actually responded to ligand stimulation. The samples then were narrowed down to 14 
colonies (summarised in Table 4.8) which were archived at -80°C. To evaluate whether cells can retain 
the episomal plasmid and demonstrate the same functionality, a fresh plate was streaked out from a 
frozen glycerol stock and the experiments were carried out on two different days to generate the 3 
independent repeats. This is important because episomal plasmids are known for mitotic instability 
[74], which would make the system unstable in the long term. However, we did not see a uniform 
effect of the freeze-thawing because the β1-AR transformants were able to demonstrate comparable 
functionality while β2-AR completely lost any function. Further investigation is needed to understand 
this receptor dependent effect.  
Although episomal plasmids were a useful tool for identification of potentially coupling MMY strains 
for the β1-AR there was overall insufficient robustness for both receptors. It was anticipated that, the 
integrative plasmids may provide to be more useful in evaluating the β2-AR functionality in this yeast 
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assay. Furthermore, the integrative plasmids were expected to show less variability between the 
different transformation colonies as they carry one copy of the plasmid in the genome. It was therefore 
decided to pursue the use of integrative vectors for all future studies. 
 
4.3. Integrative p306GPD plasmids for the expression of β1-AR and β2-AR 
 
The integrative p306GPD series vectors have some similarities to the above - described episomal 
vectors, such as the GPD promoter and CYC1 terminator elements that regulate the gene expression, 
as well as the URA3 selection marker. However, these vectors are not able to replicate independently 
and therefore have to be integrated at the URA3 locus by homologous recombination. For this reason 
the yeast transformation procedure requires an additional step, which is unfavourable for screening a 
greater number of plasmid-strain combinations. Another key difference is that the gene is maintained 
at a significantly lower copy number in the cell which is expected to result in a lower protein expression 
level when compared to expression of p426GPD transformed yeast.  
4.3.1.  The construction of the p306GPD-(MFα)-ADRB1 and p306GPD-(MFα)-ADRB2 
plasmids 
 
Based on the episomal plasmid screening results, it was anticipated that the p306GPD-MFα-ADRB1 /-
ADRB2 would be the best plasmid construct for the expression of both receptors. However, for the 
purpose of comparing both the expression level and functional expression level the ‘standard’ plasmids 
were also constructed. The Ste2L leader sequence did not appear to significantly improve the 
expression of either β1-AR or β2-AR therefore was omitted from the comparison in the integrative 
plasmid system.  
 
The ‘standard’ p306GPD-ADRB1 /-ADRB2 
The ADRB1 and ADRB2 fragments were obtained from the p426GPD-ADRB1 /-ADRB2 plasmids and 
inserted into the 5266bp long p306GPD vector at the SpeI restriction site at the 5’ end and the SalI and 
the 3’ end of the gene of interest. Both of the endonucleases were used in the enzymatic digestion 
analysis to confirm the correct insertion of the gene fragments (Figure 4.11).  
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The p306GPD-MFα-ADRB1 /-ADRB2 plasmids 
Similarly to the previous plasmids, the ADRB1 and ADRB2 genes along with the MFα leader sequence 
were cut out from the p426GPD-MFα plasmids and inserted into the MCR of the p306GPD vector a 
the SpeI site at the 5’ end of the gene and HindIII at the 3’ end (Figure 4.12).  
Figure 4.11 Construction of the p306GPD-ADRB1 and p306GPD-ADRB2. The endonuclease restriction 
analyses were performed with SpeI (lanes 2 and 5), SalI (lanes 3 and 6) which show the linearised vector of 
around 6500-6700bp, or both the enzymes (lanes 4 and 7) which show a fragment of approximately 1500bp 
in case of ADRB1 gene in lane 4, or 1200bp ADRB2 gene in lane 7. These sizes are consistent with predictions. 
Figure 4.12 Construction of the p306GPD-MFα-ADRB1 and p306GPD-MFα-ADRB2. The endonuclease 
restriction analyses were performed with SpeI (lanes 2 and 5), SalI (lanes 3 and 6) which show the linearised 
vector of around 6,500-6,700bp, or both the enzymes (lanes 4 and 7) which show a fragment of approximately 
1,500bp in case of ADRB1 gene in lane 4, or 1,200bp for the ADRB2 gene in lane 7.  
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4.3.2. The transformation of MMY12-24 yeast with the p306GPD plasmids and the 
functional colony selection 
 
To build on the findings of episomal plasmid screening for functional β1-AR and β2-AR expression in the 
MMY yeast, the p306GPD-MFα-ADRB1 and p306GPD-MFα-ADRB2 plasmids were deemed to have the 
highest likelihood of success of producing functional expression. The p306GPD-ADRB1 and p306GPD-
ADRB2 were transformed only into MMY15, to make a direct comparison with the leader sequence 
MFα-containing plasmid, as well as the episomal p426GPD plasmids in both functional assays and 
western blots.  
As with the episomal plasmids, the MMY strains with the integrated p306GPD plasmids appeared after 
48h following transformation (Figure 4.13). The irregular shape of the colonies observed in the 
p426GPD-MFα transformed yeast (Figure 4.4, insert C) was observed in a few colonies transformed 
with the p306GPD-MFα plasmid, but were far fewer in number as compared to the episomally 
transformed yeast. Generally, the transformations worked well, however, the MMY25 transformed 
yeast did not produce any colonies and MMY28 was not tested, because it was previously shown that 
the other version of the GαS strain, MMY15, was more favourable for the functional expression of β1-
AR. 
 
 
 
 
 
 
 
Because of a lower number of transformants to screen, the pre-selection step was not employed. 
Instead, 4-8 colonies from each transformed MMY strain were tested with serial 3-fold dilutions of a 
known β-AR agonist, isoprenaline. The complete data set for the β1-AR and β2-AR expressing yeast was 
collected in 4 individual experiments, using two different instruments on two different sites. In order 
to demonstrate the variation of responses, the RFU were not normalised and were instead plotted as 
RFU values from which the background RFU of a well containing only solvent was subtracted. 
Furthermore, because of different signal windows between the instruments, and indeed between 
experiments, the RFU scale was matched for all data within the same experiment. This was necessary 
A B Figure 4.13 Transformation of the MMY15 with p306GPD vectors. 
The GαS strain was transformed 
with the p306GPD-MFα-ADRB2 
vector [A], and the p306GPD-
ADRB2 vector with no leader 
sequence [B]. Unlike the episomal 
vectors, the p306GPD vectors have 
to integrate into the genome at the 
URA3 locus in order to be 
maintained and allow the cells to 
survive on a plate lacking uracil. 
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in order to distinguish which of the MMY strains demonstrated functional coupling with β-AR. For 
example, in Figure 4.14 [A], the MMY12 colonies expressing β1-AR gave very high RFUs of 
approximately 4x106, which is nearly two orders of magnitude (80 times to be precise) higher than the 
signal which was obtained from screening MMY14 and MMY24 colonies presented in [B] and [J] 
respectively. The experiment for MMY15 presented in [C] of the same figure gave RFUs of 1x105 which 
are between the ranges of the two experiments described above. This is likely to be a technical artefact 
because of several observations. The first is that the colonies for screening experiments are grown in 
96-well plates, and because of the small volume of culture, their OD600 readings tend to be lower than 
would be observed in a larger culture. As a consequence, when the cells are diluted into the assay 
mixture, the final OD600 and carry-over histidine might be higher than intended, which boosts the cell 
number and the generated RFU. The second observation is that if the receptor is unable to functionally 
couple to the chGα in a particular strain, then even at higher cell inoculation numbers the response to 
the agonist is not observed. This is particularly evident in the strains expressing β2-AR in Figure 4.15 
which responded to isoprenaline in fewer strains than β1-AR.  
It was concluded that β1-AR shows functional coupling in MMY strains 12 (Gpa1), 14 (Gαq), 15 (GαS), 
16 (Gα16), 21 (Gα14), 22(GαO), 23 (Gαi1), and 24 (Gαi3). The MMY20 (Gα13) transformant showed a very 
weak response to isoprenaline compared to other strains. The β2-AR responded to isoprenaline 
stimulation only in 5 MMY strains - 14 (Gαq), 15 (GαS), 16 (Gα16), 21 (Gα14), 23 (Gαi1). This was an 
important achievement of project’s milestone as it allowed for further pharmacological investigation 
of these receptors in the yeast as discussed in Chapter 5. 
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 Figure 4.14 The β1-AR expressing MMY strain responses to the isoprenaline stimulation. Response to 
increasing concentrations of β-AR agonist isoprenaline was detected in ten different MMY strains 
transformed with the integrating p306GPD-MFα-ADRB1 vector: [A] – MMY12 (Gpa1), [B] – MMY14 (Gαq), 
[C] – MMY 15 (GαS), [D] – MMY16 (Gα16), [E] – MMY19 (Gα12), [F] – MMY20 (Gα13), [G] – MMY21 (Gα14), 
[H] – MMY22 (GαO), [I] – MMY23 (Gαi1), [J] – MMY24 (Gαi3). The differences in the RFU scale arise from 
different days and/or instruments used for screening. The scale of RFU for each strain reflects the level of 
signal produced in comparison to other strains tested on the same experiment. n=1 
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  Figure 4.15 The β2-AR expressing MMY strain responses to the isoprenaline stimulation. Response to 
increasing concentrations of β-AR agonist isoprenaline was detected in ten different MMY strains 
transformed with the integrating p306GPD-MFα-ADRB1 vector: [A] – MMY12 (Gpa1p), [B] – MMY14 (Gαq), 
[C] – MMY 15 (Gαs), [D] – MMY16 (Gα16), [E] – MMY19 (Gα12), [F] – MMY20 (Gα13), [G] – MMY21 (Gα14), [H] 
– MMY22 (GαO), [I] – MMY23 (Gαi1), [J] – MMY24 (Gαi3). n=1 
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4.3.3.  Summary of integrated plasmid screening results 
 
The purposes of transforming the yeast strains with integrated plasmids after preliminary functional 
expression was assessed in the episomal expression system was to improve the expression of the β2-
AR receptor and to compare the two different systems. This was achieved.  
The responses in MMY12, 14, 15 and 21 observed in the p426GPD-MFα-ADRB1 tranformed yeast were 
largely replicated in the p306GPD-MFα-ADRB1 transformed yeast, with additional strains MMY16, 
MMY20, MMY23 and MMY24 showing functional coupling with this receptor. The signal window, 
however, appears to be much larger when the plasmids have been integrated. This is important when 
testing other compounds with lower levels of efficacy, which may not appear if the signal is low with 
the full agonist stimulation. 
The MMY21 strain appears to have higher unspecific background growth in the no compound well, 
which is something that has been observed before in the results of episomal plasmid screening, but 
seems to only have affected this strain. This effect was observed with transformed β1-AR and β2-AR. 
The β2-AR was for the first time observed to functionally couple in MMY strains and, as predicted, 
the construct with the MFα leader sequence was suitable for this purpose. The no leader p306GPD-
ADRB2 plasmid was tested in MMY15 to test whether it was essential. No functional response to 
isoprenaline was detected in 8 colonies tested with this plasmid (data not shown). 
  
4.4. Western blot analysis of protein expression patterns of the β1-AR and β2-AR 
 
The functional expression differences between the episomal vs integrative plasmids, with and without 
any leader sequences raised many questions about what is happening in the cell in terms of protein 
expression and localisation: 
• Is the protein expressed regardless of whether the leader sequence is present or not?  
• Do the protein levels differ between p426GPD (episomal) and p306GPD (integrating) plasmid 
expression? 
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4.4.1.  β1-AR expression in the MMY15 (GαS) strain 
 
To make a direct comparison between the expression level and pattern in different plasmid 
transformed yeast, and the functional assay data, various plasmid constructs were transformed into 
MMY15 host strain. As previously shown (Figure 4.9 and Figure 4.14) functional coupling was observed 
when either episomal or integrated plasmids were transformed, but the constructs required the MFα 
leader sequence.  
The selection of colonies freshly transformed with p426GPD-ADRB1 and p426GPD-MF-ADRB1 were 
assessed by functional assay output was performed first (Figure 4.16 [C]), however the rate of selecting 
a positive colony was low, as demonstrated previously in section 4.2.3 – only 14 functional colonies 
expressing β1-AR and β2-AR were selected from around 300 screened p426GPD plasmid transformed 
yeast. The same colonies were then examined on a western blot (Figure 4.16 [A]). The anti-β1AR 
antibody unfortunately exhibited inconsistency in unspecific background detection between the 
different batches. This made the interpretation of the results difficult and limited. To provide some 
clearance, a colony previously deemed functional was tested on the western blot presented in Figure 
4.16 [A], lane 10. Coincidently, only lane 10 shows a presence of a double band of around 22-24kDa, 
which is consistent with previous western blot of a functional colony with the same construct (insert 
[B]). The other lanes presented the pattern identical to negative control lane 2, indicating that no β1-
AR specific band is present. This is largely in agreement with the functional data in [A] – colony 62 was 
the only that demonstrated some functional signal, albeit only after 44h of incubation. Prolonged 
incubation performed on some of other colonies did not improve the signal (data not shown). 
The expression pattern of p306GPD transformed MMY15 was assessed similarly (Figure 4.17). 
However, more functional colonies were picked from the same number of total colonies screened as 
for the episomal p426GPD plasmids. The functional assay result is presented in Figure 4.17 [C] shows 
that four out of 5 colonies carrying p306GPD-MFα-ADRB1 plasmid showed a response to isoprenaline 
at variable Emax levels. Four colonies with this plasmid were analysed on the western blot presented in 
Figure 4.17 [A], along with four colonies carrying p306GPD-ADRB1 plasmid construct with no leader 
sequence. Again, there is a lot of unspecific bands, however, all colonies that show functional 
expression in the FD-glu assay experiment appear to have a double band at 22-24kDa, consistent with 
the p426GPD-MF-ADRB1 CL62 presented in Figure 4.16 [A]. This band, although smaller than expected 
size for a GPCR, has been observed previously with a batch of the same antibody which gave less 
unspecific background (insert [B]). 
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Figure 4.16 β1-AR protein expression in p426GPD vectors comparison with the functional data 
obtained from the FD-glu assay. [A] An equal number of p426GPD and p426GPD-MFα transformed 
colonies were analysed on a western blot using anti-β1AR antibody but no β1-AR specific band is thought 
to be present with the exception of possibly the double band of 22-24kDa in lane 10. [B] This size is 
consistent with a previous result. [C] None of the colonies were found to show functional expression as 
assessed by isoprenaline induced FD-glu signal.  
A B 
C 
25kDa 
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A B 
C 
Figure 4.17 β1-AR protein expression in p306GPD vectors comparison with the functional data 
obtained from the FD-glu assay. [A] An equal number of p306GPD and p306GPD-MFα transformed 
colonies were analysed on a western blot using the same anti-β1AR antibody. Bands of previously 
observed size of 22-24kDa were detected in lanes 6, 8, 9, and 10. [B] This size is consistent with a previous 
result. [C] The same colonies showed functional coupling in MMY upon stimulation with isoprenaline. 
Although various levels of Emax were observed, the intensity of the mentioned bands does not look higher 
or lower between the different colonies. 
25kDa 
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4.4.2.  β2-AR expression in the MMY15 (GαS) strain 
 
The expression of β2-AR was too investigated in both episomal and integrated plasmid constructs, 
despite the fact that no functional colonies could be detected in the episomal plasmid screening. This 
was to investigate whether the protein is expressed in non-functional colonies. For this work, 
p426GPD-ADRB2, p426GPD-MFα-ADRB2, p306GPD-ADRB2 and p306GPD-MFα-ADRB2 were freshly 
transformed into MMY15 to eliminate any effects of potential plasmid loss. As previously observed, 
the number of p426GPD-MFα-ADRB2 transformed colonies was much smaller than that of p426GPD-
ADRB2 (Figure 4.18). From each plate, 4 colonies were tested in the functional assay (Figure 4.19 [B]) 
before extracting membranes for western blot [A]. 
 
 
 
 
 
 
 
Interestingly, 3 of the 4 p426GPD-ADRB2 colonies showed a weak response to isoprenaline which 
echoes the observation in the initial testing of episomal β2-AR functional expression presented in 
Figure 4.10. The same colonies – blue, red and green – showed a double band of around 39-41kDa and 
a lower band of approximately 21kDa on the western blot (lanes 3, 4, 5 respectively). No functional 
response was found in the yeast transformed with the MFα leader sequence version of the plasmid, 
nor could any bands be detected on the western blot, suggesting that the lack of functional response 
is because there is no protein expression. Together with the consistently low number of transformed 
colonies, the results would suggest that cells that take up the plasmid do not survive long after the 
transformation to produce any visible colonies, and the ones that do appear on the plate are false 
positive colonies. 
The observation is slightly different in the p306GPD transformed yeast. The colony distribution is much 
more similar between p306GPD-ADRB2 and p306GPD-MFα-ADRB2 transformed colonies (Figure 4.13). 
However, colonies with the MFα leader sequence show the response to isoprenaline, while the no 
leader colonies do not (Figure 4.20 [B]). The same colonies that show response – green, purple and 
pink – also produced bands of 39kDa and 21kDa on the western blot ([A]).  
  
A B Figure 4.18 Transformation of MMY15 with p426GPD vectors. 
The GαS strain was transformed 
with the p426GPD-MFα-ADRB2 
vector [A], and the p426GPD-
ADRB2 vector with no leader 
sequence [B].  
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Figure 4.19 β2-AR protein expression in p306GPD vectors comparison with the functional FD-glu assay 
results. [A] The initial functional FD-glu assay has revealed that p426GPD-ADRB2 colonies 2, 4, and 6 have 
responded to isoprenaline stimulation. None of the colonies with the MFα leader sequence have responded. 
This is with an agreement with previous colony screening results presented in Figure 4.10. [B] The western 
blot analysis shows that the same p426GPD-ADRB2 colonies presented a double band at 39-41kDa and a 
smaller band of around 21kDa. The negative controls, including untransformed MMY15, and β1-AR 
transformed yeast did not show an unspecific bands. 
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Figure 4.20 β2-AR protein expression in p306GPD vectors comparison with the functional FD-glu 
assay results. [A] As before four colonies transformed with p306GPD and p306GPD-MFα construct 
were assessed by the functional FD-glu assay. Contrary to p426GPD constructs, the leader 
sequence appears to be required for functional expression. [B] Western blot analysis show that 
the same functional colonies 1, 5, and 7 of the p306GPD-MFα construct displayed a band of around 
39kDa and a smaller at around 21kDa. There is a faint band in lane 4 (p306GPD-ADRB2, CL 4) but 
no functional signal was detected in [B]. The same quantities of total membrane protein were 
loaded on the gel. The negative control lanes are clear of any unspecific bands.  
WB 1 lane 
3 
4 
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4.4.3. Summary of western blot analysis of β1-AR and β2-AR expression in MMY yeast 
 
The western blot performed in this study can provided a limited information on the relationship 
between the level of protein expression and the functional response. The first limitation is that western 
blots of the total membranes cannot inform us on how much of this protein is correctly folded and in 
what cellular compartment it resides. The only clear pattern the experiments show is that when the 
colonies show a functional response there is also a band pattern on the western blot that is not 
observed in the negative controls. When there is no functional response, most of the colonies analyse 
did not show any specific bands on the western blot, with the exception of p306GPD-ADRB2 CL4 which 
showed weakly detected bands at 40-42kDa. 
 In the colonies that present bands on a western blot and a functional signal assay no correlation 
between the level of signal intensities can be drawn. If there was a direct correlation, p306GPD-MFα-
ADRB2 CL5, WB lane 9 in Figure 4.20 B would have the strongest band signal on the western blot, but 
instead it’s p306GPD-MFα-ADRB2 CL1 in lane 7. However, there still must be a threshold of protein 
expression required for a functional response as indicated by the faint bands of colony p306GPD-
ADRB2 CL4, which produced no functional response. 
It is difficult to interpret why there is difference in functional response and western blot of β2-AR 
expressing colonies depending whether it is expressed in the p426GPD or p306GPD plasmid in that 
MFα only seemed to bring an improvement in the integrating plasmid system. There is also slightly 
different band pattern  - the colonies expressing β2-AR in p426GPD plasmid appear to have clear bands 
at 39kDa and 41kDa while those expressed in p306GPDMFα plasmid do not appear to have the 41kDa 
band or it is very faint. The p306GPD-ADRB2 CL4 colony (non-functional) which has no MFα sequence 
appear to have both bands. One of possible explanation is that the 41kDa band represents a 
hyperglycosylated protein while the 39kDa is the non-glycosylated form.  
The functional expression of β1-AR has a clearer preference for constructs with MFα leader sequence 
as demonstrated in section 4.2.4, although it was more difficult to demonstrate this on the western 
blot partly because of antibody quality issues. There too appears to be two bands of similar size, 
however it is a smaller band that would be expected for β1-AR (50kDa as estimated by Abcam).  
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Chapter 5 – The pharmacological characterisation of adrenoceptors 
β1 and β2 in yeast 
 
 
5.1. Introduction  
 
The adrenoceptors β1 and β2 have been well characterised in other recombinant hosts but scarcely in 
Saccharomyces cerevisiae. We have taken the opportunity of having obtained functional expression of 
these receptors in the MMY yeast and tested them against a panel of known agonists and antagonists 
listed in Table 5.1. The aims of this work were to: 1) characterise the activity of the ligands at these 
GPCRs coupled to chGαs proteins using MMY strains that represent different signalling pathways; 2) 
compare the values of previously obtained pEC50 and pIC50 from other assays; 2) bench-mark the yeast 
assay against the others for the same signalling pathway.  
5.2. Ligand selection and experimental set-up 
 
The IUPHAR international database hosts a comprehensive collection of information on the 
adrenoceptors including lists of known agonists and antagonists. This information source was used to 
select the ligands for this study. Those that were available on the GSK’s UK based compound library 
were used and are listed in the Table 5.1. The third column notes the interaction also retrieved from 
the IUPHAR. 
Initially, the interacting strains were identified by their response to a full agonist isoprenaline 
(isoproterenol). The agonist assay data have also been normalised to this ligand where the baseline 
(bottom) of isoprenaline is 0% response and its maximal response (top) is the 100%. The top and 
bottom values were obtained from the three parameter non-linear regression curve fit on GraphPad 
Prism V7.03. Nine MMY strains were identified to respond to isoprenaline when β1-AR was present, as 
shown in Chapter 4 – MMY12 (Gpa1), MMY14 (Gαq), MMY15 (GαS), MMY16 (Gα16), MMY20 (Gα13), 
MMY21 (Gα14), MMY22 (Gαo), MMY23 (Gαi1), and MMY24 (Gαi3).  For the β2-AR five strains were 
identified as responsive to receptor-pathway coupling - MMY14 (Gαq), MMY15 (GαS), MMY16 (Gα16), 
MMY21 (Gα14), and MMY23 (Gαi1). 
For the antagonist assays the receptors were stimulated with 2.5µM of isoprenaline to demonstrate 
the inhibition of growth by antagonist action. Antagonism data were normalised against control 
compound carvedilol (C30) in the same way as agonist data were normalised against isoprenaline. 
Each assay was carried out for 24h; readings were taken at 18h and 24h. The data presented in this 
chapter are the mean of three independent experiments read at 24h; the error bars represent S.E.M. 
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Agonists 
  
   
Compound ID  Generic name Receptor interaction (from IUPHAR) 
C21 orciprenaline  β2 agonist 
C22 xamoterol β1 partial agonist 
C25 dobutamine  β1 and β2 partial agonist 
C31 procaterol  β2 agonist 
C33 zinterol  β2 agonist 
C34 fenoterol  β2 agonist 
C36 terbutaline  β2 partial agonist 
C39 mirabegron  β1 and β2 agonist 
C40 indacaterol  β1 and β2 agonist 
C42 isoprenaline  β1 and β2 full agonist 
C46 pindolol  β1 and β2 partial agonist 
   
Antagonists   
   
Compound ID  Generic name Receptor interaction (from IUPHAR) 
C20 levobetaxolol  β1 and β2 antagonist 
C23 labetalol  β1 and β2 antagonist 
C24 metoprolol  β1 and β2 antagonist 
C26 nadolol  β1 and β2 antagonist 
C27 propranolol  β1 and β2 antagonist 
C28 alprenolol  β2 antagonist 
C29 sotalol  β1 and β2 antagonist 
C30 carvedilol  β1 and β2 antagonist 
C35 levobunolol  β1 and β2 antagonist 
C37 esmolol β1 antagonist 
C38 propafenone  β1 and β2 antagonist 
C41 atenolol  β1 and β2 antagonist 
C43 acebutolol β1 antagonist 
C44 practolol β1 antagonist 
C48 bupranolol  β1 and β2 antagonist 
C49 betaxolol  β1 and β2 antagonist 
Table 5.1 List of β1-AR and β2-AR agonists and antagonists used in this study. The list was compiled based on 
the information available on the IUPHAR database. 
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5.3. Pharmacological characterisation of the β1-AR in MMY strains 
 
5.3.1. Agonist assay  
 
The compound testing results presented in Figure 5.2 give an overview of agonist activity in the nine 
MMY strains expressing β1-AR. The Gpa1, Gαq, GαS, Gα16, Gαi1, and Gαi3 strains at the first glance look 
the most similar to each other in terms of order of agonist potency and maximum efficacy. The Table 
5.3 in which both these parameters are listed reiterates this observed pattern. There are some 
differences between these strains too, for example C22 – xamoterol – appears to have partial agonist 
activity in GαS, Gα16, and Gαi1 but no agonism in Gpa1 or Gαq strains.  
The remaining strains Gα13, Gα14, and Gαo demonstrate much more distinct profiles. In the Gα13 strain 
most of agonist show a very week or no agonism on the receptor (Figure 5.2). Orciprenaline (C21) and 
fenoterol (C34) have comparable efficacy to isoprenaline (C42), terbutaline (C36) has a slightly lower 
and dobutamine (C25) appears to have a much higher Emax compared to isoprenaline albeit large error 
bars and low potency (Figure 5.4). Other compounds C22, C31, C33, C39, and C46 do not appear to 
have any effect on the β1-AR in this strain contrary to the observation in other strains. Another 
interesting aspect about this strain is that several listed antagonists show an ability to inhibit baseline 
yeast growth which could be interpreted as inverse agonism. They are highlighted in orange in Table 
5.3. These are compounds C27, C35, C37, C43 and C48; they have no other activity in other strains, 
similarly to C30 shown Figure 5.4. Carvedilol (C30) is the most potent out of these with pEC50=6.5. 
Compounds C23 and C38 show very small agonist activity in the Gα14 strain (C23 shown in Figure 5.4) 
but are inhibiting growth in the Gα13 strain. Indacaterol (C40), a potent agonist in most strains, not only 
has no activity as an agonist in this strain, but also shows some inhibition of growth in Gα13 similar to 
the mentioned antagonists (Figure 5.4). Overall, many compounds show no ability to induce growth 
or sometimes even inhibit it. 
Another MMY strain which stands out is MMY21 (Gα14) in which almost the opposite effects are 
observed. For example, C22, C28, C31, C46 show 55-84% of Emax, (Table 5.3) whereas in other strains 
it is less than 14-31%. Xamoterol (C22) is listed as partial β1-AR agonist, as it appears to be in GαS, Gα16 
and Gαi1, however in this strain it is approximately three times more efficacious; this is well illustrated 
in Figure 5.4. Alprenonol (C28) is listed as β2-AR antagonist in the IUPHAR database and has some 
activity as an antagonists in β1-AR, but again, Gα14 is an exception – the ligand appears to have partial 
agonist activity (Figure 5.4). Pindolol (C46) also shows higher efficacy in this strain compared to others 
is listed as partial β1-AR and β2-AR agonist. Often agonists shat show activity in most of the strains 
appear to be most potent in Gα14, for example C36, C39, C42, C42. The Go similarly to Gα13 appears to 
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poorly respond to most agonist stimulation, although order of potencies is similar to those observed 
in Gαq and Gpa1 strains. 
Figure 5.2 The summary of agonist assay results in β1-AR expressing MMY strains. Responses were 
normalised against full agonist isoprenaline. n=3 
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Figure 5.4 Selected compound response on the β1-AR presented in all strains. This graph 
illustrates some responses that were different in particular strains. n=3 
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5.3.2. Antagonist assay 
 
The antagonist assay using β1-AR expressed in the same MMY strains is presented in Figure 5.5 and 
the pIC50 and Emax values in Table 5.6. The raw values were normalised against carvedilol (C30) and 
therefore any agonist activity appears on the negative Y axis.  
Based on the overview in Figure 5.5 the antagonism of the β1-AR in different strains appears more 
uniform than agonism. Some of the individual compounds are shown in Figure 5.7 and are discussed 
below.  
The first compound presented is xamoterol (C22) which as discussed in the agonist section has strong 
agonist activity in Gα14. However, when tested in an antagonist assay it exhibited antagonistic activity 
in Gαq, Gpa1, Gαi3, GαO but not in GαS, Gα16, Gα13, Gα14 or Gαi1 strains.  Procaterol (C31) demonstrates 
variable potencies and efficacies. It is most potent in Gα16 although Emax is lower than in Gpa1, Gαq, 
Gαi1 and GαO strains. Very low or no antagonistic effect in GαS, Gα13, Gα14, Gαi3. Indacaterol (C40) 
mirrors the activity that was seen in the agonist assay – agonistic effect of various degrees in all strains 
but Gα13 and Gα14. Very weak or no antagonist activity in Gα13 was also produced by majority of 
compounds listed as antagonists – C24, C26, C28, C29, C41, C44, C48, and C49. Antagonist C20, C23, 
C27, C35, C37, C46 although produced comparable inhibition on Gα13 strain when compared with 
others, showed lower potencies in this strain (Table 5.6). Other compounds not mentioned in this 
paragraph had either comparable antagonism to that of control compound carvedilol or only agonistic 
affect that was observed in the agonist assay, including isoprenaline. Individual graphs of all 
compounds not shown in Figure 5.7 can be found in the appendix D. 
The agonist in this panel of compounds produced agonism (induction of growth), which is expected. 
However, the level of induction was different between the strains. This can be explained by strain 
background growth and because agonist assay results were normalised against an agonist, all other 
compound responses are relative to agonist and therefore do not appear so different as when they 
were normalised to an antagonist carvedilol.  
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Figure 5.5 The summary of antagonist assay results in β1-AR expressing MMY strains. The data 
was normalised against antagonist carvedilol. n=3 
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 Figure 5.7 Selected compound antagonism on the β1-AR presented in all strains. The majority of 
antagonist compounds showed the same level of inhibition of growth in MMY strains expressing the 
β1-AR similar to control compound carvedilol, and therefore are not shown in this graph. Xameterol 
(C22) and pindolol (C46) are listed as partial agonists and procaterol (C31) as β2-AR antagonist but 
have demonstrated some antagonistic activity on this receptor.  
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5.4. Pharmacological characterisation of the β2-AR in MMY strains 
 
5.4.1. Agonist assay 
 
As mentioned in the introduction, only 5 MMY strains showed response to isoprenaline in the initial 
strain screening experiments. The agonist assay result overview is presented in Figure 5.8. The agonist 
responses in GαS, Gα16 and Gα14 strains look the most similar, while in Gαq and Gαi1 appear to have 
lower efficacy with the exception of isoprenaline against which the interacting strains were selected.  
Indeed, most of listed β2-AR agonists and partial agonists  – C21, C25, C31, C33, C34, C36, and C40 
show a much lower efficacy in Gαq and Gαi1 (Table 5.9 and Figure 5.10). The exception to this are C39 
and C46 which are listed as partial β2-AR agonists but show no activity on this receptor in the tested 
strains. 
Interestingly, idacaterol (C40) as well as showing partial agonism in Gαq and Gαi1 do not fit the 
sigmoidal curve of three-parameter fit very well, but does fit a biphasic sigmoid curve as noted in 
dashed line in Figure 5.10.  
As shown in β1-AR results, carvedilol (C30), and to lower extent C38 and C49, demonstrate the ability 
to inhibit baseline yeast growth in Gα16 strain, characteristic of inverse agonist. However this effect 
appears to be lower than that seen in the β1-AR transformed yeast.  
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  Figure 5.8 The summary of agonist assay results in β2-AR expressing MMY strains. As described in 
Chapter 4, 5 MMY strains showed response to isoprenaline – MMY 14 (Gαq), MMY15 (GαS), MMY16 
(Gα16), MMY21 (Gα14), and MMY23 (Gαi1). Responses were normalised against full agonist 
isoprenaline. n=3 
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Figure 5.10 Selected agonist responses on β2-AR expressing strains. The examples clearly illustrate 
that much weaker responses were observed in Gαq (red) and Gαi1 (teal) strains. Carvedilol and 
propafenone showed weak inverse agonist activity. 
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5.4.2. Antagonist assay 
 
The antagonist assay against MMY strains expressing β2-AR was set up in the same way as for the β1-
AR and normalised against carvedilol (C30). The agonist again appear on the negative Y axis. The 
overview presented in Figure 5.11 does not show the differences in antagonist activity between the 
strains, but the agonists appear much more efficacious in the Gαq strain; again, this could be an artefact 
of the strain background. 
To get a clearer view of antagonist activity the data of individual ligands in the different MMY strains 
was plotted as before. Selected results are presented in Figure 5.13. The ligands not presented in this 
figure either demonstrate agonist activity comparable to that shown in the agonist assay or are 
antagonists which have an activity in all tested strains comparable to the control compound carvedilol 
(shown in Figure 5.13).  
One compound that stands out from this data set, as well as other assays discussed in this chapter is 
xamoterol (C22). It has been described as β1-AR partial agonist with no activity on the β2-AR, and 
indeed in the agonist assay did not show activity on the β2-AR. However, when tested with isoprenaline 
for the antagonist assay it does appear to have some agonistic effect, albeit low potency, in GαS and 
to lesser extent Gα16 and Gα14, but appear so have slightly inhibitory effect in Gαq and Gαi1. The 
summary of the effects of C22 in different assays is presented in Figure 5.14.  
Compounds C27, C28, and 48 results in Gαq, GαS and Gαi1 strains do not fit the sigmoidal curve very 
well. 
Compound C39 (mirabegron) appears to have strong antagonistic effect in Gαq and Gαi1 strains and 
weaker in GαS and Gα16 strains; it did not show significant activity as an agonist on β2-AR. This is in 
agreement with mirabegron’s therapeutic use as selective β3-AR agonists.  
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  Figure 5.11 The summary of antagonist assay results in β2-AR expressing MMY strains. Responses 
were normalised against carvedilol. Agonist responses therefore appear on the negative scale. n=3 
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Figure 5.13 Selected antagonist responses on β2-AR expressing strains. Propranolol and alprenolol 
show markedly increased potencies in Gαs and Gαq strains respectively (see also Table 5.12). 
Mirabegron, which is primarily β3-AR agonist exhibit antagonistic properties on β2-AR. 
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Figure 5.14 Summary of xamoterol (22) pharmacology on β-adrenoceptors in yeast. As an agonist 
xamoterol only showed marked activity on β1-AR in the Gα14 strain. It has also displayed antagonist 
effect on both receptors at various degrees in MMY strains.  
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5.5. Comparison of signalling pathways for β1-AR and β2-AR in yeast 
 
 
To better illustrate the trends observed in data presented in sections 5.3 and 5.4 correlation analyses 
were performed and presented in Figure 5.15. The pEC50 and pIC50 values of agonist and antagonist 
Figure 5.15 Correlation plots of pEC50 and pIC  values between those obtained in GαS strain and other 
chGα strains. The comparisons were carried out for agonist β1-AR [A] and β2-AR [B] data, and antagonist 
β1-AR [C] and β2-AR [D] data to show if there is significant shift in coupling between the strains or 
particular ligands-outliers, which are noted on the scatter plots. Agonist values ≥20% Emax and 
antagonist values ≥50% Emax were used. Linear regression plots represent the fit between data points; R2 
and P values shown in [E].  
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responses in GαS strain were compared to data generated in other strains. Only agonist values of ≥20% 
Emax and antagonist of ≥50% Emax were compared to avoid any insignificant outliers. The lines represent 
linear regression analysis which compare the goodness of fit between the data points in the set and 
compare the slopes. 
The agonist values on β1-AR expressed in MMY strains correlate significantly with each other – 
correlation r2 values between 0.90-0.99 (Table 5.16 [A]), P values indicate the data is not picked 
randomly, meaning that the correlation is significant. Linear regression analysis show the goodness of 
fit is above R2 0.90 (Figure 5.16 [E]) and that although the slopes are not significantly different, there 
is approximately 1.5 log difference between MMY21 (Gα14) and MMY20 (Gα13) data values, well 
reflecting the trend that was observed in Figure 5.2 where the Gα14 strain demonstrated the strongest 
coupling across all compounds tested.  
The β2-AR agonist data in Gα16 and Gα14 correlate strongly with the data in GαS, but Gαq and Gαi1 
correlated poorly (Table 5.16 [C]). The goodness of fit of these two strains data is poor too as indicated 
by P values in Figure 5.15 [E] and similarly in Table 5.16 [C], however this could be explained by an 
outlier – procaterol. The pEC50 values differ by approximately 0.5-2 log between the well correlating 
Gα16 and Gα14 and the Gαq and Gαi1 strains as indicated by linear regression plots (Figure 5.15 [B]). This 
observation reflects the pattern shown in Figure 5.10 were 7 agonists appeared to have lower 
potencies and efficacies in the two strains with lower correlation while the control agonist isoprenaline 
had the same effect in all strains.  
As for antagonist analysis, significant correlation of antagonists on β1-AR in most strains was found. 
Only the Gα13 data did not correlate with GαS which can be clearly seen by the linear regression plot 
and the associated parameters. This agrees with a previous observation that antagonists on this strain 
produced either lower efficacies or lower potencies in comparison with the values produced in other 
strains (Table 5.6).  Antagonists on β2-AR also correlated according to the correlation coefficient r2. 
The slope of Gαq and Gαi1 strain data was slightly different to other strains as observed on agonist 
values in the same strains; however, this is likely to be an artefact produced by xameterol outlier data.   
In summary the correlation analysis echoes the patterns that were observed in data presented earlier 
in this chapter. The most notable observation is the poor correlation of antagonist Gα13 strain data on 
β1-AR as compared with other strain data, however, as shown in Figure 5.2 and 5.5 the coupling in this 
strain to β1-AR was overall low therefore lack of correlation is not significant. As for β2-AR several log 
differences in agonist pEC50 values produced in GαS, Gα16 and Gα14 and those in Gαq and Gαi1, which 
indicate lower coupling efficiencies in these two strains. Procaterol on agonist data and xameterol on 
antagonist data correlation (Figure 5.15 [B] and [D]) point out that these compounds may be exhibiting 
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bias agonism towards coupling to particular strains which is an interesting point for futher 
investigation. 
 
 
Table 5.16 Pearson’s correlation analysis of pEC50 and pIC50 values. The values obtained from GαS strain 
experiment data were compared to those obtained in other chGα strains. This data complements 
the scatter plots presented in Figure 5.15. The analyses were obtained for agonist β1-AR [A] and β2-AR [C] 
data, and antagonist β1-AR [B] and β2-AR [D] data. The Pearson R2 coefficient indicate whether there is 
correlation, two-tailed P values indicate whether the correlation is significant or random. Analyses were 
obtained from GraphPad Prism 7. 
β1-AR Agonist
pEC50 GaS
vs.
pEC50 Gaq
pEC50 GaS
vs.
pEC50 GpaI
pEC50 GaS
vs.
pEC50 Ga16
pEC50 GaS
vs.
pEC50 Ga13
pEC50 GaS
vs.
pEC50 Ga14
pEC50 GaS
vs.
pEC50 Gao
pEC50 GaS
vs.
pEC50 Gai1
pEC50 GaS
vs.
pEC50 Gai3
Pearson r
  R squared 0.9422 0.979 0.9739 0.933 0.9334 0.9069 0.9929 0.9805
  P (two-tailed) <0.0001 <0.0001 <0.0001 0.0075 <0.0001 0.0003 <0.0001 <0.0001
  P value summary **** **** **** ** **** *** **** ****
  Significant? (alpha = 0.05) Yes Yes Yes Yes Yes Yes Yes Yes
Number of XY Pairs 7 8 8 4 8 5 8 7
β1-AR Antagonist
pIC50 GaS
vs.
pIC50 Gaq
pIC50 GaS
vs.
pIC50 GpaI
pIC50 GaS
vs.
pIC50 Ga16
pIC50 GaS
vs.
pIC50 Ga13
pIC50 GaS
vs.
pIC50 Ga14
pIC50 GaS
vs.
pIC50 Gao
pIC50 GaS
vs.
pIC50 Gai1
pIC50 GaS
vs.
pIC50 Gai3
Pearson r
  R squared 0.9475 0.8353 0.8198 0.0001 0.8184 0.5815 0.8084 0.7833
  P (two-tailed) <0.0001 <0.0001 <0.0001 0.9807 0.0001 0.0009 <0.0001 <0.0001
  P value summary **** **** **** ns *** *** **** ****
  Significant? (alpha = 0.05) Yes Yes Yes No Yes Yes Yes Yes
Number of XY Pairs 16 15 16 10 11 15 16 16
β2-AR Agonist
pEC50 Gas
vs.
pEC50Gaq
pEC50 Gas
vs.
pEC50Ga16
pEC50 Gas
vs.
pEC50 Ga14
pEC50 Gas
vs.
pEC50 Gai1
Pearson r
  R squared 0.562 0.9839 0.9828 0.7919
  P (two-tailed) 0.0322 <0.0001 <0.0001 0.0031
  P value summary * **** **** **
  Significant? (alpha = 0.05) Yes Yes Yes Yes
Number of XY Pairs 3 8 8 5
β2-AR Antagonist
pIC50 Gas
vs.
pIC50Gaq
pIC50 Gas
vs.
pIC50Ga16
pIC50 Gas
vs.
pIC50 Ga14
pIC50 Gas
vs.
pIC50 Gai1
Pearson r
  R squared 0.5478 0.7903 0.8384 0.5572
  P (two-tailed) 0.0007 <0.0001 <0.0001 0.0006
  P value summary *** **** **** ***
  Significant? (alpha = 0.05) Yes Yes Yes Yes
Number of XY Pairs 17 17 17 17
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5.6. Comparison of the functional yeast assay for GPCRs against other assays in a 
high-throughput screening setting 
 
Another interesting question to ask of from the available data was how well the values obtained in 
yeast compared to other high-throughput screening mammalian cell-based assays and between these 
assays themselves. Because β-adrenoceptors are well known drug targets, a substantial amount of 
data were available in the internal GSK database. For this analysis values for compounds described in 
this chapter, as well as an additional 19 GSK proprietary compounds were used. The data for full-curve 
pEC50 and pIC50 values for agonists and antagonists respectively were retrieved from the data-base and 
grouped according to the assay’s identifiers (Figure 5.17). Interestingly all the previous screening data 
were obtained from assays that fell largely in the two categories – cAMP measured by enzyme 
fragment complementation (EFC) and immunoassay for cAMP detection by fluorophore-conjugated 
antibody and subsequent time-resolved fluorescence energy transfer (TR-FRET) measurement (Figure 
1.2). According to the information available on assay providers’ literature, the assays noted as LANCE 
(Perkin Elmer) cAMP in [A] and [C], HTRF cAMP (also a TR-FRET assay [75]) [E] measure cAMP from a 
cell lysate, while EFC cAMP (DiscoverX) [B], [F], [G] measure cAMP in an intact engineered cell line [15, 
16]. All assays use the CHO-K1 stably transfected cell line which overexpresses β-adrenoceptor and the 
second messenger cAMP is used to monitor ligand induced coupling or inhibition of GαS and Gαi 
pathways. The two DiscoverX assays in [B] and [F] are based on the EFC cAMP luminescence 
measurement and the differences likely to lie within the protocols. The other DiscovereX EFC in [G] 
assay measures the activation of the β-arrestin pathway, not the production of cAMP.  
The analysis showed variable correlations between the yeast agonist and antagonist data obtained in 
the GαS strain and CHO assays. For β1-AR receptor agonist cAMP LANCE assay in Figure 5.17 [A] showed 
week correlation and stronger correlation with the antagonist EFC assay [D], although due to small 
sample size, correlation was deemed insignificant (Table 5.18). A few more assays were available for 
comparison of β2-AR yeast data also generated in the GαS strain. Moderate correlation was observed 
in 5 out of 7 assays with the following r2 coefficient rank: Human Antagonist - EFC – pKi [D] > Agonism 
ß-arrestin EFC – PathHunter [G] > Agonist cAMP LANCE TR-FRET [A] > DiscoverX HitHunter cAMP EFC 
[F] > Antagonist cAMP LANCE TR-FRET [C] in Table 5.18; P values indicate that the correlation is 
significant. A correlation matrix between the CHO cAMP assays was also performed; statistical 
parameters are presented in Table 5.19. It is perhaps not surprising that the correlation of CHO assays 
is stronger than that with the yeast assay data since all CHO assays compared used the same cell 
background and measured the same cAMP second messenger, which is different from the growth 
measured in yeast. The major differences between these assays are the assay protocols and the type 
of reporter (fluorescence vs luminescence) used. Even within this set of data some variation in the r2 
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values was observed. For example, HTRF cAMP agonist assay correlated weaker with DiscoverX cAMP 
EFC (cell based assay, likely to be cAMP Hunter assay) as shown in Table 5.19. 
Figure 5.17 Yeast GαS agonist and antagonist assay correlation comparison with various cAMP assays 
in CHO cell background. Several cAMP assays were found in GSK databases from previous screening 
experiments. All assays detected change in cellular cAMP by antibody detection or enzyme fragment 
complementation (EFC). Upon detection of cAMP the signal is detected – either FRET (fluorescence) or 
luminescence respectively.  
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Table 5.18 Yeast GαS agonist and antagonist assay comparison with various cAMP assays in CHO cell 
background – correlation parameter analysis. The Pearson r2 value indicates the correlation between the 
assays where 1 is perfect correlation and 0 is no correlation. The two-tailed test P values indicate whether 
the probability of the correlation is significant. The letters above the tables indicate the scatter plots 
presented in Figure 5.17. 
A B C D
β1-AR assay correlation 
comparison
Agonist cAMP 
LANCE TR-FRET
DiscoverX EFC 
cAMP (Cell 
based)
Antagonist cAMP 
LANCE TR-FRET
Human 
Antagonist - EFC - 
pKi
Pearson r
  R squared 0.3056 0.1795 0.0143 0.952
P value
  P (two-tailed) 0.0326 0.2955 0.6591 0.1407
  P value summary * ns ns ns
  Significant? (alpha = 0.05) Yes No No No
Number of XY Pairs 15 8 16 3
A B C D E F G
β2-AR assay correlation 
comparison
Agonist cAMP 
LANCE TR-FRET
DiscoverX EFC 
cAMP (Cell 
based)
Antagonist cAMP 
LANCE TR-FRET
Human 
Antagonist - EFC - 
pKi
Human agonist 
cAMP HTRF
DiscoverX 
HitHunter cAMP 
EFC
Agonism ß-
arrestin EFC - 
PathHunter
Pearson r
  R squared 0.4119 0.1755 0.3562 0.7373 0.1953 0.3829 0.4377
P value
  P (two-tailed) 0.0134 0.4084 0.0016 0.003 0.2009 0.0242 0.0372
  P value summary * ns ** ** ns * *
  Significant? (alpha = 0.05) Yes No Yes Yes No Yes Yes
Number of XY Pairs 14 6 25 9 10 13 10
130 
 
  
β1-AR Assay Pearson's r
2
Agonist cAMP 
LANCE TR-
FRET
DiscoverX 
EFC cAMP 
(Cell based)
Human 
Antagonist - 
EFC pKi
Antagonist 
cAMP LANCE 
TR-FRET
Agonist cAMP LANCE TR-FRET 0.885
DiscoverX EFC cAMP (Cell based) 0.885
Human Antagonist - EFC pKi
Antagonist cAMP LANCE TR-FRET
P=0.019
β2-AR Assay Pearson's r
2 Human agonist 
cAMP HTRF
DiscoverX 
HitHunter 
cAMP EFC
Agonist cAMP 
LANCE TR-
FRET
DiscoverX 
EFC cAMP 
(Cell based)
Agonism ß-
arrestin EFC - 
PathHunter
Human 
Antagonist - 
EFC - pKi
Antagonist 
cAMP LANCE 
TR-FRET
Human agonist cAMP HTRF 0.891 0.978 0.547 0.898
DiscoverX HitHunter cAMP EFC 0.891 0.932 0.993 0.902 -0.976
Agonist cAMP LANCE TR-FRET 0.978 0.932 0.992 0.913 -0.897
DiscoverX EFC cAMP (Cell based) 0.547 0.993 0.992 0.989
Agonism ß-arrestin EFC - PathHunter 0.898 0.902 0.913 0.989
Human Antagonist - EFC - pKi 0.990
Antagonist cAMP LANCE TR-FRET -0.976 -0.897 0.990
β2-AR Assay correlation P values Human agonist 
cAMP HTRF
DiscoverX  
HitHunter 
cAMP EFC
Agonist cAMP 
LANCE TR-
FRET
DiscoverX 
EFC cAMP 
(Cell based)
Agonism ß-
arrestin EFC - 
PathHunter
Human 
Antagonist - 
EFC - pKi
Antagonist 
cAMP LANCE 
TR-FRET
Human agonist cAMP HTRF 0.00298 0.00001 0.45297 0.00042
DiscoverX HitHunter cAMP EFC 0.00298 0.00001 0.00661 0.00221 0.13911
Agonist cAMP LANCE TR-FRET 0.00001 0.00001 0.00084 0.00058 0.03929
DiscoverX EFC cAMP (Cell based) 0.45297 0.00661 0.00084 0.01115
Agonism ß-arrestin EFC - PathHunter 0.00042 0.00221 0.00058 0.01115
Human Antagonist - EFC - pKi 0.00000
Antagonist cAMP LANCE TR-FRET 0.13911 0.03929 0.00000
Table 5.19 Correlation matrix analysis of CHO cAMP assay produced pEC50 and pIC50 on β1-AR and β2-AR 
collected from GSK database. Pearson’s correlation r2 coefficients were compared. Correlaiton was significant 
if P<0.05.   
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5.7. Chapter summary 
 
The pharmacological characterisations of β-adrenoceptor functional coupling to a range of chimeric 
Gαs are presented in this chapter. For the initial identification of β-adrenoceptor coupling to the chGαs 
a full agonist isoprenaline was used (Figures 4.14 and 4.15). Although it is possible that for some β-AR-
G-protein interactions isoprenaline was not optimal for inducing full agonism, many studies use this 
compound as a gold standard for β-adrenoceptor agonism. Furthermore, isoprenaline stimulated β1-
AR was able to couple to Gpa1, Gα13, GαO and Gαi3, but the β2-AR did not show such response, 
suggesting that isoprenaline was a good choice for the experimental design.    
Overall a range of pharmacological responses were observed including full agonism (isoprenaline, 
oricprenaline), partial agonism (xamoterol, pindolol), inverse agonism (carvedilol) and antagonism 
(propranolol, propafenone). The pharmacological profiles largely agree with the data observed in 
mammalian assay data; however there are some previously uncharacterised interactions too.  
It is unusual in an industrial setting to be able to characterise such a diversity of G coupling in a uniform 
cell background and other assay variables, therefore this makes a valuable comparison of individual 
compounds’ ability to induce or inhibit receptor’s coupling to a range of Gαs. As was shown by 
correlation analysis even the same cellular messenger can be measured by different reporters and 
under different assay conditions. Further details of the protocols are needed to say exactly what 
purpose the different assays served, although it is likely that the changes in assay methods were 
influenced by other non-biological factors such as newer and improved assays becoming available on 
the market, change in supplier or other requirements for a particular screening programme. The only 
significant protocol aspect that is currently unknown is whether the protocol included forskolin-
induced cAMP stimulation which would indicate whether Gαs or Gαi pathway was targeted.   
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Chapter 6 – The engineering of Saccharomyces cerevisiae strains 
 
 
6.1. Introduction 
 
In this chapter the objectives and strategies for further engineering of Saccharomyces cerevisiae are 
outlined. The chapter is divided into two major parts, in which two different strategies are described. 
The first strategy concerns the deletion of the selectable marker, the URA3 gene. The parental strain 
W303-1A, from which the MMY strains were engineered, possesses ura3-1 marker gene which is only 
a point mutation resulting substitution from glycine to glutamate. It is thought to cause selection of 
false positive colonies when transforming the MMY strains. Because uracil selection is relied upon for 
the uptake of p426GPD and p306GPD and selection of positive colonies, it was important to look into 
improving this selection strategy. As an interim solution, the MMY strains were subjected to several 
rounds of counter-selection agent 5-fluroorotic acid (5-FOA) to enforce the Ura- phenotype. Later, a 
complete deletion of the ura3-1 gene was attempted in MMY11 from which other MMY strains were 
originally constructed. This was done with the aim to construct a new set of MMY strains that would 
be less prone to false positive colony formation.  
The second part describes the strategy for introducing a cholesterol synthesis pathway and 
consequential disruption of the ergosterol synthesis pathway in the MMY strains. This strategy was 
devised based on three published studies [56-58] that all target ERG5 and ERG6 genes in the ergosterol 
synthesis pathway and introduce DHCR7 and DHCR24 genes of the cholesterol synthesis pathway. 
Described in detail are the engineering of plasmids and attempts at integration of these plasmids into 
the MMY11 strain genome. The application of cholesterol-producing yeast can be very broad but is of 
an interest in membrane protein research, and in particular GPRC studies. With emerging details on 
how cholesterol influences β2-AR signalling a greater need for understanding the role of lipids in cell 
signalling has been hypothesised. Because a lot of membrane research is carried out in recombinant 
hosts, such as yeast [37, 59], the aim of this work was to address the need of studying the GPCRs, and 
other membrane proteins, in a more native-like membrane environment.  
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6.2. The engineering of ura3Δ MMY11 strain 
 
Throughout this project and in the past at GSK, it was observed that negative control cells with no 
plasmid were able to grow on uracil depleted medium. Therefore a question was raised whether these 
strains are truly Ura-, or perhaps they are mixed Ura- and Ura+ populations of cells. To answer these 
questions, selection on uracil-depleted medium and the counter-selective agent 5-FOA were 
performed to show that based on the cells’ ability to grow on both types of medium, the population is 
mixed (6.2.1). Furthermore, a genetic investigation showed that two versions of the gene – full length 
and truncated URA3 – can be detected in the genomic DNA of MMY strains (6.2.2). Following this 
discovery, it was decided to delete the full length gene to test the hypothesis that the full length gene 
is the source of the reversion to Ura+ phenotype. The strategy and the preliminary results of this work 
are detailed in section 6.2.3. 
6.2.1. Saccharomyces cerevisiae strain MMY12-28 counter-selection with 5-FOA 
 
The counter-selective agent 5 fluoroorotic acid (5-FOA) was used to select MMY12-28 strain clones 
exhibiting a Ura- phenotype. Eight colonies of each MMY strain were picked from stock YPD plates and 
streaked as a single line on 5-FOA/YPD and WHAUL+His-Ura (–Ura  plates for short) plates. All plates 
were incubated at 30°C until growth was apparent after 24h. With the exception of MMY28, colonies 
on –Ura plate did not show any signs of grow after 24h, however, after an extended period of 
incubation, round colonies started to emerge on some of the streaked lines. As shown in Figure 6.2, 
such growth and reversion to Ura+ phenotype was noted out of 8 colonies streaked on uracil depleted 
medium plates. For example, the MMY12 in the first generation selection produced growth on 4 out 
of 8 streaks (Figure 6.2, first panel). Two colonies on the same line were counted as 1 reversion (for 
example MMY12, 20, and 23 on the second generation shown in the middle panel), because all colonies 
on the same line originated from a single clonal cell. These results formed generation 1 selection. To 
enhance selective pressure, generations 2 and 3 were produced, however, this time the colonies were 
picked not from the original YPD stock, but from the plate of the preceding generation. Similar results 
were observed in generation 2 and 3 selection, as in generation 1. The reversion to Ura+ phenotype 
became apparent after 48-72h incubation. Results are summarised in Table 6.1. 
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Overall, with the exception of MMY22, all strains produced at least one Ura+ reverted colony when 
nutrient selective pressure was applied. MMY28 grew exceptionally well in all three generation on 
both 5-FOA and –Ura plates, requiring only 24 hours to grow. All eight colonies of MMY24 reverted at 
least once in three generation selection and although the reversion was not as prominent as for 
MMY28, the high instability made it difficult to select which colony should be archived in   ̶80°C freezer. 
Overall this shows that there is significant genetic variation in the URA3 locus amongst the MMY 
strains. 
 
 
  
MMY 
strains G α sub-unit 
Number of reverted colonies out of 8 Colonies that did 
NOT revert Generation 1  Generation 2 Generation 3 
12 Gpa1 4 2 2 1, 6 
14 Gpa1-Gq 2 4 1 2, 4, 7 
16 Gpa1-G16 2 4 0 2, 4, 5 
19 Gpa1-G12 2 4 2 1, 4, 8 
20 Gpa1-G13 0 4 4 4 
21 Gpa1-G14 0 4 3 1, 4 
22 Gpa1-Go 0 0 0 all 
23 Gpa1-Gi1 0 4 1 2, 5, 7, 8 
24 Gpa1-Gi3 2 7 2 none 
25 Gpa1-Gz 1 0 1 1, 2, 3, 5, 7, 8 
28 Gpa1-Gs 8 8 8 none 
Table 6.1 Summary of 5-FOA selection results. Each MMY strain produced a variable number of reverted 
colonies, which had to transform to Ura+ phenotype in order to grow in uracil depleted media. The exception 
to that, however are MMY22, highlighted in green, which despite repeated selective pressure did not produce 
any revertants, and MMY28, in red, which in contrast was able to adapt very quickly to both selective 
pressures. Colonies that did not revert at all within the 3 selective generations are noted in the last column. 
Highlighted in green are those strains in which at least half of all colonies did not revert. Similarly, in red are 
those strains for which all colonies reverted at least once.  
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6.2.2.  Design of genomic PCR test for the detection of trURA3 and flURA3 genotypes 
 
The instability of Ura- phenotype amongst the different MMY strains prompted an investigation of the 
genomic ura3 locus for possible causes. To predict what might be expected of genomic PCR, a set of 
primers were first optimised using a p140 vector (Table 2.7) which carried a truncated URA3 gene and 
p426GPD vector with a full length URA3.  
The reason for selecting the p140 vector was because it was used to engineer the MMY strains. The 
genes FAR1, SST2, and STE2 were deleted using a plasmid which had a URA3 marker for the selection 
of successful deletion events by cultivation on uracil-depleted media, as the original W303-1A strain 
has a mutant URA3 gene as described previously [76, 77]. To restore the Ura- phenotype, these URA3 
genes were deleted using a vector derived from pUC19 in which URA3 with additional restriction sites 
EcoRV and StuI was ligated at SalI site. After digestion with EcoRV and StuI a 247 bp fragment from the 
middle coding region of URA3 was released, leaving 5’ and 3’ ends intact. The re-ligated disrupted gene 
can replace the genomic URA3 genes. Successful deletion events were confirmed using 5-FOA which 
kills Ura+ phenotype carrying cells [78]. So it was hypothesised that the ~250 bp smaller URA3 gene 
(trURA3) band would be detected in the MMY genome. The full URA3 gene (flURA3), like the wild type 
found on the expression plasmids p426GPD and p306GPD, was also expected to be found if the 
endogenous mutated gene was the cause of the reverted Ura+ phenotype.  
 
 
p426
GPD + 
URA3 
3000 
1000 
800 
500 
MMY
28 + 
URA3 
MMY
22 + 
URA3 
MMY
28 + 
YAP1 
MMY
22 + 
YAP1 
p426
GPD 
p140 
3000 
1000 
800 
500 
Figure 6.3 Optimisation of primers for URA3 detection. The primers 1_URA3 and 2_URA3 were designed 
to amplify both flURA3 and trURA3 from gDNA. [A] Primer optimisation on p426GPD vector carrying 
flURA3 and p140 with trURA3 showed the later to produce a band 200bp shorter than flURA3. [B] Both full 
length and truncated URA3 were detected in gDNA of MMY28 which phenotypically showed to be able to 
switch between Ura+ and Ura- phenotypes. MMY22 gDNA showed only the truncated gene version present; 
it was also unable to demonstrate Ura+ phenotype. YAP1 primers were used as a positive control for gDNA 
quality.  
A B 
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Indeed when the primers were optimised using the plasmid-borne URA3 genes, two different PCR 
product sizes were observed (Figure 6.3 A). The 1_URA3 and 2_URA3 primers were designed to anneal 
at the far 5’ and the far 3’ end of the reading frame, so that the pair would amplify most of the reading 
frame and that would also amplify the gene if it was truncated in the middle section.  
The next challenge was to test the primers with the genomic DNA. The genomic DNA was extracted 
from the MMY22 and MMY28 based on the different phenotypic behaviour of these strains described 
in 6.2.1 (Table 6.1). Interestingly, the PCR detected both full length and truncated gene versions in 
both MMY22 and MMY28 but the dominant gene in MMY28 was flURA3, while in MMY22 the 
dominant band was of the trURA3 gene, with a very faint band of flURA3. This result can be related 
back to the fact that MMY22 was unable to revert under the selective pressure of 5-FOA and displayed 
strictly Ura- phenotype. In contrary, MMY28 has displayed a very adaptive phenotype. 
6.2.3. The deletion of the full length URA3 gene 
 
In order to eliminate any possibility of the ura3 (original mutation in the W303-1A strain) reverting to 
the wild type, methods for a complete gene deletion were investigated. The strategy used by 
Brachmann et al in the paper describing a set of S. cerevisiae deletion strains [79] where a URA3 
deletion cassette was designed to include flanking regions of upstream from the 5’ and downstream 
from the 3’ ends. This cassette when integrated in the URA3 locus, deletes the reading frame 
completely. The pJL164 vector used in this study is deposited in the ATCC collection and therefore was 
available to be purchased (Table 2.7). The deletion fragment was released from the vector by SpeI + 
XhoI digestion and was used to transform MMY11 using standard methods. The integration event was 
enforced by the 5-FOA selective pressure [79]. However, a very large number of colonies were 
observed following transformations. An additional step involving growing the cells for approximately 
one generation in a liquid 5-FOA/YPD was included (see section 2.2.1.3) to increase the stringency of 
the selective pressure. Even then, a large number of colonies growing on 5-FOA/YPD medium were 
also able to grow on –Ura+Trp (tryptophan required for MMY11 only because it is Trp-) medium. 
Approximately 40 colonies which passed the phenotypic screening were analysed by PCR with the 
primers described in the previous section until one colony was identified displaying only the trURA3 
gene (Figure 6.4). 
This colony named MMY11_ura3Δ was incapable of forming any colonies on uracil deficient plates 
even when large numbers were plated on several occasions. These observations together with the PCR 
test indicate that this train is truly ura3Δ.  
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The ura3 gene deletion was attempted in MMY11 first, because it was soon apparent that deleting the 
gene in all 11 progeny strains (MMY12-28) simultaneously would not be feasible. Instead, introducing 
the chimeric Gpa1-Gα proteins was expected to be a more straight-forward process.   
 
6.3. The engineering of cholesterol biosynthesis pathway in S. cerevisiae MMY 
strains 
 
Sterols play a vital role in the normal plasma membrane physiology in eukaryotic cells. They create a 
microenvironment for the membrane proteins. The details of how sterols actually bring about their 
function are only starting to emerge and a lot is still unknown. What is known is that some functions 
are more structure dependent than others in the membrane, for example, the substitution of 
ergosterol in yeast with a mammalian cholesterol or plant campesterol was adequate for function of 
Tat2p and Ste2p but not Pdr12p or Can1p [56, 58]. Indeed, it is common for human membrane 
proteins, such as GPCRs, ABCs, transmembrane ATPases and others to have cholesterol binding sites 
which play a role in their function. Not surprisingly, putting those receptors in an environment that 
does not contain cholesterol, be it a foreign yeast membrane or a solubilising agent, can alter their 
pharmacological activity or render  them completely inactive. There is also evidence that upon 
recombinant protein production in a non-native host, such as yeast, protein becomes inactive because 
if fails to be inserted in the right environment and is sent to be degraded reducing overall production 
yields. 
Three independent published studies attempted to replace ergosterol, a native sterol in yeast 
membranes, with the cholesterol that is found in mammalian membranes by genetically engineering 
the yeast. Two genes were identified as key in achieving this – DHCR7 and DHCR24, and their 
competing counterparts – ERG5 and ERG6.  [56-58]. The cholesterol synthesis pathway enzymes 7-
Figure 6.4 The detection of flURA3Δ by genomic PCR. A colony screen 
was performed during which one colony in lane 1 was as identified 
carrying only trURA3. In contrast the colony in the lane 2 demonstrated 
the presence of flURA3.  3000 
1000 
800 
500 
MMY
11 
ura3Δ 
MMY
11 
neg 
1 2 
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dehydrosterol reductase and 24-dehydrosterol reductase – gene products of DHCR7 and DHCR24 
respectively – saturate the sterol intermediates at positions C-7 and C-24 [80-83] in cholesterol but not 
ergosterol in synthesis, while Erg5 introduces double bond at position C-22 and Erg6p adds methyl 
group at position C-24 in ergosterol synthesis therefore also competes with Dhrc24 for the substrate 
(summarised in Figure 6.5). 
Figure 6.5 The summary of key enzymes and their substrates for shifting the sterol synthesis from 
ergosterol to cholesterol in yeast. The sterol intermediates and enzymes marked in green are 
involved in ergosterol synthesis while the ones marked in red are for cholesterol synthesis. The 
diagram is simplified to show only key enzymes relevant to this engineering strategy. 
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This subchapter describes the strategy for the integration of DHCR24 and DHCR7 genes (6.3.1), 
followed by a detail account of how the plasmids were constructed (6.3.2). The first attempt to 
integrate the erg5Δ::DHCR24 is described in section 6.3.3 and future work is summarised in section 
6.3.4. 
 
6.3.1.  The design of erg5Δ::DHCR24 and erg6Δ::DHCR7 integration cassettes 
 
Human DHCR genes containing cassettes were used to disrupt S. cerevisiae ERG5/6 genes in the study 
reported by Marioka et al. DHCR7 was used to replace ERG6 and DHCR24 replaced ERG5. Firstly, 
DHCR7/24 genes were inserted in between a GAPDH promoter and CYC1 terminator in pRS416 vector, 
then the promoter-gene-terminator sequence fragments were amplified with PCR primers to include 
flanking regions of ERG5/6 loci. Resulting fragments were inserted in pAUR135 plasmids containing 
aureobasidin A (AUR1-C) selection gene in between ERG gene promoter region and a region containing 
the initiation codon. AUR1-C is recyclable marker which can be removed once the plasmid is integrated 
into the genome by growing cells on galactose containing medium [58]. The pAUR135 vector 
aureobasidin A selection described in this study was used as a platform for our engineering strategy 
because a lot of selection markers were unavailable to use due to the heavily-engineered nature of the 
MMY strains. However, some modification to the construct were made.  
It was reported that  copies of DHCR7 and DHCR24 genes obtained from the cDNA of zebrafish Danio 
rerio (Genbank NM_201330 and BC086711 respectively), and codon optimised for S. cerevisiae, 
produced better results than Xenopus laevis or human gene products [56]. The DHCR7 and DCHR24 
genes in this work have also originated from D. rerio and were codon optimised for the expression in 
yeast by GenScript who synthesised the gene.  
GPD promoters were used in all three studies, AOX1 terminator for P. pastoris expression plasmids and 
CYC1-term for S. cerevisiae [56-58], which controlled the transcription of the recombinant genes. 
However, since the GPD promoter was already used for the expression of chimeric Gpa1-Gα proteins 
and the recombinant GPCRs, we wanted to avoid overburdening the cell’s translational machinery. 
Therefore a possibility of utilising the endogenous promoters was explored. It has been previously 
demonstrated that the deletion of other ergosterol biosynthesis pathway genes resulted in an 
accumulation of intermediates and the subsequent transcriptional activation at the locus of the 
deleted gene [84, 85]. It was hypothesised that lack of Erg5 and Erg6 would activate the transcription 
of DHCR24 and DHCR7.  
Figure 6.6 outlines the design of the cholesterol gene integration and simultaneous ergosterol gene 
deletion in MMY 11 strain. As described in Marioka et al., marker recycling requires colony selection 
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on galactose after the initial selection for integration on aureobasidin A (AbA). The growth on galactose 
medium results in transcriptional activation on the Gal10 promoter, which on the integrated plasmid 
induces the overexpression of GIN11M86 sequences that inhibit cell growth [86]. This can result in two 
scenarios: in the first, the genetic rearrangement reverts the genomic locus to the original structure 
removing the pAUR vector completely, in the second, a desired deletion results. 
 
  Figure 6.6 An overview of the strategy for cholesterol pathway engineering in MMY yeast. The deletion 
cassettes present in the pAUR135 vector first have to be integrated upstream of the reading frame of 
ERG5/6 upon the selection pressure of aureobasidin A. The subsequent selection on galactose induces 
the expression of toxic sequences under the transcriptional regulation of GAL10 promoter which 
promotes the cell to ‘loop out’ this element along with the AUR1-C gene. This allows the marker to be 
recycled. Because of the flanking 5’ and 3’ ERG5/6 sequences present upstream and downstream of the 
DHCR24/-7-cyc1t construct it is able to replace the ERG5/6 reading frame; alternatively this can be 
removed along with the selection marker,  returning the genetic loci to the original structure.  
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6.3.2.  The engineering of pAUR135-erg5-DHCR24-erg5-cys1t and pAUR135-erg6-
DHCR7-erg6-cys1t plasmids 
 
In order to obtain the plasmids for the integration of cholesterol genes DHCR7 and DHCR24, two 
intermediate plasmids had to be made first. The p426GPD vector was selected as the backbone for the 
insertions of the deletion cassette elements because it was readily available and is episomally 
maintained at a high copy number, which is required for the recovery of the plasmid back from the 
yeast when the yeast gap repair is attempted.  
 
p426GPD-ERG5 and p426-ERG6 
 
In order to integrate the deletion cassette, it had to have a sequence homologous to the genomic 
ERG5/6 loci. Therefore the first step was to amplify the genomic loci and insert it into the intermediate 
plasmid as depicted in Figure 6.7. The amplification was designed so that the sequence upstream from 
the 5’ of the reading frame was modified as little as possible in the hope that the features of the 
transcription machinery binding would be preserved.  
For the ERG5 PCR amplification and subsequent insertion this was relatively easy because the EcoRI 
restriction sites were conveniently located 740bp upsream from the ATG codon and 265bp 
downstream from the 3’ of the reading frame. The PCR product was digested with EcoRI and inserted 
Figure 6.7 The schematic representation of the construction of p426GPD-ERG5. Both ERG5 and ERG6 
genomic regions were amplified by PCR and then inserted into intermediate vector p426GPD.  
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by conventional ligation methods. The ERG6 genomic locus did not have such suitable restriction sites, 
therefore the primers were designed to add SacI at the 5’ end and EcoRI at the 3’ end. There restriction 
sites were chosen because they were compatible with the ligation strategy both in relation to the 
vector backbone and the PCR-amplified DNA fragment.  
The correct plasmid ligations were confirmed using several restriction enzymes. For the ERG5 insertion, 
SacI was used to select the plasmid clones in which the fragment was inserted at the correct 
orientation. Van91I was also used to indicate that the fragment contained ERG5 or ERG6 reading 
frame; this enzyme does not cut within the p426GPD vector. And finally, SacI and EcoRI digestion of 
the p426-ERG6 colonies demonstrated that digestion with these enzymes cut out a fragment of the 
same size as the PCR product. Out of tested plasmid clones, 1 showed the correct ligation of p426GPD-
ERG5 and 3 colonies of p426-ERG6 (Figure 6.8). 
 
p426GPD-erg5-DHCR24-cys1t-erg5 
The second engineering step relied on the yeast DNA repair machinery to ligate the DHCR24 gene into 
p426GPD-ERG5, replacing the reading frame of ERG5 with that of DHCR24 (Figure 6.9). The DHCR24 
ERG5 ERG6 
SacI Van91I Van91I SacI + EcoRI 
1 2 3 4 5 6 7 8 9 10 11 12 
8000 
3000 
1200 
2500 
Figure 6.8 The restriction digestion analysis of p426GPD-ERG5 and p426-ERG6 vectors. The ERG5 
inserted at the correct orientation was predicted to appear as 1160bp + 8064bp bands when digested 
with SacI. The clone in lane 2 appears to have the predicted sizes, while clones in lanes 1 and 3 do not, 
despite all three having the ERG5 gene inserted, as indicated by Van91I digestion in lanes 4-6. The 
ERG6 insertion was less equivocal because two different restriction sites were used and as a result all 
3 colonies chosen for the analysis displayed the expected digestion pattern.  
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gene from Danio rerio (the zebrafish) was synthesised by GenScript, optimising the codon for use in S. 
cerevisiae. The synthesised fragment also included the 273bp 5’ flanking sequence upstream from the 
ERG5 reading frame, and 100bp downstream from the end of the reading frame. These homologous 
sequences were required to ligate the desired plasmid in yeast by gap repair mechanism (more details 
in Materials and Methods section). The cys1 terminator sequence is located between the DHCR24 3’ 
end and the 100bp of the homologous ERG5 sequence. 
The original p426GPD-ERG5 and p426GPD-erg5-DHCR24-cys1t-erg5 did not differ much in size, 
therefore differences in restriction sites were utilised to select successful ligations. It was predicted, 
that in the presence of ERG5 gene the HindIII digestion would result in two fragments of 1376bp + 
7848bp but if the DHCR24 has successfully replaced the ERG5 reading frame the plasmid would be 
linearised only once. As shown in Figure 6.10, both negative and positive ligation patterns are observed 
and clone in lane 2 was determined to be successfully ligated p426GPD-erg5-DHCR24-cys1t-erg5 
plasmid.  
Figure 6.9 Schematic representation of the ‘gap repair’ cloning of the p426GPD-erg5-DHCR24-
cys1t-erg5 and p426-erg6-DHCR7-cys1t-erg6 vectors. The homologous ERG5/6 sequences on the 
synthesised DHCR24/7 fragments and the p426GPD-ERG5/6 vector allowed the ligtion where the 
ERG5/6 reading frame is replaced by DHCR24/7. 
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p426GPD-erg6-DHCR7-cys1t-erg6 
A similar design and strategy for cloning was planned for the p426GPD-erg5-DHCR24-cys1t-erg5 
plasmid. However, no colonies could be generated following the yeast gap repair. Instead, Gibson 
Assembly was used. This method relies on homologous overlapping sequences present on the 
fragments to be ligated together [87]. Therefore, the synthesised erg6-DHCR7-cys1t-erg6 fragment 
could be ligated into p426-ERG6 where the sequences overlap (essentially by the same mechanism as 
the gap repair).  
Four colonies were selected for analysis with BamHI, HindIII, and PvuII enzymes which cut the DHCR7 
and ERG6 gene-containing plasmids differently: 
1) BamHI:  
1586 + 7374 bp if DHCR7 present; 
8420 bp if ERG6 present. 
2) HindIII: 
1103 + 7857 bp if DHCR7 present; 
8420 bp if ERG6 present. 
3) PvuII: 
603 + 1361 + 5274 + 1722 bp if DHCR7 present; 
5274 + 3146 bp if ERG6 present. 
 
Shown in Figure 6.11 are the restriction digestion analysis which indicate that 3 out of 4 colonies had 
a successful ligation.  
8000 
3000 
1200 
2500 
1 2 3 
Figure 6.10 The selection of successfully ligated p426GPD-erg5-
DHCR24-cys1t-erg5. Following ligation 3, colonies were digested 
with HindII which cuts ERG5 containing vector into two fragments 
as can be seen in lanes 1 and 3, while DHCR24 containing vectors 
would be linearised only once like in lane 2. 
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pAUR135-erg5-DHCR24-cys1t-erg5 and pAUR135-erg6-DHCR7-cys1t-erg6 
The last step in engineering these plasmids was achieved by a standard ligation method where the 
deletion cassette was inserted into the pAUR135 vector. The erg5-DHCR24-cys1t-erg5 cassette was 
inserted at the EcoRI restriction site and the erg6-DHCR7-cys1t-erg6 at the SacI and EcoRI sites.  
One colony of pAUR135-erg5-DHCR24-cys1t-erg5 was analysed by restriction digestion with XhoI, NcoI, 
SmaI and NdeI, all of which confirmed the expected digestion pattern (Figure 6.12 [A]). The later has 
also indicated that the fragment was inserted at the right orientation, since the same restriction site 
was used for 5’ and 3’ end digestion. 
For the selection of pAUR135-erg6-DHCR7-cys1t-erg6, 4 plasmids were selected and digested with 
BamHI, AvrII or PvuII. All 4 plasmids showed the correct digestion pattern (Figure 6.12 [B]). 
The digestion pattern predictions are summarised in Figure 6.12 [C]. 
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I 
HindIII PvuII 
Figure 6.11 The selection of successfully ligated p426-erg6-DHCR7-cys1t-erg6. Based on the 
digestion patterns of BamHI, HindIII and PvuII 3 vectors were deemed to have the correct DHCR7 
fragment ligated into the p426-ERG6. 
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Enzyme Predicted pAUR135-erg5-DHCR24-cys1t-erg5 sizes 
 Enzyme Predicted pAUR135-erg6-DHCR7-cys1t-erg6 sizes 
XhoI 8885bp  BamHI 4608 + 2869 + 1586 + 54bp 
NcoI 4804 + 3820 + 261bp  AvrII 9117bp 
SmaI 8885bp  PvuII 5116 + 2364 + 1034 + 603bp 
NdeI 6103 + 2782bp if correct 
8430 + 455bp if reverse 
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Figure 6.12 The selection of successfully ligated pAUR135-erg5-DHCR24-cys1t-erg5 and 
pAUR135-erg6-DHCR7-cys1t-erg6. [A] Digestion pattern of pAUR135-erg5-DHCR24-cys1t-erg5 
vector. [B] Digestion pattern and selection of the pAUR135-erg6-DHCR7-cys1t-erg6 vector. [C] 
Summary of each vectors’ expected digestion pattern.  
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6.3.3.  The selection of the MMY11 erg5Δ::DHCR24 strain 
 
The pAUR135-erg5-DHCR24-cys1t-erg5 was designed to integrate within the upstream flanking region, 
where the promoter would be expected to be. For this, the plasmid was linearised at AvrII unique 
restriction site. Following standard yeast transformation protocol MMY11_ura3Δ colonies growing on 
AbA were picked for PCR analysis. Primers 39 and 40 (Table 2.6) were designed to anneal at 884bp 
upstream from the ERG5 reading frame and 323bp downstream from the end of the reading frame. 
These positions were outside the PCR amplified region inserted in the transformation plasmid 
therefore would only amplify the genomic region. However, it was predicted that upon the insertion 
of the transformation plasmid the PCR product would be 10049bp instead of the 2784bp which was 
observed during primer optimisation. This size difference was utilised for positive integration selection. 
As demonstrated in Figure 6.13, both size fragments were observed in 10 out of 17 screened colonies. 
It is unclear whether the lower band has resulted from a mixed population in the sample or as a non-
specific PCR product. It was noted that the intensity of the top band in relation to the lower band 
differed between the test samples. The sample in lane 14 was clearly negative with only the lower size 
band. Other samples did not show any bands or they are very faint. This could be due to the quality of 
the gDNA sample. Based on the intensity of the top band, colonies represented in lanes 1, 2 and 13 we 
selected for the next step involving the galactose-induced selection. 
 
Several WHAUL+His+Ura+Trp + galactose plates (WHAUL+gal for short) were inoculated with selected 
colonies to induce the looping out of the selection marker AUR1C cassette. 10 colonies were picked 
for PCR screening which is depicted in Figure 6.14 [A]. The pAUR135 vector was designed so that the 
GAL10-prom induced expression of toxic GIN11M86 sequences to drive the cell’s genetic 
Figure 6.13 PCR screening of the integration of pAUR135-erg5-DHCR24-cys1t-erg5 into MMY11_ura3Δ. 
The primers 39 + 40 were designed to amplify the genomic locus of ERG5 which appears as a band of 
approximately 3,000bp in the untransformed strain, and was expected to appear as a 10,000bp band upon 
a successful integration of the vector. Colonies represented in lanes 1, 2, 4-6, 8, 10-13 appear to have both 
the band characteristic of the wild type locus and that containing the vector. Samples in lanes 3, 14, and 
15 indicate that no integration tool place and samples in lanes 7, 9, 16, 17 are inconclusive. 
1 2 3 4 5 6 8 10 7 9 11 12 13 14 15 16 17 
10000 
3000 
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rearrangement to the original locus or the erg5Δ::DHCR24 version (outlined in Figure 6.6). The same 
primers 39 and 40 can amplify either of those regions, however, distinction by PCR alone is difficult 
because of less than 200bp size difference between the two resulting loci. The solution to this was to 
digest the PCR products with two enzymes – XhoI and HindII – which were predicted to cut the 
fragment differently depending on whether ERG5 or DHCR25 was present. As shown in Figure 6.14 [B], 
two colonies in lanes 1, 8 and 5, 12 appeared to have the digestion pattern predicted to appear if 
DHCR24 is present.  
 
  
Figure 6.14 The selection of MMY11 erg5Δ::DHCR24 colonies. [A] The initial PCR screening of 
galactose selected colonies showed bands of very similar sizes, therefore further analysis by 
restriction digestion, shown in [B], had to be performed. The predicted digestion pattern allowed 
the selection of two colonies which are believed to have the desired genomic locus structure, in 
which ERG5 reading frame has been deleted and replaced with DHCR24. 
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6.3.4. Future work 
 
The integration of the DHCR7 gene was also attempted several times, and although the integration of 
the AUR135-erg6-DHCR7-cys1t-erg6 could be detected, following the galactose selection all colonies 
appeared to have reverted to the original locus structure. Given the number of attempts to integrate, 
it may be necessary to redesign the deletion cassette.  
The success of the engineering strategy would eventually have to be confirmed by analysing the sterol 
composition of engineered yeast, as was described in the original studies. Even the intermediate strain 
MMY11 erg5Δ::DHCR24 is expected to produce ergosterol/cholesterol intermediates. A mass 
spectrometry method therefore needs to be optimised for the detection of ergosterol, cholesterol and 
their intermediates.   
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Chapter 7 – Discussion and future work 
 
The results presented in this thesis were carried out in yeast engineered for the functional investigation 
of GPCR pharmacology. The aim of this study was to optimise the functional expression of adrenergic 
receptors that had previously been difficult to express and/or characterise pharmacologically in these 
yeast strains. Further understanding of the host’s response to protein expression was sought after 
along this process. The sections below discuss the findings presented in Chapters 3, 4, 5, and 6. 
 
7.1. MMY yeast are a powerful tool for GPCR drug discovery 
 
Throughout this thesis a few examples of compound screening experiments have been presented in 
Chapter 3 and 5. It’s quick and inexpensive set up makes is it very attractive for screening programmes 
where the aim is to identify potential interacting (in an agonistic or antagonistic manner) compounds 
for further development and characterisation. However, as any assay it does require some 
optimisation. At GSK, where these yeast were engineered, parameters such as concentration of 3-AT, 
incubation time, inoculation density, substrate concentration have been recognised to make a 
difference on the signal window. The data presented in Chapter 3 illustrates this with some examples. 
The variation of 3-AT concentration, as already discussed, has provided to be a useful in controlling 
unspecific background growth and as was shown in Figures 3.3, 3.4 and 3.9 where the level of control 
needed depended greatly on the receptor. What is interesting is that 3-AT concentration did not have 
a uniform effect on all tested compounds in terms of efficacy. For example, compound 9 retained Emax 
of approximately 6x106 at 2mM and 10mM of 3-AT, while compound 11 dropped from 5x106 to 3x106 
RFUs. Similarly, inverse agonists 4, 8 and 21 were able to inhibit growth regardless of overall high 
unspecific growth (Figure 3.9 [B]). Therefore particular caution has to be taken when interpreting 
efficacy of a ligand. When a screening assay is set up for a new receptor, a reference known agonist is 
included along with a no compound control to determine a signal window. Another useful control 
could be a known partial agonist acting on the same signalling pathway as the reference agonist. By 
tuning the 3-AT concentration to match the curve profiles of both full and partial agonists the assay 
conditions can be optimised to better represent the efficacies of test compounds.  
Another novel observation arising from the data presented in Chapter 3 is the variation between 
different instruments, especially in terms of their dynamic range (Figure 3.6 and 3.7). Each instrument 
manufacturer have their unique features but generally the fluorophore excitation is achieved by either 
a monochromator which generates any desired wavelength or by the light passing through a filter. 
Generally, the optical filter based fluorescence readers are considered to be more sensitive because 
the filter eliminates wavelengths other than the selected one; a filter at a different wavelength is 
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required for emission. Four different fluorescence readers were used in this thesis project – three 
described in Chapter and the fourth one – Spectrafluor Plus (Tecan) – used for generating Chapter 5 
data. Out of these Gemini (Molecular Devices) is a dual monochromator based reader while the other 
three are filter-based readers. The Gemini instrument produced a lowest magnitude of RFUs in a range 
of 103 RFU, while the filter-based readers generated between 104-106 RFUs (including SpectraFluor 
Plus instrument). The magnitude of the signal window produced by background fluorescence and the 
agonist stimulation produced fluorescence were also different. For this work instrument dependent 
settings were not optimised, however, this is something that should be considered if the signal window 
is not satisfactory. For example, the α2B strain YIG153 has demonstrated consistently to have a higher 
background growth produced signal, however, as demonstrated in Figure 3.7 some strength of that 
signal may be masked by instrument settings. 
 
7.2. A comparison of episomal and integrative plasmid functional expression 
systems – which is better? 
 
The results presented in Chapter 4 describe a detailed comparison of two systems for recombinant 
gene introduction into yeast and the resulting protein translations. For the functional expression of 
the β-adrenoceptors the p306GPD vector provided several benefits. Firstly, the positive colony 
selection process was more robust and unambiguous and overall a lot more positive colonies could be 
selected. Secondly, the signal window on the functional FD-glu assay was wider and less variable 
between the different colonies of the same strain-vector combination (Figures 4.15 and 4.16). 
Together with a lower frequency of positive colony selection, smaller signal window and three 
combinations of vector constructs (with/without leader sequence) made the selection process quite 
laborious. Although the episomal vectors do not need to be linearised prior transformation, which is 
considered to speed up the process, in retrospective it did not provide a great advantage over the 
integrative vectors which had to be linearised. However the most disappointing property of p426GPD 
transformed colonies was the disappearance of functional signal in β2-AR transformed yeast. This 
prompted the decision not to carry out any compound profiling experiments with these constructs and 
move on to the integrative system.  
Despite early reports of generation instability of the 2µ vectors [74, 88] they are still widely used for 
expression of GPCRs in yeast. Successful reports of functional GPCR studies in MMY strains 
transformed with high copy number producing 2µ vectors have also been reported [2, 47, 48, 50, 89-
91]. Although the study investigating adenosine A1 reported lower agonist efficacy in GαO when 
compared to data produced in Chinese hamster ovary (CHO) cells [47]. The authors argue that the 
yeast pheromone signalling pathway has a lower signal amplification which explains a weaker coupling 
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of lower efficacy ligands. Other reasons thought to influence the results are sub-optimal design of 
chimeric Gα proteins, different compartmentalisation and/or lack of other signalling components [47]. 
However, the receptors in these studies were expressed in an episomal expression system and no 
apparent leader sequences were added to their constructs. It could be argued that the lack of 
sensitivity of the yeast system they experienced could have been alleviated with additional 
optimisation of the expression vector, as it has in the work presented here. The episomal expression 
in p426 vector was suboptimal for the β1-AR and β2-AR functional expression in the same yeast strains 
as used in their studies.  
Based on the published evidence and the ones presented in this thesis it is difficult to say that the 
integrative system is better for functional expression of GPCRs in MMY yeast over the episomal or vice 
versa. The cellular responses that made the functional expression of the adrenoceptors more robust 
in p306GPD transformed yeast remains unknown, although it has been shown in the literature that 
high copy number does not always correlate with increased expression yields [92]. It is possible that 
the high copy number of the gene and hence increased expression burden to the cell is the driving 
force for plasmid loss, and the genomic integration not only reduces that burden but is also unlikely to 
be removed from the genome. In theory the CEN-ARS which are episomal vectors, such as p41X and 
p31X [79, 93], maintained at lower copy number (1-2 per cell) would alleviate the translational burden 
if that is an issue.  
 
7.3. Protein expression level and functional expression of the β-adrenoceptors 
 
The comparison of different expression vectors in the search of an ideal construct for functional 
expression of the β-adrenoceptors has also created a platform for investigating cellular responses to 
GPCR production. As mentioned in the previous section, by introducing a single gene copy via p306GPD 
vector construct for both receptors a functional expression has improved, which posed a question 
whether protein expression levels differed. The western blot experiments described in section 4.4 
attempted to answer this question. However, no correlation between the relative protein quantity and 
functional signal strength could be drawn based on presented results. However, it is not to say that 
there is no correlation at all. The total membrane western blot does not give an information about the 
folding status of detected proteins – it is possible that expression via high copy number vector results 
in more misfolded protein. Nor does this method indicate which membranes these proteins are 
associated with. The yeast Gpa1 (a Gα subunit) and the Ste4-Ste18 (Gβγ) complex are located on the 
plasma membrane when the signalling takes place therefore the receptor would be expected to be 
predominantly located there as well. The mating factor α (MFα) secretion signal would be also 
expected to enhance receptor’s functional expression and trafficking to the plasma membrane.  
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A more detailed investigation into these theories could be achieved by separating the membrane 
fractions and combining with radio-labelled ligand studies, which are often used to quantify and 
confirm receptor folding status [38]. There are various well established methods such as membrane 
fraction separation on sucrose gradient or biotinylation of the cell surface and a subsequent plasma 
membrane isolation with the help of an antibody. Yeast microscopy is another method of visually 
assessing the receptor’s location by either tagging it with a fluorescent protein, such as mCherry, yeast 
enhanced or conventional GFP [49, 90, 94], or by fluorophore conjugated antibodies. The microscopy 
was attempted on MMY15 expressing functional untagged β-adrenoceptors, however, the antibodies 
available did not provide sufficient sensitivity to give any conclusive results. A small tag, such as FLAG 
tag or poly-histidine tag would provide minimal interference with the receptors signalling yet giving an 
array of antibodies and protocols for protein detection on a western blot, microscopy or cell 
fractionation.  
In regards to the detected band sizes the β2-AR signal on the western blot is somewhat more conclusive 
than the β1-AR signal. The expected size of β2-AR is 46-48kDa for a monomer and around 68kDA for a 
dimer when expressed in mammalian cells (Abcam, cat# ab182136, cat# ab137494, cat# ab61778). The 
detected top bands in yeast were around 39-41kDa which is not largely different to the expected size, 
or the size of β2-AR and other GPCRs expressed in yeast [11, 94, 95] and mammalian cells [96]. The 
presence of a double band in p426GPD-MFα expressed plasmid compared to a single 39kDa band in 
p306GPD-MFα plasmid is an interesting observation. A post-translational modification such as 
glycosylation has been described in the literature to results in similar size difference between the 
bands [95, 97, 98] and although is not essential for the native GPCR Ste2, the role of glycosylation on 
the β-adrenoceptors might be to aid the receptor’s localisation to plasma membrane [99]. The 
glycosylation can be cleaved off with Peptide -N-Glycosidase F or Endoglycosidase H enzymes which 
would reduce the size of the protein if the glycosylation is responsible for shift in the size [97, 98]. The 
same double size bands were observed on β1-AR western blots, although almost twice smaller than 
the β2-AR protein sizes. This reduction in size likely indicates protein degradation. Whether these bands 
actually represent the receptor could be confirmed by protein sequence. However, overall it would be 
beneficial to add an already mentioned Flag, poly-histidine or biotin tag for further investigation as the 
tested antibodies have provided limitations to further investigation.  
 
7.4. Fixing the uracil selection marker deletion in the MMY yeast strains 
 
Despite the inconclusive band sizes one pattern observed from the western blot analysis was quite 
clear – the non-functional colonies picked for analysis showed no presence of the β-adrenoceptor at 
the protein level. During the functional colony selection of p426GPD episomally transformed yeast 
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described in section 4.4 a large number of colonies picked for pre-screening and later full-curve analysis 
did not show any response to isoprenaline, despite being picked from a selection plate after the 
transformation. Some of these colonies were still able to grow on the selection medium when first 
selected and also when grown in a larger volumes for membrane isolation. The lack of expression could 
be due to many reasons: transcription inhibition, poor translation or rapid degradation due to 
missfolding. However, we also had concerns about the auxotrophy of uracil marker (ura3-1) and 
therefore made further investigation as described in sub-chapter 6.1. 
Several so called ‘Designer strains’ were engineered based on two most popular S. cerevisiae genetic 
backgrounds – S288C and W303-1a [79, 100]. In these strains the coding sequences of the auxotrophic 
markers were completely deleted. The rationale for this was that point mutations, small internal 
deletions and Ty insertions on auxotrophic marker genes leave large fragments of sequences 
homologous to the wild type sequences located on transformation vectors. This can result in the repair 
of the auxotrophy rather than an integration of the desired gene carried out on a vector or PCR 
generated fragment. The way to circumvent this issues is to delete those homologous sequences on 
the genome so that there is no way for the exogenous markers to cross over to the original locus.  
The Ura- phenotype of the W303-1A strain from which the MMY yeast were engineered is brought 
about by a point mutation (ura3-1) therefore it is highly likely that the ‘false-positive’ selected yeast 
colonies the recombination took place and the phenotype reverted to Ura+. However, even without 
the introduction of the exogenous URA3 gene colonies were able to display Ura+ phenotype (Figure 
6.2), questioning the reliability of that point mutation.  
Furthermore, some 426GPD transformed yeast colonies did show functional expression but failed to 
retain it after freeze-thaw cycle (Figure 4.10), suggesting that these cells did initially uptake the plasmid 
but the marker repair did not take place, because the cells also struggled to grow in the selection 
medium upon presumed plasmid loss. As further investigated by PCR showed that two distinct 
population of cells existed – flURA3 and trURA3 – and that the strains displaying a full length gene, 
presumably the original ura3-1 locus, were more likely to revert to Ura+ phenotype than the ones 
carrying a truncated gene fragment resulting from marker recycling (section 6.2.2, Figures 6.2 and 6.3). 
Whether reversion to Ura+ phenotype was due to reverted point-mutation or repair by homologous 
recombination upon transformation with URA3 carrying vector, the observations pointed towards the 
problem with the full length ura3-1 gene. To test this theory and potentially resolve this ‘false-positive’ 
colony selection issue the same strategy described in ‘Designer strain’ engineering studies was 
employed [79, 100]. The pJL164 vector designed to generate ura3Δ0 allele was transformed into 
MMY11 which lacks the chimeric Gα proteins. The remake of MMY12-28 strains from MMY ura3Δ0 
could potentially make the selection process for functional GPCR expression much quicker and is 
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expected to result in smaller number of transformation colonies which would be the result of reduced 
‘false-positive’ background. 
 
7.5. Pharmacology of β1-AR and β2-AR – the Devil is in the (structural) details 
 
The yeast assay for functional GPCR studies was designed to produce the best coupling interactions 
between the mammalian receptor and the chGα as discussed in section 1.3.6 and reviewed in [1]. A 
high signal induction upon ligand stimulation, or inverse relationship for inhibition by antagonists and 
inverse agonists, is a desirable feature for high-throughput screening of compound libraries in an 
industrial setting. As demonstrated in Chapters 3, 4 and 5 this can be achieved in yeast by optimising 
assay conditions or expression vector design. However, since the design of this assay a lot more details 
have emerged about the mechanism of synthetic ligand-induced GPCR signalling, such as β-arrestin 
signalling, bias agonism and allosteric modulation. Therefore a question to ask is how the yeast assay 
can be used to investigate a more complex pharmacology. A few published studies have already 
demonstrated that ligand bias can be observed in the yeast assay and confirmed in mammalian cell 
assays [48, 49]. The data presented in Chapter 5 can perhaps be used to gain more understanding of 
interactions between the receptor and the Gα subunit.  
The recently proposed kinetics of GPCR pharmacology suggest that binding of a ligand promotes 
association with the GαS protein, for which cytoplasmic ends of H3, H5 and H6 form a pocket for Gαs 
N terminus interaction. The engagement in coupling is required to stabilise the receptor and increases 
its affinity for the ligand [65]. From the results presented in Chapter 5 it was clear that most agonists, 
with the exception of isoprenaline, have stronger β2-AR coupling with GαS, Gα14, and Gα16 strains and 
weaker with Gαq and Gαi1. As the differences were fairly consistent it suggests that the pocket formed 
by the active receptor conformation is suboptimal for all necessary contacts with the 5α helix of chGα 
to completely stabilise the interaction and efficient GDP exchange to GTP on the chGα subunit. A 
receptor-G protein interactions in the presence of various ligands could be investigated by modelling 
techniques. Particularly interesting experiments would be with outliers, such as procaterol and 
xamoterol, presented in Figure 5.15. By comparing models of receptor-ligand complex coupling to 
mammalian Gα, yeast Gpa1 and chGα can potentially inform on which residues bring about the 
specificity of ligand-induced interactions and explain any observed pharmacological differences.  
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7.6. Thesis summary 
 
This following objectives were achieved: 
• Assay parameters were described in well coupling α2A and α2B adrenoceptors. Receptor 
dependent variables and technical parameter optimisation was established (Chapter 3). 
 
• A systematic comparison between different expression vector designs was performed and 
identified that the addition of the mating factor α (MF-α) leader sequence to the amino-
terminus of the β1- and β2-adrenoceptors was required to produce and retain a 
pharmacological response in the yeast assay (Chapter 4). 
 
• A pharmacological characterisation of the β-adrenoceptors was performed. To gain more 
insight into the signalling mechanisms and coupling interaction of these receptors a more 
detailed modelling studies could be performed (Chapter 5). 
 
• Strategies were designed to further engineer the host to produce cholesterol instead of the 
yeast ergosterol which is hypothesised to provide a more native-like environment for the G 
protein coupled receptors and increase the number of pharmacological targets that can be 
tested in the yeast system (Chapter 6).  
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Appendix A – Gα protein sequence alignment 
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Appendix B – Vector and plasmid maps 
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Appendix C – compound structures 
 
Agonists 
   
    
Compound ID  Generic name Receptor interaction (from 
IUPHAR) 
Structure 
C21 orciprenaline  β2 agonist 
 
C22 xamoterol β1 partial agonist 
 
C25 dobutamine  β1 and β2 partial agonist 
 
C31 procaterol  β2 agonist 
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Compound ID  Generic name Receptor interaction (from 
IUPHAR) 
Structure 
    
C34 fenoterol  β2 agonist 
 
C36 terbutaline  β2 partial agonist 
 
C39 mirabegron  β1 and β2 agonist 
 
C40 indacaterol  β1 and β2 agonist 
 
C42 isoprenaline  β1 and β2 full agonist 
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Compound ID  Generic name Receptor interaction (from 
IUPHAR) 
Structure 
C46 pindolol  β1 and β2 partial agonist 
 
    
Antagonists 
   
C20 levobetaxolol  β1 and β2 antagonist 
 
C23 labetalol  β1 and β2 antagonist 
 
C24 metoprolol  β1 and β2 antagonist 
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Compound ID  Generic name Receptor interaction (from 
IUPHAR) 
Structure 
 
C26 nadolol  β1 and β2 antagonist 
 
C27 propranolol  β1 and β2 antagonist 
 
C28 alprenolol  β2 antagonist 
 
C29 sotalol  β1 and β2 antagonist 
 
C30 carvedilol  β1 and β2 antagonist 
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Compound ID  Generic name Receptor interaction (from 
IUPHAR) 
Structure 
C35 levobunolol  β1 and β2 antagonist 
 
C37 esmolol β1 antagonist 
 
C38 propafenone  β1 and β2 antagonist 
 
C41 atenolol  β1 and β2 antagonist 
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Compound ID  Generic name Receptor interaction (from 
IUPHAR) 
Structure 
C43 acebutolol β1 antagonist 
 
C44 practolol β1 antagonist 
 
C48 bupranolol  β1 and β2 antagonist 
 
C49 betaxolol  β1 and β2 antagonist 
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Appendix D – supplementary compound profiling data 
 
β1-AR agonist responses in various strains 
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β1-AR antagonist responses in various strains 
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β2-AR agonist responses in various strains  
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β2-AR antagonist responses in various strains 
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Appendix E – Assay correlation data 
 
The pEC50 and pIC50 (marked in red) values used for comparison between the Yeast GαS and CHO 
assays presented in Figure 5.17 and Table 5.18.  
 
β1-AR comparison 
  
Yeast assay 
in Gαs
Agonist cAMP 
LANCE TR-
FRET
DiscoverX EFC 
cAMP (Cell 
based)
Human 
Antagonist - 
EFC pKi
Antagonist 
cAMP LANCE 
TR-FRET
C1 6.0 9.0 8.1
C2 4.3 5.2 5.1
C3 8.0 8.3
C4 6.8 6.6 5.3
C5 5.6 7.1
C6 3.6 4.5
C7 8.4 8.3
C8 6.6 7.4
C9 6.2 6.0
C10 6.7 6.2 4.1
C11 5.8
C12 5.6 4.5
C13 6.8 8.0 7.1
C14 6.6 7.1
C15 4.1 6.9
C16 6.5 4.5
C17 6.0 7.7
C18 7.6
C19 6.5
C20 7.4
C21 7.0 7.1
C22 7.3 8.2
C23 7.1 7.6
C24 6.5
C25 5.7 7.1
C26 6.2 7.5
C27 6.9 4.5
C28 6.9 6.1
C29 5.5 4.9
C30 7.3 4.5
C31 5.2 5.0
C33 7.3
C34 7.0 6.2
C35 7.1
C36 6.1 5.4 5.4
C37 6.2 7.9
C38 5.1 6.3
C39 6.4 6.2 6.0
C40 8.4 8.3
C41 6.6
C42 5.7 9.0 8.1
C43 6.3
C44 6.2
C46 7.5 4.2
C48 7.4
C49 7.0
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β2-AR comparison 
 
  
Yeast assay 
in Gαs
Human 
agonist 
cAMP HTRF
DiscoverX 
HitHunter 
cAMP EFC
Agonist cAMP 
LANCE TR-
FRET
DiscoverX EFC 
cAMP (Cell 
based)
Agonism ß-
arrestin EFC - 
PathHunter
Human 
Antagonist - 
EFC - pKi
Antagonist 
cAMP LANCE 
TR-FRET
C1 5.7 9.7 8.8 8.3 7.4 6.8
C2 6.7 4.5 6.2 5.8
C3 7.8 9.9 9.7
C4 8.2 9.2 9.6 8.2
C5 5.3 7.3 6.4 6.6 4.3
C6 4.5 6.4 4.5
C7 8.4 11.4 9.3 9.1 8.1
C8 7 8
C9 7.4 9 7.1 7.3 6.9
C10 5.7 6.3 5.2 4.8
C11 6 6.1 6
C12 5.9 7.3
C13 7.3 8.5
C14 7.8 8.3
C15 4.2 5.2
C16 6 6.2
C17 7.3 9.2 8.6
C18 3.9 5.5
C19 7.7 9
C20 6.8
C21 7.1 6.2 7.1 6.2 5.2
C22 6.1 5.3
C23 7.5 7.1
C24 6 6.2
C25 5.5 7.3 6.4 6.6 4.3
C26 7 8.5
C27 8.7 9.1 8.6
C28 7.4 9.6
C29 6.4 6.6
C30 7.7 9
C31 7.7
C33 8.6
C34 8.2 7.8 7.2 6.4
C35 8.2 9
C36 7.3 8.4 6.9 6.5 5.7 4.5
C37 5.4 4.6
C38 6.4 6.3
C39 6.2 5.5 5.3
C40 8.9 11.4 9.3 9.1 8.1 4.5
C41 5.5 5.1 5.1
C42 5.5 9.7 8.8 8.3 7.4 6.8 4.5
C43 5.2 5
C44
C46 7.9 7.1 9 8.6
C48 9
C49 6.4 6
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Appendix F – Publications arising from this thesis 
 
 
